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The FERM domain protein Merlin, encoded by the NF2 tumor suppressor 
gene, regulates cell proliferation in response to adhesion signaling. The growth 
inhibitory function of Merlin is induced by intercellular adhesions and inactivated 
by joint integrin/receptor tyrosine kinase signaling. Merlin contributes to the 
formation of cell junctions in polarized tissues, activates anti-mitogenic signaling 
at tight-junctions, and inhibits oncogenic gene expression. Thus, inactivation of 
Merlin causes uncontrolled mitogenic signaling and tumorigenesis. The 
underlying molecular mechanisms driving Merlin’s tumor suppressive functions 
have remained largely elusive since its discovery over two decades ago. We 
show that Merlin’s predominant tumor suppressive functions are attributable to its 
inhibition of the CRL4DCAF1 E3 ubiquitin ligase in the nucleus. These findings are 
supported using in vitro and in vivo binding assays, multiple lines of genetic 
evidence, in vitro mouse models, and freshly explanted NF2 patient samples. We 
subsequently show that Merlin’s nuclear translocation and inhibition of CRL4DCAF1 
suppresses inhibition of the Hippo tumor suppressor pathway kinases Lats1 and 
2. Merlin’s inhibition of CRL4DCAF1 therefore promotes inhibition of the YAP and 
TAZ transcriptional coactivators and abrogates oncogenic signaling. I further 
develop a conditional Dcaf1 allele to assess the in vivo role of CRL4DCAF1 in 
 Merlin-deficient mouse models. A rapid non-germline genetically engineered 
mouse model using fetal liver progenitor cells shows that DCAF1 is necessary for 
Merlin-deficient tumorigenesis. However, Dcaf1 deletion in the adult liver 
exacerbates hepatomegaly and tumorigenesis, which likely stems from the 
expansion of a bipotential hepatobiliary niche. I also set out to develop a rapid 
malignant pleural mesothelioma (MPM) mouse model using virally delivered 
constructs to simultaneously recombine conditional alleles and inhibit or 
somatically mutate cooperating tumor suppressors. Finally, I show that 
CRL4DCAF1 inhibition using the NEDD8 Activating Enzyme inhibitor MLN4924 
reduces oncogenic signaling in Merlin-deficient MPM. Combining MLN4924 with 
traditional chemotherapy or mechanism-based therapy significantly delays the 
growth of Merlin-deficient MPM, a cancer that is highly refractory to standard 
chemotherapeutics. These latter findings support the use of MLN4924 in 
combination with mTOR/PI3K inhibitors for the treatment of Merlin-deficient 
tumors. 
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Chapter One 
Introduction 
 
1.1: A primer on NF2/Merlin 
The ability of normal cells to survive and proliferate is dictated by 
environmental cues including intercellular and matrix adhesions as well as the 
presence of growth factors. Normal cells undergo growth arrest when detached 
from the extracellular matrix or when they come into contact with adjacent cells 
and form intercellular junctions (1). Neoplastic cells evade contact inhibition of 
proliferation, which leads to the disruption of tissue organization - a distinguishing 
event in cancer (2). The NF2 (Neurofibromatosis Type 2) tumor suppressor gene 
encodes the FERM (4.1 protein/Ezrin/Radixin/Moesin) domain protein Merlin, 
which is coordinately regulated by intercellular adhesion and attachment to the 
extracellular matrix (3-7). Cadherin engagement inactivates PAK, causing an 
accumulation of the active, dephosphorylated form of Merlin. Notably, since 
integrin attachment to the extracellular matrix activates PAK, Merlin can therefore 
be regulated independently of contact-mediated signaling events (7). 
Neurofibromatosis type 2 patients carry a single mutated NF2 allele and 
develop a highly specific subset of central and peripheral nervous system 
tumors. NF2-associated tumors include schwannomas, meningiomas, and 
ependymomas, which arise from the Schwann cells comprising the myelin sheath 
surrounding sensory and motor neurons, arachnoid cap cells within the 
arachnoid villi in the meninges, and ependymal cells lining the CSF-filled 
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ventricles of the brain and central spinal canal, respectively. In addition to the 
autosomal dominant NF2 disorder, non-germline Merlin deficiency is a driving 
force in sporadic occurrences of nearly all vestibular schwannomas, a majority of 
meningiomas, and a notable fraction of ependymomas. Moreover, Merlin was 
found to be inactivated in a large proportion of malignant mesotheliomas (8, 9) 
and to a lesser extent in other solid tumors (10-13).  
Due in large part to Merlin’s high sequence homology to the ERM 
(Ezrin/Radixin/Moesin) family of cytoskeletal linker proteins (Figure 1.1), it was 
widely assumed that Merlin suppresses mitogenic signaling at the cell cortex to 
mediate contact inhibition and tumor suppression (14). Active Merlin suppresses 
Rac-PAK signaling (7, 15-17), restrains activation of mTORC1 independently of 
Akt (18, 19), inhibits PI3K-Akt and FAK-Src signaling (20, 21), and negatively 
regulates the EGFR-Ras-ERK pathway (22, 23). However, the mechanisms by 
which Merlin inhibits these pathways remain unclear, and furthermore, the 
relative contribution of these pro-mitogenic signals to various Merlin-deficient 
malignancies is unknown. Interestingly, Merlin activates the Hippo tumor 
suppressor pathway to suppress the transcriptional coactivators YAP/TAZ in 
mammals or the Drosophila ortholog Yorkie, revealing a conserved role for Merlin 
in regulation of organ size, stem cell behavior, and cell proliferation (24-26). 
Notably, few germline or somatic mutations of Hippo pathway components have 
been discovered in human tumors - the exception being Merlin, which remains as 
one of the only bona fide tumor suppressors in the Hippo pathway (27). 
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Figure 1.1: Overview of Merlin and ERM domain organization 
Merlin and other canonical ERM proteins have a similar domain organization 
consisting of an N-terminal FERM domain that is divided into three subdomains. 
The following 150-200 residues consist of an α-helical rich coiled coil domain, 
and the proteins terminate with a hydrophilic tail. Whereas canonical ERM 
proteins contain an actin-binding carboxy-terminal ERM-associated domain (C-
ERMAD; purple), Merlin contains no canonical actin-binding domain and, further, 
has an extended N-terminal 17 residues (green) unique among ERM proteins, 
illustrating divergent functions with other ERM proteins. Merlin’s phosphorylation 
sites are indicated. 
4 
 
Post-translational modification of Merlin is vitally important to its 
conversion between dormant and growth-inhibitory states, where the 
dephosphorylated and more open state is now considered to be active in contact 
inhibition and tumor suppression (28). However, without crystallographic 
analyses of full-length Merlin in both its active and inactive conformations, 
structural inferences drawn from biochemical experiments must be approached 
with caution. Apropos of the myriad upstream signals and modifications affecting 
Merlin, the downstream biochemical functions of Merlin have been the subject of 
intensive research for over two decades, yet a consensus mechanism for 
Merlin’s function in normal tissues has not been reached. It is becoming apparent 
that Merlin functions primarily in two branches – contact inhibition of proliferation 
and tumor suppression. Although these branches are naturally intertwined, the 
distinct locations of Merlin function and respective interactors in those subcellular 
compartments lend credence to a concept of a bimodal function. 
Recent studies among the ever-increasing breadth of NF2 literature have 
revealed important high-affinity interactors governing Merlin’s biochemical 
function. Notably, Merlin regulates tight junction-associated Angiomotin to inhibit 
Rac signaling (29), and nuclear-localized Merlin inhibits the CRL4DCAF1 E3 
ubiquitin ligase to suppress oncogenic gene expression (30). Moreover, Merlin’s 
regulation of YAP/TAZ is a burgeoning and highly provocative field due to the 
multifarious roles of Hippo signaling in organ growth, stem cell maintenance, and 
cancer. Recent studies have also shed light on Merlin’s conformational changes 
that regulate its intramolecular associations and downstream signaling, providing 
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fundamental insight into Merlin’s regulation and biochemical function. In this 
chapter, we will explore Merlin’s rich biochemical background and examine new 
insights that are shaping our understanding of Merlin’s role in normal biology and 
how its loss leads to the deregulation of a multitude of signaling pathways 
leading to tumorigenesis. 
 
1.2: The NF2 gene 
NF2 maps to the long arm of chromosome 22 and encodes two Merlin 
isoforms. The longer, dominant Merlin isoform 1 (Merlin-1 or Merlin), has an 
extended carboxy-terminal tail that is encoded by exon 17 (Figure 1.2). Merlin 
isoform 2 (Merlin-2), on the other hand, contains the alternatively spliced exon 16 
which ends in a stop codon, encoding 11 unique residues following amino acid 
579 as compared to Merlin-1 (10). Notably, Merlin-2 lacks carboxy-terminal 
residues required for intramolecular binding between the amino-terminal FERM 
domain and the carboxy-terminal tail, possibly leading to a constitutively open 
conformation (31, 32). Recent studies have found that Merlin-2 inhibits cell 
proliferation and attenuates downstream mitogenic signaling to the same extent 
as Merlin-1 (28, 33). Recent mouse genetics studies comparing Nf2 isoform 1 
and isoform 2 knockout animals revealed Merlin-1 and Merlin-2 are both fully 
functional tumor suppressors since knockout of either singly does not result 
cause tumorigenesis (34). 
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Figure 1.2: Merlin structure and overview of pathogenic mutations 
Merlin is a 595-residue protein divided into three structurally distinct regions – an 
amino-terminal FERM domain, an α-helical coiled-coil domain, and a carboxy-
terminal hydrophilic tail. Merlin’s FERM domain is further subdivided into three 
globular subdomains. NF2 encodes 16 exons, terminating with exon 17 in the 
canonical Merlin isoform. The positions of patient-derived missense mutations or 
single residue deletions are indicated below the exon schematic, with mutation 
frequency indicated by a heat map. Either these mutations underlie NF2 tracked 
within a family, were found in two or more unrelated patients, or experimental 
evidence was obtained to confirm their pathogenicity. Mutational data were 
obtained from Ahronowitz et al, 2007 (35) and Li et al, 2010 (30). 
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1.3: Merlin protein structure and intramolecular association 
The biochemical functions of Merlin are imparted by three mechanisms - 
post-translational modification, localization, and interaction with downstream 
effectors. Merlin is composed of a globular amino-terminal FERM domain and a 
carboxy-terminal hydrophilic tail joined by a flexible coiled-coil segment, 
displaying structural resemblance to the FERM domain-containing ERM proteins 
(Figure 1.1) (36, 37). This resemblance is most apparent in the first 300 residues 
of Merlin’s FERM domain, which share ~65% sequence identity with canonical 
ERMs. However, Merlin has several notable differences in its primary sequence 
that distinguish it in form and function from its ERM counterparts. Merlin’s amino-
terminus contains a 7-residue conserved Blue box motif and 17 unique amino-
terminal residues (38, 39). Importantly, Merlin lacks a canonical actin-binding 
motif that is otherwise conserved among ERMs and paramount to their function 
at the cortical cytoskeleton (14). 
A central mechanism in Merlin and ERM function is the formation of homo- 
and heterotypic interactions that regulate their activity. The majority of ERMs 
within cells are held in a dormant state imparted by an intramolecular association 
between the FERM domain and the C-terminal tail (40-42). Disruption of this 
association and subsequent activation is achieved by phosphorylation of an ERM 
C-terminal threonine residue by Rho kinase (Figure. 1.3). Active ERMs bind to 
cytoplasmic domains of cell-adhesion receptors such as CD44 and ICAM via 
their FERM domains while their C-termini interact with and regulate the cortical 
actin cytoskeleton (43, 44). Furthermore, once opened, active ERM proteins may
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Figure 1.3: Phosphoregulation of ERM proteins 
Canonical ERM proteins are maintained in an inactive state by intramolecular 
interaction between the C-terminal tail and FERM domain. Phosphorylation of a 
c-terminal threonine by Rho kinase - which may be aided by recruitment to 
membrane regions rich in phosphatidylinositol 4,5-bisphosphate - activates 
canonical ERM proteins by disrupting the head-to-tail interaction. 
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form interactions amongst themselves and with Merlin (40). Merlin’s 
intramolecular associations and subsequent activation states have been a 
subject of intensive study for nearly 20 years (28, 31, 32, 41, 45-47), yet a 
consensus model to explain the relationship between its phosphorylation and 
interdomain binding in the context of seemingly contrary genetic evidence has 
only recently been uncovered. 
It is well established that Merlin switches from an active state to an 
inactive state by phosphorylation at serine 518 (Figure 1.4A) (48). Phospho-
mimetic (S518D) or phospho-deficient (S518A) permutations strongly correlate 
with Merlin’s growth-permissive or growth-inhibitory functions, respectively (28, 
30, 49). Essentially, serine 518 phosphorylation acts as a binary switch in which 
dephosphorylated Merlin functions in adhesion signaling while phosphorylated 
Merlin remains dormant, although studies within the last five years have shown 
this to be an oversimplified interpretation. Several lines of evidence suggest that 
Merlin exists in multiple states that vary between “fully open” and “fully closed” 
forms which are regulated primarily by S518 phosphorylation, and moreover, 
FRET studies reveal that Merlin’s FERM domain and carboxy-terminus are 
constitutively held in close proximity, undergoing only subtle changes upon post-
translational modification (28, 50). A classic study found that Merlin-2 – which 
lacks the carboxy-terminal residues necessary for intramolecular interaction – is 
unable to function in contact inhibition or tumor suppression (31). This 
10 
 
Figure 1.4: Adhesion-mediated regulation of the Merlin activation cycle 
(A) In proliferating cells, integrin-mediated anchorage to the cell matrix and 
stimulation of receptor tyrosine kinases (RTKs) activate Rac, in turn activating 
PAK and leading to phosphorylation of Merlin at Serine 518. In response to high 
cyclic AMP levels, PKA also phosphorylates Merlin at serine 518. Serine 518 
phosphorylation increases the interdomain binding between Merlin’s carboxy-
terminus and FERM domain, maintaining Merlin in a more closed, inactive form. 
(B) Conversely, in contact-inhibited cells, dephosphorylated Merlin accumulates 
as a result of intercellular adhesions which lead to PAK inhibition. Merlin may 
also be activated via MYPT1-mediated dephosphorylation.  
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observation led to a hypothesis that was held for over a decade positing that 
dephosphorylated and active Merlin functions in a closed conformation. 
Recently, two independent laboratories found that Merlin-2 suppresses 
growth in mammalian cell lines, suggesting that interdomain binding is 
dispensable for Merlin’s adhesion signaling (28, 33). Through comprehensive 
biochemical investigation, Anthony Bretscher’s group reported that 
phosphorylated Merlin displays higher interdomain binding and that Merlin 
therefore inhibits cell growth in its open state (28). These results are underscored 
by the observation that a stably closed Merlin mutant does not suppress cell 
growth, whereas Merlin-2 and the S518A mutant - which are both defective in 
interdomain binding and therefore more open - suppress growth to the same 
extent as wild-type Merlin. Cumulatively, these results reveal that S518 
phosphorylation and mutations that cause Merlin to become more closed result in 
decreased growth inhibition, whereas more open forms of Merlin – those that are 
increasingly defective in interdomain binding – are more active in growth 
inhibition. This finding contributes greatly to a consensus of Merlin structure and 
function as it relates to normal biology and tumor suppression, resolving a 
decade-old schism between biochemical observations and in vivo genetic 
studies. 
Biochemical studies have provided essential insight into Merlin’s 
conformational changes and resulting activation, which are now largely 
corroborated by genetic data. Most patient-derived truncations and a vast 
majority of non-truncating mutations occur within the FERM domain (Figure 1.2), 
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lending credence to its quintessential role in anti-mitogenic signaling and tumor 
suppression (35). Initially discovered in Drosophila, the “Blue box motif” is a 
conserved region within the FERM subdomain F2 corresponding to residues 177-
183 in human Merlin. Substitution of these residues with alanines imparts loss of 
contact inhibition and promotes tumorigenesis in NIH-3T3 cells (51). Mutations in 
the Blue box act in a dominant negative manner in both Drosophila and 
mammals, displaying the importance of the FERM domain in Merlin’s tumor 
suppressive function. As compared to the FERM domain, mutations are scarce in 
Merlin’s carboxy-terminal tail and are dramatically reduced in the central α-helical 
domain, again implying that Merlin’s downstream tumor suppressive functions 
are imposed by the FERM domain (Figure 1.2) (35). Notably, replacement of 
Merlin’s F2 subdomain with that of the ERM protein Ezrin abolishes its growth 
suppressive activity, while individual or combined replacement of subdomains F1 
and F3 do not affect proliferation (33). These results imply that subdomain F2 of 
Merlin’s FERM domain is largely responsible for Merlin’s growth inhibitory effects. 
Truncating mutations correlate with increased NF2 severity and predominate 
among NF2 patients, while missense mutations – although more rare - allow for a 
more systematic interpretation of Merlin’s biochemical role in tumor suppression. 
Merlin’s FERM domain interacts directly with the CRL4DCAF1 E3 ubiquitin ligase, 
inhibiting its ubiquitylation activity and downstream oncogenic signaling. Multiple 
patient-derived missense mutants, including those mapping to subdomain F2, 
are defective in CRL4DCAF1 interaction, despite the fact that some of these 
mutations were predicted to cause little structural perturbation (30, 37).  
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Recent biochemical insights combined with more than a decade of patient-
derived genetic data provide crucial insight into Merlin’s normal biochemical 
function and role in tumor suppression. Merlin’s α-helical domain and carboxy-
terminus function in maintaining Merlin in an inactive conformation during normal 
biological function, and may further be necessary for functions underneath the 
cell cortex in the organization of cell junctions and in contact inhibition. However, 
while interdomain binding is an important part of Merlin’s regulation and normal 
cellular functions, the overall structure and specific protein-interacting domains 
within Merlin’s amino-terminal FERM domain are essential for contact inhibition 
and tumor suppression. 
 
1.4: Post-translational modification of Merlin 
Merlin is regulated by multiple post-translational modifications downstream 
of an ever-expanding array of intracellular and extracellular cues. Receptor 
tyrosine kinases and integrins relay pro-mitogenic signals by activating CDC42 
and Rac, which in turn activate p21-activated kinase (PAK) (Figure 1.4A). 
Activated PAK directly phosphorylates Merlin at serine 518, leading to an 
increase in carboxy-terminal association with the FERM domain and subsequent 
inactivation, presumably through masking of protein-interacting domains on the 
FERM domain which are necessary for downstream signaling or occlusion of a 
nuclear localization signal (30, 36). Since Merlin has a long half-life within cells, it 
is a compelling hypothesis that phosphatases exist to dephosphorylate Merlin at 
serine 518 and dynamically control levels of the dephosphorylated active form. 
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MYPT1-PP1δ (MYPT1) is a phosphatase that was shown to dephosphorylate 
Merlin (22) (Figure 1.4B), and recent evidence revealed that it may be inhibited 
by Integrin-linked kinase (ILK) (52). It remains to be determined whether MYPT1-
mediated Merlin activation via dephosphorylation is a major mechanism in NF2 
pathogenesis and Merlin-deficient tumors, or whether nascent and 
dephosphorylated Merlin largely functions in this capacity. 
The phosphorylation status of serine 518 drives Merlin’s activation cycle, 
although other modifications modulate Merlin’s conformation and downstream 
biochemical functions. Phospho-peptide mapping and band-shift experiments 
revealed that Merlin is phosphorylated at multiple sites and that serine 518 
phosphorylation may be necessary for subsequent phosphorylation at other 
residues (17, 53). In addition to PAK-mediated phosphorylation, PKA was shown 
to independently phosphorylate Merlin at serine 518 and serine 10, the latter 
modification affecting the actin cytoskeleton (54, 55). Merlin’s phosphoregulation 
by PKA may be an important mechanism in cells which are sensitive to the cyclic 
AMP-PKA signaling axis, including the pathogenically relevant Schwann cells 
(56). AKT phosphorylates Merlin at two additional sites – threonine 230 and 
serine 315 – and this phosphorylation causes decreased interdomain binding, 
intermolecular binding to phosphoinositides and PIKE-L (a GTPase that 
enhances PI3K activity), and ubiquitylation (57). The observation that AKT-
mediated phosphorylation blocks Merlin’s interaction with PIKE-L supports an 
inhibitory role for this interaction (20, 57). This finding also raises the possibility 
that constitutive activation of the PI3K-Akt pathway resulting from PTEN loss or 
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activating PI3K mutations would lead to Merlin inactivation, imparting a PI3K 
feed-forward mechanism. However, speculation that Merlin is inactivated by 
decreased interdomain binding conflicts with the recent observations that the 
open form of Merlin is active (28, 33). Moreover, the importance of the ubiquitin-
proteasome system in Merlin’s degradation is debatable, as cycloheximide chase 
experiments revealed that Merlin has a half-life exceeding 24 hours (30), 
although this does not rule out other ubiquitylation-mediated effects on Merlin 
function. Akt- and PAK-mediated phosphorylation of Merlin was recently shown 
to promote its sumoylation - an ubiquitin-like modification - which was found to 
affect Merlin’s subcellular localization, interdomain binding, and growth-inhibitory 
activity (58). However, the requirement for sumoylation in Merlin’s normal 
function and in tumor suppression remains incompletely understood since serine 
518 phosphorylation, which renders Merlin inactive, appears to promote its 
sumoylation.  
 
1.5: Merlin functions at the plasma membrane, cell cortex, and cytoskeleton 
As cells become confluent, Merlin interacts with membrane-associated 
proteins where it regulates the formation of membrane domains (59). Merlin’s 
organization of intercellular contacts is central to its normal function in contact 
inhibition, which is disrupted in Merlin-deficient tissues (60). Indeed, Merlin was 
initially interpreted as functioning at the cell cortex due to its homology to ERM 
proteins and its localization by immunostaining (61). This notion was supported in 
Drosophila by the observation that nascent Merlin is recruited to the plasma 
17 
 
membrane (39, 62). These observations were corroborated by Merlin’s role in the 
establishment of adherens junctions in confluent cells and localization in 
lamellipodia and membrane ruffles (5, 7, 63-65). Merlin interacts with a number 
of proteins that are localized at or underneath the plasma membrane, including 
other ERMs, NHERF, the intracellular domain of CD44, α-catenin at maturing 
adherens junctions, and Angiomotin at tight junctions (6, 29, 60, 61, 66). 
In keratinocytes and skin epithelium, Merlin is recruited to α-catenin and 
promotes its binding to Par3, aiding in the maturation of adherens junctions 
(Figure 1.5) (60). This is consistent with the disruption of adherens junctions in 
Merlin-deficient primary fibroblasts and keratinocytes (5). Interestingly, α-catenin 
can bind to 14-3-3 protein, which sequesters phosphorylated YAP in the 
cytoplasm and suppresses YAP-mediated transcription (67, 68). Moreover, it was 
recently discovered that α-catenin interacts with the APC tumor suppressor to 
promote the ubiquitylation and degradation of β-catenin as well as repression of 
Wnt target genes in the nucleus (69). Since Merlin’s interaction with α-catenin 
and its role in junction formation was exclusively studied in skin and fibroblasts, it 
is difficult to put this mechanism in the context of NF2 pathogenesis and other 
Merlin-deficient malignancies. It will be of great interest to see whether Merlin’s 
interactions with α-catenin leads to the suppression of YAP- and β-catenin-
mediated oncogenic gene expression in pathogenically-relevant tissues. 
Merlin interacts with the scaffold and signaling protein Angiomotin at 
mature tight junctions, regulating contact inhibition and potentially tumor 
suppression (Figure 1.6) (29). Angiomotin exists in two isoforms - both of which 
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Figure 1.5: Merlin functions in the assembly of adherens junctions 
Merlin is recruited to nascent adherens junctions by α-catenin and contributes to 
the activation of Hippo signaling by cooperating with Kibra to activate the 
classical core kinase cascade, or by enabling α-catenin to sequester 
phosphorylated Yap in the cytoplasm through 14-3-3 proteins. 
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Figure 1.6: Merlin regulates Angiomotin 
Upon assembly of tight junctions, Merlin binds to Angiomotin and displaces the 
Rac GAP Rich, thereby inhibiting Rac. In addition, Merlin might assist Angiomotin 
in coordinating the activation of the Hippo core kinase cascade. 
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interact with Merlin - and associate with tight junctions through interactions with 
Patj, Pals1, and Mupp1 (70, 71). At assembled tight junctions, Merlin binds to 
Angiomotin and displaces Rich - a GTPase Activating Protein for Rac - thus 
suppressing Rac-PAK signaling (29). Therefore, Merlin’s inhibition of Rac at tight 
junctions promotes contact inhibition and acts as a barrier to mitogenic signaling 
(7). One major caveat to this finding is that Angiomotin interacts not only with 
Merlin’s α-helical and carboxy-terminal domains, but also with phospho-deficient 
and phospho-mimetic Merlin mutants (29). These results strongly imply that 
Merlin binds to Angiomotin regardless of its activation status, and therefore, 
independently of growth suppressive stimuli. Further work is needed to fully 
understand the role of Angiomotin in Merlin’s function in normal cells and in 
Merlin-deficient tumorigenesis. 
A fraction of Merlin has been found to localize to cholesterol-dependent 
membrane domains - which were interpreted as lipid rafts - as a result of 
phosphoinositide binding (72, 73). Active Merlin was shown to bind 
phosphoinositides in several studies, although there is contradicting evidence as 
to whether this occurs in Merlin’s active or inactive forms (73, 74), raising 
uncertainty over the relevance of this interaction to adhesion signaling. However, 
a Merlin mutant lacking residues necessary for phosphoinositide binding – K79, 
K80, K269, E270, K278, and K279 – was significantly defective in suppressing 
growth of Merlin-deficient cells (73). This observation was supported by 
experiments confirming that the Merlin mutant retained normal folding. However, 
the ability of the phosphoinositide-binding mutant to interact with other proteins 
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that were previously shown to mediate Merlin’s function was not tested. Notably, 
mutation of Merlin E270 abolishes interaction with CRL4DCAF1, which could 
explain the growth-suppression defects of the phosphoinositide-binding mutant 
(30). Merlin’s phosphoinositide binding and potential localization to lipid rafts 
requires further scrutiny to determine its relevance both in normal biological 
function and in Merlin-deficient pathogenesis. 
In addition to Merlin’s localization at the cortex and contact-dependent 
membrane domains, Merlin functions in the cytoplasm to control cytoskeletal 
dynamics and vesicular transport. Merlin associates with actin and tubulin in the 
cytoplasm (33, 75, 76), although Merlin’s association with the actin cytoskeleton 
is dispensable for tumorigenesis (33, 77). Merlin migrates along microtubules in a 
kinesin-1- and dynein-dependent manner (76), and Merlin was recently found to 
slow the turnover of microtubules, thus stabilizing them (78). In addition, Merlin 
has been found to promote microtubule-mediated anterograde transport of 
vesicles (79), which could function in promoting the transport of anti-mitogenic 
biomolecules or regulating the availability of growth factors at the plasma 
membrane. Merlin’s effects on the actin cytoskeleton do not appear to be 
pathogenically relevant, and it remains to be demonstrated whether regulation of 
microtubule dynamics is necessary in Merlin-mediated contact inhibition and 
tumor suppression in vivo. Therefore, current models imply that Merlin largely 
enforces contact inhibition and the organization of membrane domains by acting 
at the plasma membrane or cortex, while Merlin’s strongest tumor suppressive 
functions are enforced in another cellular compartment. 
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1.6: Merlin interacts with the CRL4DCAF1 E3 Ubiquitin ligase in the nucleus 
Prior research in our lab led to the discovery that wild-type Merlin, but not 
a patient-derived missense mutant, interacts with the CRL4DCAF1 E3 ubiquitin 
ligase (Figures 1.7A and B) (30). Wild-type Merlin and the phosphorylation-
resistant mutant S518D, canonically interpreted as the active conformer, 
preferentially interact with DCAF1 while phospho-mimetic and patient-derived 
mutants lack binding (Fig. 1.7C). Immunoblotting Flag-HA-tagged (FH) DCAF1 
precipitates with an antibody recognizing phosphorylated Merlin confirmed that 
de-phosphorylated Merlin preferentially interacts with DCAF1 (Figure 1.7D). Wei 
Li, a former postdoctoral fellow who spearheaded this project following the 
departure of his co-author Liru You, carried out further experiments to identify the 
cellular compartment in which Merlin and CRL4DCAF1 interact. He found that 
DCAF1 can localize to the nucleus (Figures 1.8A and B), as might be expected 
based on the localization and function of other CRL4 ligases (80, 81). Notably, 
Wei found that Merlin can localize in the nucleus (Figures 1.8A and B) and that 
Merlin interacts with DCAF1 specifically in this compartment despite these 
proteins’ ability to localize in both the cytosolic/crude membrane and nuclear 
soluble fractions (Figure 1.8D) (30). Importantly, these observations constituted 
the first identification of a nuclear binding partner for Merlin. 
Further observation that the dephosphorylated form of Merlin preferentially 
translocates to the nucleus while the phosphorylated form is largely excluded is 
consistent with the long-standing observation that Merlin suppresses 
tumorigenesis in its dephosphorylated form (28, 30, 33, 51). Moreover, several 
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Figure 1.7: Merlin associates with CRL4DCAF1 
Modified from Li et al. 2010 (30). Experiments performed by Liru You and Wei Li. 
(A) COS-7 cells were transfected with the indicated FH-tagged (FH; FLAG-HA) 
forms of Merlin and subjected to TAP. Proteins were separated by SDS-PAGE 
and stained with Colloidal Blue. Dots point to the FH-tagged baits and asterisks 
to the 169 and 127 kD bands identified by mass spectrometry as DCAF1 and 
DDB1, respectively. 
(B) 293T cells were transfected with moderate amounts of FH-tagged DCAF1 or 
empty vector. Total lysates and Flag-immunoprecipitates (M2) were subjected to 
immunoblotting with antibodies to the indicated proteins. 
(C) As in (B), with transfection of moderate amounts of the indicated constructs 
and immunoprecipitation with anti-FLAG (M2) or control (C) antibodies. 
(D) As in (B), with co-transfection of Myc-Merlin or empty vector and 
immunoprecipitation with anti-FLAG (M2) or control (C).To control for the 
specificity of the anti-p-Merlin antibodies, the indicated sample was treated with 
calf intestinal alkaline phosphatase (CIP) prior to SDS-PAGE. Endogenous 
Merlin was detected upon longer exposure. 
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Figure 1.8: Merlin interacts with CRL4DCAF1 in the nucleus 
Modified from Li et al. 2010. Experiments performed by Wei Li. 
(A) Meso-33 cells were transiently transfected with moderate amounts of the 
indicated constructs and subjected to double immunofluorescent staining with 
anti-HA and anti-Myc followed by DAPI. 
(B) MCF-10A cells were subjected to subcellular fractionation. Equal amounts of 
proteins from the nuclear (NF) and non-nuclear (CM; cytosol + crude 
membranes) fraction were subjected to immunoblotting with antibodies to the 
indicated proteins. 
(C) HEI286 untransformed Schwann cells, LP9 untransformed mesothelial cells, 
and MCF-10A untransformed mammary epithelial cells were stained with affinity-
purified antibodies to the N-terminal segment of Merlin followed by DAPI. 
(D) Equal amounts of proteins from the non-nuclear (CM) and nuclear-soluble 
(NS) fraction of HeLa cells and Merlin-immunoprecipitates were immunoblotted 
as indicated. Anti-Cul4 recognizes Cul4A and a higher molecular weight band, 
possibly corresponding to Neddylated Cul4A or Cul4B (asterisk). 
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reports have characterized Merlin’s localization in the nucleus, and Merlin 
migrates towards the nucleus by microtubule-based transport in Drosophila (58, 
76, 82, 83). Although Merlin lacks a canonical nuclear localization sequence, it 
contains a motif on its carboxy-terminus that promotes nuclear export by the 
CRM1-exportin pathway (83) and truncations that remove these residues show 
increased nuclear localization (30, 33). Interestingly, the isolated FERM domain 
of Merlin is necessary and sufficient for nuclear localization, once again 
highlighting the importance of Merlin’s FERM domain in its normal function (30). 
Moreover, the dephosphorylated form of Merlin preferentially localizes to the 
nucleus in confluent and growth factor-deprived cells, when Merlin’s anti-
mitogenic effects would be most active (30). As the phosphorylated, more closed 
form of Merlin is excluded from the nucleus, interdomain binding imposed by 
S518 phosphorylation may occlude the FERM domain residues necessary for 
nuclear translocation (28, 30). Since a large proportion of Merlin shuttles to the 
nucleus in contact-inhibited cells, Merlin’s nuclear function – particularly inhibition 
of the oncogenic CRL4DCAF1 ubiquitin ligase – may be vital for growth 
suppression (30). Understanding more about CRL4DCAF1 biology and its 
interaction with Merlin and other binding partners is an important step in 
conceptualizing how Merlin’s inhibition of this E3 ligase is an important stepping 
stone in the control of multiple pro-oncogenic signaling pathways. 
DCAF1 (DDB1 and Cul4-Associated Factor 1) was originally identified as 
VprBp (Vpr-binding protein) – a cytoplasmic protein that binds to the HIV-1 viral 
accessory protein Vpr (84, 85), before it was found to function as the substrate 
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recognition subunit of the CRL4DCAF1 E3 ubiquitin ligase (86). Viral Vpr and the 
related Vpx proteins promote HIV and SIV infection by functioning as adaptors 
that bind to DCAF1 and usurp its recruitment of substrates to degrade proteins 
that normally suppress viral infectivity (87, 88). In fact, viral subversion of E3 
ubiquitin ligases occurs in a number of human diseases (34, 86, 89-91). 
SAMHD1 is a viral restriction factor that functions in myeloid-lineage cells and 
resting CD4+ T-cells by reducing the concentration of cellular dNTPs and thus 
inhibiting the viral reverse transcriptase. In HIV-2 and SIV, Vpx binds to DCAF1 
and acts as an adaptor to co-opt the ubiquitin-conjugating machinery to target 
and degrade SAMHD1 (92-97). A recent landmark study found that Vpx binds the 
WD40 domain of DCAF1 to produce a new surface that recruits SAMHD1, 
providing the first structural elucidation of lentiviral hijacking of the cell’s ubiquitin-
proteasome system (98). These studies provide a starting point to understand 
how CRL4DCAF1 binds its targets. 
Structural analysis of the DCAF1-Vpx-SAMHD1 complex revealed that 
Vpx creates a new binding surface by enclosing a portion of the DCAF1 WD40 
domain. The WD40 domain of DCAF1, near the carboxy-terminus, is a seven-
bladed β-propeller that forms an overall fan shape (98). Residues within the 
WD40 domain are necessary for interacting with DDB1 and therefore docking to 
the CRL4 complex (86). As Vpx-associated DCAF1 is able to recruit SAMHD1 
and mediate its ubiquitylation (98), it is plausible that DCAF1 uses portions of its 
WD40 domain to bind native targets. A recent study found that DCAF1 can 
recruit mono-methylated proteins using the hydrophobic pocket within its chromo 
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domain, which resides in the amino-terminal half of the protein (99). In addition to 
the role of CRL4DCAF1 in ubiquitylation, DCAF1 has a putative kinase domain near 
the amino-terminus which imparts intrinsic kinase activity towards histone H2A to 
downregulate anti-mitogenic genes (100). Combined, these studies reveal that 
DCAF1 can interact with multiple target proteins using several distinct regions 
spanning its primary sequence. However, without further structural 
characterization of full-length DCAF1, it cannot be ruled out that these domains 
are juxtaposed, and that one or more protein-interacting regions act in a single 
multifunctional recruitment domain. 
DCAF1 was established as the substrate recognition component of the 
CRL4DCAF1 E3 ligase nearly ten years ago (86), and several CRL4DCAF1 targets 
have been discovered. Vpr- and Vpx-mediated targeting of SAMHD1 and the 
uracil DNA glycosylase UNG2 direct these proteins to proteasomal degradation 
(93, 101). Moreover, it was found that CRL4DCAF1 is recruited by Vpr to activate 
the SLX4 complex, a structure-specific endonuclease whose ectopic activation 
results in G2/M arrest and evasion of innate immunity in HIV-infected cells (102). 
Native DCAF1-binding proteins include Merlin, the nuclear orphan receptor Rorα, 
histones H2A and H3, HDAC, the polarity protein Lgl, the lymphoid cell-specific 
V(D)J recombination protein RAG1, the protein phosphatase PPP2R1A, and the 
replication factor Mcm10 (30, 99, 103-107). Several of these proteins – 
particularly the histones and HDAC – can broadly affect epigenetics, suggesting 
that Merlin’s inhibition of CRL4DCAF1 can greatly alter gene expression. It was 
recently observed that CRL4DCAF1 interacts with and promotes activation of TET 
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proteins, a family of enzymes that convert 5-methylcytosine to 5-
hydroxymethylcytosine (5hmC) (108). These conversions cause epigenetic 
modifications that regulates DNA demethylation and therefore gene transcription, 
which were shown to have dramatic effects during embryonic development and 
tumorigenesis. Notably, loss of TET2 is a common occurrence in myeloid 
leukemia and 5hmC reduction is a distinguishing feature of melanoma and is 
observed in a range of other solid tumors (109). However, the mechanism by 
which CRL4DCAF1 regulates TET proteins – whether by ubiquitylation or another 
modification – is currently unknown. Indeed, the mechanism by which CRL4DCAF1 
modulates several bona fide interactors remains elusive, and it is unclear 
whether ubiquitylation of these targets is necessary or sufficient for their 
regulation. Regardless, these findings suggest that CRLDCAF1 can multifariously 
modulate epigenetics. 
 
1.7: Convergence on YAP and TAZ 
The size of multicellular organisms and their composite tissues is tightly 
regulated by restricting cell size and proliferation (93, 94). The Hippo pathway 
has emerged as a potent regulator of organ size throughout the animal kingdom. 
Notably, genetic experiments in Drosophila and mice revealed that the Hippo 
pathway controls cell proliferation and promotes apoptosis, and disruption of the 
pathway at multiple levels leads to tissue overgrowth and tumorigenesis (110, 
111). This is particularly evident in mouse genetic models, where dysregulation 
of Hippo pathway proteins in the liver elicits dramatic hepatomegaly and 
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development of a range of tumors (24, 112-115). The Hippo pathway is 
canonically driven by a core kinase cascade consisting of the Ste20-like kinases 
Mst1 and Mst2 (Mst1/2), which in conjunction with Sav1, phosphorylate and 
activate the NDR family kinases Lats1 and Lats2 (Lats1/2) along with cofactors 
Mob1A and Mob1B. Active Lats kinases phosphorylate and inactivate the YAP 
and TAZ transcriptional coactivators (Figure 1.9A). In the absence of Hippo 
signaling, active YAP and TAZ translocate to the nucleus to promote transcription 
of genes that drive proliferation, evasion of apoptosis, and stemness (Figure 
1.9B) (26, 116). The atypical cadherin Fat, along with the apical polarity protein 
Crumbs, function in Drosophila to activate the Hippo pathway. These proteins 
activate the FERM domain protein Expanded, which complexes with Merlin and 
Kibra to activate the core kinase cascade (96, 97, 117, 118). Although the core 
kinase cascade is evolutionarily conserved between Mammals and Drosophila, 
the upstream signaling promoting activation of the Hippo pathway has diverged. 
It has recently become evident that some of the key proteins regulating 
the core Hippo cascade in Drosophila evolved after the divergence of arthropods. 
It is unclear whether Drosophila Expanded (Ex) and Fat have orthologs in 
vertebrates, and the mammalian proteins which bare closest resemblance 
appear to function primarily through Hippo-independent mechanisms (119-122). 
The adherens junction protein Echinoid and the unconventional myosin Dachs - a 
downstream target of Fat - regulate the Drosophila Hippo pathway but are absent 
in vertebrates. Angiomotin was retained during the evolution of chordates as a 
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Figure 1.9: The core Hippo pathway kinase cascade 
(A) The Hippo tumor suppressor pathway was originally identified in flies and in 
the past decade has emerged as a regulator of several mechanisms of cancer 
progression, regulation of organ development, regeneration, and stemness. The 
Hippo pathway consists of a kinase module that is regulated by upstream 
signaling and a transcription module that can drive oncogenesis in many tissues. 
In canonical Hippo signaling, the STE2-like kinases MST1 and 2 and their 
adaptor protein Sav1 activate the NDR-like kinases LATS1 and 2 along with their 
adaptors MOB1A and B. The LATS proteins phosphorylate YAP and TAZ, 
leading to their cytosolic sequestration which simultaneously excludes them from 
functioning as co-transcriptional activators along with TEAD family proteins but 
also primes them for degradation. 
(B) In the absence of active LATS1 or 2, YAP and TAZ translocate to the nucleus 
where they bind to and activate TEAD-dependent transcription of pro-proliferative 
and anti-apoptotic genes. Since both DCAF1 and Merlin appear to affect Hippo 
pathway target genes, we wanted to know whether expression of Merlin and 
DCAF1 regulate the activity of YAP. 
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regulator of Hippo signaling but was replaced with Ex at the base of the 
arthropod lineage (122). The evolution of a novel domain in Ex to bind Yki – the 
Drosophila ortholog of YAP - reestablished Crumbs-mediated regulation of Hippo 
signaling which was uncoupled when the PDZ-binding motif of Yki was lost 
during arthropod evolution. In addition to these evolutionary shifts in regulation of 
Hippo signaling, Merlin’s input into the pathway appears to be more complicated 
in mammals. 
It is becomingly increasingly clear in mammals that multiple signals 
converge to affect the Hippo core kinase cascade in addition to canonical Hippo 
signaling (116). Upstream of the core cassette, Merlin can interact with Kibra to 
activate the Hippo kinase cascade, although the biochemical mechanism is 
unclear (24, 96). Merlin is recruited to tight junctions by Angiomotin, which serves 
as a scaffold for PDZ- and WW-domain- containing proteins including Hippo 
pathway components (Figure 1.6) (123-126). Interestingly, tight junction-
associated Angiomotin directly binds phosphorylated YAP and TAZ and retains 
them at the cortex (123, 126) and also serves as a scaffold for activation of the 
Hippo core kinases Mst2 and Lats2, promoting canonical YAP/TAZ inhibition 
(124). Since Merlin binds to Angiomotin and displaces other complexed proteins, 
it is plausible that Merlin’s binding could modulate Angiomotin recruitment of 
Hippo components. It remains to be tested whether Merlin promotes or inhibits 
Angiomotin’s direct effects on Hippo signaling. Recently it was found that the 
p130 isoform of Angiomotin promotes YAP function by disrupting its association 
with Lats1 in the cytoplasm, and furthermore, by binding to YAP in the nucleus to 
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drive expression of a subset of YAP target genes to drive tumorigenesis (Figure 
1.6) (127). It will be of great interest to determine whether Angiomotin is shuttled 
to the nucleus to promote YAP function in sparse cells or cells that have had their 
tight junctions disrupted. Combined, these results suggest Angiomotin has tumor 
suppressive and growth-promoting functions, which may depend on the tissue, 
cellular, or biochemical environment. Identification of the contexts in which 
Angiomotin functions to inhibit or promote Hippo signaling - including the 
biochemical function of Merlin in these processes – will provide important 
mechanistic insight into both Merlin function and Hippo signaling. 
 
1.8: Questions to address 
Merlin inhibits several important pro-mitogenic pathways and its 
inactivation drives tumorigenesis in multiple tissues. Despite decades of 
research, the biochemical mechanism underlying Merlin’s regulation of 
oncogenic signaling remained elusive. During my thesis studies, I set out to 
determine how Merlin suppresses tumorigenesis and whether we could use our 
findings to derive mechanistic-based therapies for Merlin-deficient malignancies. 
In the following chapter, I will discuss how Merlin suppresses tumorigenesis in 
the nucleus by inhibiting CRL4DCAF1, an oncogenic E3 ubiquitin ligase. I will 
subsequently reveal a direct link between Merlin’s inhibition of CRL4DCAF1 in the 
nucleus and regulation of the Hippo tumor suppressor pathway. Subsequently, I 
will address the in vivo role of CRL4DCAF1 in mouse models of Merlin-deficient 
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tumorigenesis. Lastly, I will show how we exploited the mechanisms we 
uncovered for preclinical therapy of Merlin-deficient tumorigenesis. 
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Chapter Two 
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase 
CRL4DCAF1 in the nucleus 
 
2.1: Merlin inhibits CRL4DCAF1-dependent ubiquitylation 
Initial experiments revealed that Merlin is not a ubiquitylation target of the 
CRL4DCAF1 ligase, raising the possibility that Merlin functions upstream of the 
ligase (30). I set up an in vivo ubiquitylation assay to examine the effect of Merlin 
expression on the ubiquitin conjugating activity of CRL4DCAF1. I transfected COS-
7 cells with Flag-HA-tagged DCAF1 (FH-DCAF1) and Myc-ubiquitin, treated the 
cells with the proteasome inhibitor MG132 to accumulate ubiquitylated species, 
and immunoprecipitated CRL4DCAF1 and its associated ubiquitylated products 
using anti-Flag. Myc immunoblotting revealed that FH-DCAF1 isolated from 
MG132-treated cells coprecipitates ubiquitylated species of apparent molecular 
weight ranging from 55 to 300 kDa. This implies that CRL4DCAF1 targets one or 
more substrates which remain associated with the complex through the 
immunoprecipitation (Figure 2.1A, top). FH-DCAF1 isolated from untreated cells 
coprecipitated only a modest amount of ubiquitylated species ranging from 180 to 
250 kDa. Importantly, co-transfection of increasing concentrations of HA-tagged 
Merlin caused a dose-dependent suppression of the recruitment of ubiquitylated 
products. These results suggest that Merlin suppresses the ubiquitin conjugating 
activity of CRL4DCAF1. Re-probing the blot with anti-HA indicated that the fraction 
of recombinant Merlin coprecipitated by FH-DCAF1 does not noticeably become
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Figure 2.1: Merlin inhibits CRL4DCAF1 
(A) COS-7 cells were transfected with 3 µg of FH-DCAF1 and 2 µg of Myc-
Ubiquitin in combination with the indicated amounts of HA-Merlin, treated with 25 
µM MG132 for 6 hours or left untreated. Flag- or control-immunoprecipitates (M2 
and C, respectively) were subjected to immunoblotting with anti-Myc to visualize 
ubiquitylated proteins (top) or anti-HA to visualize DCAF1 and Merlin (bottom). 
Upper arrow points to DCAF1 and lower arrow to Merlin. 
(B) Total lysates from (A) were blotted to verify expression levels. 
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ubiquitylated in vivo, supporting the notion that Merlin acts upstream of 
CRL4DCAF1 rather than serving as a substrate of the ligase (Figure 2.1A, bottom). 
Immunoblotting the input revealed similar expression levels for the recombinant 
proteins but indicated that proteasome inhibition partially stabilizes DCAF1 
(Figure 2.1B). These observations suggest that Merlin binds to CRL4DCAF1 and 
suppresses its ability to mediate ubiquitin conjugation of its targets. 
I subsequently tested the effect of Merlin depletion on CRL4DCAF1 activity. I 
infected COS-7 cells with control or Merlin shRNA-encoding lentivirus and then 
subjected the resulting lysates to an in vivo ubiquitylation assay. This assay 
indicated that Merlin depletion causes a dramatic increase in CRL4DCAF1 ubiquitin 
conjugating activity (Figure 2.2). This effect was specific since was suppressed 
by overexpression of Merlin but not Ezrin, the latter of which does not associate 
with FH-DCAF1 (30). These results of positive expression and depletion provide 
compelling evidence that Merlin negatively regulates CRL4DCAF1 (Figure 2.3A). 
We hypothesized that in Merlin-deficient cells or when Merlin is inactive, 
CRL4DCAF1 ubiquitylates proteins and elicits growth-promoting or oncogenic 
signaling (Figure. 2.3B). 
 
2.2: DCAF1 mediates hyperproliferation in Merlin-deficient cells 
Prior studies in our lab revealed that loss of Merlin promotes progression 
through G1 (19), raising the possibility that DCAF1 affects this specific phase of 
the cell cycle. BrdU incorporation assays performed by Wei Li confirmed that 
DCAF1 depletion inhibits the ability of G0 synchronized Meso-33 – a Merlin-
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Figure 2.2: Merlin depletion promotes CRL4DCAF1-mediated ubiquitylation 
Cos7 cells stably infected with lentiviral vectors encoding a control shRNA or a 
shRNA targeting Merlin were subjected to immunoblotting (left) or transfected 
with FH-DCAF1 and Myc-Ubiquitin followed by immunoblotting of Flag- or 
control-immunoprecipitates with anti-Myc (middle) or anti-HA (right). 
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Figure 2.3: A hypothetical model of Merlin-mediated inhibition of CRL4DCAF1 
(A) Active Merlin translocates to the nucleus and binds to the carboxy-terminus 
of DCAF1, acting as a pseudo-substrate to block CRL4DCAF1 from recruiting and 
ubiquitylating target proteins. We propose Merlin’s inhibition of CRL4DCAF1 
suppresses oncogenic gene expression. 
(B) CRL4DCAF1 is an E3 ubiquitin ligase consisting of the substrate-recruiting 
DCAF1 protein that is linked to the amino-terminal domain of a cullin (Cul4A/B) 
backbone through DDB1, which is itself a large multi-domain protein. Bound to 
the cullin carboxy-terminal domain, Rbx1 uses its RING domain to recruit a 
ubiquitin-charged E2, which directs conjugation of ubiquitin to a DCAF1-bound 
target protein. 
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deficient mesothelioma cell line – to progress through G1 and enter S phase in 
response to mitogens (30). This effect appeared to be specific since DCAF1 
depletion in the Merlin-positive mesothelial line Met5a had only a modest effect 
on progression through G1. These results suggested that Merlin-deficient cells 
are more sensitive to DCAF1 inactivation than their normal counterparts. FACS 
analysis confirmed that DCAF1 depletion primarily inhibits progression through 
G1 (30). As these results suggest that Merlin suppresses cell proliferation by 
inhibiting CRL4DCAF1, we reasoned that expression of a mutant form of DCAF1 
that is unable to interact with Merlin should counteract Merlin’s antimitogenic 
effects. To test this hypothesis, I transfected Meso-33 cells with FH-Merlin, alone 
or in combination with wild-type DCAF1 or DCAF1-1417X (Figure 2.4A). DCAF1-
1417X is a mutant that lacks a distal carboxy-terminal motif which is bound by 
Merlin, making this mutant Merlin-resistant. Wei Li found that that expression of 
Merlin-resistant DCAF1-1417X in these samples fully rescued Meso-33 cells 
from undergoing growth arrest upon introduction of Merlin (Figure 2.4B). Wild-
type DCAF1 exhibited only a moderate growth rescue. We noted that despite a 
higher level of Merlin expression in these samples (Figure 2.4A), Merlin does not 
bind stoichiometrically to wild-type DCAF1 in this experiment (Figure 2.4C). We 
speculate that overexpressed Merlin may saturate the cellular machinery 
required for modification of Merlin to enable its binding to CRL4DCAF1 in this cell 
line. Taken together, these data provide compelling evidence that Merlin 
suppresses cell proliferation by inhibiting CRL4DCAF1. 
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Figure 2.4: DCAF1 mediates hyperproliferation in Merlin-deficient cells 
The experiment in figure (B) was performed by Wei Li.  
(A) Meso-33 cells were transiently transfected with the indicated micrograms of 
vectors encoding HA-Merlin, alone or in combination with FH-DCAF1 or FH-
DCAF1 (1-1417), and subjected to immunoblotting as indicated. The anti-HA 
blots including FH-DCAF1 and HA-Merlin were exposed for the same time. 
(B) The cells in (A) were subjected to a BrdU incorporation assay by Wei Li. The 
graph shows the percentage (+ SEM) of BrdU+ cells. 
(C) Flag (M2) or control (C) immunoprecipitates from lysates containing 0.3 mg of 
total proteins from Meso-33 cells transfected with FH-DCAF1 WT and HA-Merlin 
(same treatment as lane 3 from (A)) were immunoblotted with anti-HA. Note that 
DCAF1 is not saturated by Merlin under these experimental conditions. 
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2.3: Tumor-derived mutations prevent Merlin’s ability to interact with or to 
inhibit CRL4DCAF1 
A majority of NF2 missense mutants map to the amino terminal FERM 
domain (Figure 1.2) (35). To further study the relevance of Merlin’s interaction 
with CRL4DCAF1 for tumor suppression, we examined a panel of tumor-derived 
missense mutants. The Merlin mutations L46R, F62S, L64P, L141, A211D, and 
E270G are likely bona fide pathogenic mutations since they were found in two or 
more unrelated NF2 patients or were known to track with disease in individual 
families. In contrast, G197C, which was identified in a single patient affected by 
mild bilateral Schwannoma, may represent a polymorphism or a passenger 
mutation (35). Structural analyses by Stephen B. Long on a published crystal 
structure of the Merlin FERM domain (37) suggested that L46R, F62S, L64P, 
L141, and A211D disrupt the hydrophobic core of two subdomains of the FERM 
domain in which they reside. Notably, E270G simply removes a surface charge 
from a surface-exposed loop on a FERM subdomain. Wei Li evaluated the 
growth suppressive function of the panel of Merlin missense mutants in the 
Merlin-deficient Meso-33 cell line and found that all of the bona fide pathogenic 
mutants were devoid of growth inhibitory activity, whereas the putative passenger 
mutant G197C suppressed proliferation to the same extent as wild type Merlin 
(30). Wei reasoned that structural defects elicited by pathogenic missense 
mutations may affect their ability to interact with CRL4DCAF1, as the FERM domain 
directly interacts with the carboxy terminus of DCAF1 (30). Strikingly, 
immunoprecipitations using FH-Merlin and its mutants revealed that none of the 
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bone fide tumor-derived missense mutants associated with CRL4DCAF1 (30). This 
provided preliminary evidence that Merlin needs to combine with CRL4DCAF1 to 
suppress tumorigenesis. 
To assess the ability of tumor-derived Merlin missense mutants to directly 
interact with CRL4DCAF, I engineered each mutation into a GST fusion protein 
comprising the isolated FERM domain of Merlin, which we had found to bind 
efficiently to in vitro translated DCAF1 (30). GST-FERM-A211D bound DCAF1 in 
vitro almost as efficiently as wild type GST-FERM or GST-FERM-G197C, 
suggesting that the A211D mutant does not interact in vivo with CRL4DCAF1 due 
to an alternative mechanism (Figure 2.5A and B). The remaining mutant FERM 
domains displayed decreased binding to recombinant DCAF1 - L46R, L64P, and 
E270G did not bind at all under my experimental conditions, whereas F62S and 
L141P displayed defective binding. Subcellular fractionation experiments 
performed by Wei Li revealed that the A211D mutant which displayed abrogated 
in vivo interaction with CRL4DCAF1 but retained in vitro binding was defective in 
nuclear translocation (30). Additionally, since F62S and E270G were able to 
accumulate in the nucleus to normal or near normal levels, we inferred that they 
do not combine in vivo with CRL4DCAF1 because they are unable to directly 
interact with DCAF1. Of particular note, the E270G mutation was predicted to not 
overtly affect the overall structure of the FERM domain since it can theoretically 
be accommodated by a small adjustment of the surface loop in which it resides. 
This implicated the loop containing residue 270 as a surface that may be 
involved in direct interaction with DCAF1 and also confirmed the high specificity 
47 
 
Figure 2.5: Pathogenic mutations disrupt the ability of Merlin to bind to 
DCAF1 or to inhibit CRL4DCAF1 
The experiment in (D) was performed by Liru You. 
(A) In vitro translated and TNT-labeled DCAF1 was incubated with 0.5, 1, and 2 
µg of GST fusion proteins comprising the FERM domain of wild type Merlin or 
indicated mutants. GST-bound DCAF1 was detected by blotting with 
Streptavidin-HRP. 
(B) Densitometric analysis of (A). The graph shows the binding values in 
arbitrary units. 
(C) COS-7 cells were transfected with the indicated FH-tagged forms of Merlin 
and subjected to immunoprecipitation with control (C) or anti-Flag (M2) 
antibodies followed by immunoblotting. 
(D) COS-7 cells were transfected with FH-DCAF1 and HA-Ubiquitin in 
combination with Myc-tagged Merlin wild type, Merlin-339X, Ezrin, or empty 
vector and treated with 25 µM MG132. Flag- or control-immunoprecipitates were 
immunoblotted with anti-HA (left). Total lysates were immunoblotted with anti-
Myc (right). 
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of the interaction of Merlin with DCAF1. In contrast to the other mutations, both 
defective nuclear accumulation and deficient binding to DCAF1 contribute to the 
inability of L46R, L64P, and L141P to interact with CRLDCAF1 in vivo. Together, 
these experiments indicate that the six tumor-derived missense mutants that we 
tested do not combine with CRL4DCAF1 in vivo, owing to defective accumulation in 
the nucleus, deficient binding to DCAF1, or a combination of the two 
mechanisms. These results are summarized in Table 2.1.  
We speculated that mutations that introduce stop codons within Merlin’s 
FERM domain would likely give rise to misfolded and therefore unstable protein 
products. However, certain nonsense mutations truncate only the carboxy 
terminal domain. Based on the findings by Wei Li that intramolecular associations 
of the FERM domain with the carboxy terminal tail promotes nuclear 
accumulation of Merlin (30), we speculated that deletion of Merlin’s carboxy 
terminus would affect the ability of Merlin to maintain a closed – and presumably 
active – conformation. To examine if tumor-derived nonsense mutations affect 
the ability of Merlin to interact with or to suppress CRL4DCAF1, I examined two 
prevalent truncation mutants - Merlin 466X (which lacks the C-terminal portion of 
α-helical domain and the carboxy terminal domain) and Merlin 341X (which 
retains the FERM domain but lacks both the α-helical and the carboxy terminal 
domain) (35). Immunoprecipitation of Flag-HA-tagged WT Merlin and its 
truncation mutants indicated that loss of the Merlin’s carboxy terminus along with 
the central coiled-coil domain do not disrupt their ability to interact with 
CRL4DCAF1 in vivo (Figure 2.5C). In fact, progressive deletion from the carboxy 
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Table 2.1: Patient-derived NF2 mutations abrogate Merlin’s regulation of 
CRL4DCAF1 
Patient-derived NF2 mutations abrogate Merlin’s regulation of CRL4DCAF1. The 
indicated patient-derived missense and truncation mutants are defective in 
nuclear translocation, direct binding to CRL4DCAF1, suppression of CRL4DCAF1-
mediated ubiquitylation, or a combination of these mechanisms. As a result, the 
NF2-derived missense mutants are unable to interact with CRL4DCAF1 in vivo, 
permitting the dysregulated ligase to promote tumorigenesis. NT, not tested. 
Data were obtained from experiments performed by Jonathan Cooper, Wei Li, 
and Liru You (30). 
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terminus resulted in augmented binding of Merlin to the ligase. Since the isolated 
FERM domain of Merlin accumulates in the nucleus to a larger extent than the 
wild type protein, whereas the C-terminal portion of Merlin including the α-helical 
and carboxy terminal domain remains in the cytoplasm (30), it is possible that 
increased nuclear accumulation facilitates the interaction of tumor-derived 
truncations mutants with CRL4DCAF1. Although the isolated Merlin FERM domain 
binds to CRL4DCAF1 better than WT Merlin, Liru You found that the FERM domain 
did not suppress CRL4DCAF1 ligase activity in vivo as efficiently as wild type Merlin 
(Figure 2.5D), indicating that the α-helical and carboxy terminal domain 
contribute to Merlin’s inhibitory activity. These results suggest that the tumor-
derived truncation mutants of Merlin that retain the FERM domain are able to 
interact with CRL4DCAF1 but fail to suppress its activity. The observation that eight 
distinct tumor-derived mutations impair Merlin’s ability to translocate into the 
nucleus, to bind to DCAF1, or to inhibit CRL4DCAF1 activity (Table 2.1) provides 
strong genetic evidence that Merlin suppresses tumorigenesis by inhibiting 
CRL4DCAF1. 
 
2.4: Silencing of DCAF1 suppresses the tumorigenic potential of Merlin-
deficient cells 
Wei Li found that DCAF1 depletion in Merlin-deficient Meso-33 
mesothelioma cells and in the Nf2-null FC-1801 schwannoma line reduced the 
ability of these cells to grow in soft agar (Figure 2.6A-C) (30). The anti-mitogenic 
and anti-tumorigenic effect of DCAF1 depletion Merlin-deficient cells was specific 
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Figure 2.6: Silencing of DCAF1 suppresses the tumorigenic potential of 
Merlin-deficient cells 
This figure was adapted from Li et al. 2010. The experiments were performed by 
Wei Li (A-E) and Lu Zhou (F). 
(A) Meso-33 cells were infected with lentiviral vectors encoding two distinct 
shRNAs targeting DCAF1 (sh-1 and sh-2) or a control shRNA (sh-Contr.) and 
subjected to immunoblotting. 
(B) FC-1801 cells treated as in (A). Cells infected with sh-1 were also infected 
with a retroviral vector encoding a shRNA-resistant version of DCAF1 or with 
empty vector. Lysates were immunoblotted as indicated. 
(C) Meso-33 cells infected with the indicated lentiviral vectors were subjected to 
soft agar assay. The graph illustrates the total number (+ SEM) of colonies 
present in each well after 2 weeks of culture. Representative images shown. 
(D, E) 2 x 106 FC-1801 cells infected with the indicated lentiviral vectors were 
injected subcutaneously in nude mice. (D) shows the increase in volume (+ SEM) 
over time of tumors generated by cells infected with lentiviruses encoding a 
control shRNA (sh-Control) or two distinct shRNAs targeting DCAF1 (sh-1 and 
sh-2). (E) shows the increase in volume (+ SEM) over time of tumors generated 
by cells infected with sh-1 and super-infected with a retroviral vector encoding a 
shRNA-resistant version of DCAF1 or with empty vector. Data were obtained 
from the same experiment. Note the different scale of the Y axes of the two 
graphs. 
(F) Primary Schwann cells from 2 normal individuals (NF2+/+) and Schwannoma 
cells from 2 NF2 patients (NF2-/-) were infected with lentiviruses encoding a 
shRNA targeting DCAF1 (sh-2) or a control shRNA (sh-Co.), deprived of growth 
factors, re-stimulated with mitogens in the presence of BrdU, and subjected to 
anti-BrdU staining. The graph shows the percentage (+ SEM) of BrdU+ cells. 
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since the proliferation and soft agar growth of Ras- or Src-transformed 3T3 cells 
was unaffected by DCAF1 depletion (30). FC-1801 schwannoma cells express 
robust levels of DCAF1 and gave rise to large tumors in less than 4 weeks upon 
subcutaneous injection in nude mice (Figure 2.6D). Wei found that DCAF1 
silencing significantly and dramatically inhibited tumor growth in vivo. 
Overexpression of a shRNA-resistant DCAF1 construct rescued the ability of 
DCAF1-depleted FC-1801 cells to grow as xenografts, underscoring the 
specificity of DCAF1 silencing (Figure 2.6E). Compellingly, the tumors with 
overexpressed DCAF1 grew much faster than their control counterparts 
(compare the Y-axes of Figures 2.6D and E), suggesting that elevated DCAF1 
levels promotes tumorigenesis. 
To explore the clinical relevance of our findings in the context of NF2, we 
collaborated with C. Oliver Hanemann and Lu Zhou at the University of 
Plymouth, UK. They found that silencing of DCAF1 in freshly explanted NF2-
deficient schwannoma cells suppressed progression through G1 in response to 
mitogens (Figure 2.6F). Conversely, DCAF1 depletion had no effect on the 
proliferation of control human Schwann cells. Together, these results showed 
that CRL4DCAF1 is necessary for Merlin-deficient hyperproliferation, anchorage-
independent growth, and tumorigenesis. 
 
2.5: Discussion 
Prior to these studies, the underlying molecular mechanisms by which 
Merlin suppresses tumorigenesis had eluded NF2 research for nearly two 
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decades. These results revealed that dephosphorylated Merlin translocates to 
the nucleus where it binds to and inhibits the CRL4DCAF1 E3 ubiquitin ligase 
(Figure 2.7) (30). Notably, our discovery that several tumor-derived Merlin 
mutants display impaired nuclear translocation, abrogated binding to CRL4DCAF1, 
or attenuated CRLDCAF1 ligase inhibition provided compelling genetic evidence 
that CRL4DCAF1 is necessary to drive tumorigenesis in Merlin-deficient tumors. 
Wei also found that dysregulation following Merlin deficiency shifts cells towards 
an oncogenic gene expression program (30). Indeed, Merlin expression and 
DCAF1 knockdown in Merlin-deficient cells reveal that Merlin suppresses 
tumorigenesis largely through DCAF1 inhibition, providing further support that 
Merlin regulates oncogenic gene expression through its inhibition of the 
CRL4DCAF1 E3 ubiquitin ligase. 
Our experiments revealed that Merlin’s FERM domain binds the carboxy-
terminal acidic tail of DCAF1, which is outside of the WD40 domain (30). Since 
the DCAF1 acidic tail is adjacent to its WD40 domain in its primary sequence, it 
is possible that Merlin’s binding to the tail brings it in close proximity to the 
binding surface of the WD40 propeller. However, many possibilities exist to 
explain how Merlin can reduce CRL4DCAF1 activity, which is further complicated 
by the multiple protein-interacting domains within DCAF1. It is possible that 
Merlin occludes one or more of the DCAF1 targeting domains without significant 
structural perturbation. In addition to - or instead of - direct competition of target 
recruitment, Merlin’s binding may cause dramatic structural alterations, thus 
attenuating DCAF1 target recruitment. A study using Merlin’s FERM domain and 
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Figure 2.7: Active Merlin inhibits CRL4DCAF1 in the nucleus. 
Engagement of E-cadherin or loss of integrin-mediated adhesion leads to 
inactivation of PAK, promoting an accumulation of the de-phosphorylated (active) 
form of Merlin. Active Merlin enters the nucleus and inhibits the E3 ubiquitin 
ligase CRL4DCAF1, thereby suppressing the expression of multiple pro-oncogenic 
genes. 
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an isolated FERM-binding DCAF1 region confirmed that the distal carboxy-
terminal 30 residues of DCAF1 are necessary for binding to Merlin’s FERM 
domain (128), although without full-length proteins it is difficult to interpret how 
Merlin’s binding may affect DCAF1 function. Further biochemical studies and 
structural analyses will be paramount in gaining mechanistic insight into Merlin’s 
inhibition of CRL4DCAF1. 
Our study was the first to identify a nuclear binding partner for Merlin, and 
further, delineated an unusual mechanism whereby an intracellular signal hijacks 
a cortical protein to suppress oncogenic signaling in the nucleus. These findings 
motivated us to identify the downstream targets of CRL4DCAF1 to further elucidate 
Merlin’s tumor suppressive mechanism and provide a framework for mechanism 
based therapies. 
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Chapter Three 
Merlin/NF2 loss-driven tumorigenesis is linked to CRL4DCAF1-mediated 
inhibition of the Hippo pathway kinases Lats1 and 2 in the nucleus 
 
3.1: Deregulated CRL4DCAF1 induces activation of YAP 
We previously showed that Merlin regulates several Hippo pathway target 
genes through inhibition of CRL4DCAF1, raising the possibility that a Hippo 
pathway effector lies downstream of CRL4DCAF1 (30). Preliminary experiments 
performed by Wei Li revealed that Merlin expression in NF2-deficient Meso-33 
cells causef an increase in phosphorylation of YAP at S127, its major negative 
regulatory site (129). Phosphorylation of YAP at S127 causes its recruitment by 
14-3-3 proteins which sequesters YAP in the cytoplasm, thereby reducing the 
levels of YAP in the nucleus. Subsequent expression of DCAF1 partially reversed 
the inhibitory phosphorylation of YAP. Expression of DCAF1-1417X, a Merlin-
resistant DCAF1 mutant, almost completely counteracted Merlin’s inhibition of 
YAP. DCAF1 knockdown similarly increased the inhibitory phosphorylation and 
induced YAP extrusion from the nucleus in Nf2-mutant FC-1801 schwannoma 
cells. Merlin expression and DCAF1 depletion in FC-1801 causes a significant 
decrease of luciferase reporter expression for TEAD, the cognate transcription 
factor most commonly attributed to the function of the YAP and TAZ 
transcriptional coactivators. These observations showed that Merlin expression 
or DCAF1 depletion reduce YAP activity (129). Further experiments revealed that 
CRL4DCAF1 activated YAP independently of MST or Salvador, two essential 
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components of the Hippo kinase cascade. These results suggested that Merlin 
and CRL4DCAF1 may orthogonally regulate the Hippo kinases Lats1 and 2, which 
functions downstream of MST and Salvador. 
 
3.2: DCAF1 interacts with and ubiquitylates Lats1/2 in vivo 
We examined the hypothesis that CRL4DCAF1 inhibits Lats1 and 2 by 
promoting their ubiquitylation. Flag-HA-tagged DCAF1 (FH-DCAF1) associated 
efficiently with endogenous Lats1 and 2 (Figures 3.1A and B) but not with MST1 
or 2 in 293T cells (129). To further address whether flux through the Hippo 
kinase cascade affects the interaction between DCAF1 and Lats, I carried out 
immunoprecipitations using WT FH-Lats1 and phospho-resistant 
(S909A/T1079A) and phospho-mimetic (S909D/T1079D) Lats1 mutants. I found 
that both phospho-resistant and phospho-mimetic mutants precipitated HA-
DCAF1 as efficiently as WT Lats1 (Figure 3.2). I next carried out mutagenesis 
experiments to map the region of Lats1 that binds to DCAF1. I found that DCAF1 
bound the carboxy terminal kinase domain of Lats1 (Figures 3.1C and D). I then 
performed in vitro binding assays using GST-Lats1 fusion proteins and in vitro 
translated DCAF1 fragments to determine whether these proteins directly 
interact. I found that the C-terminal segment of DCAF1 interacted directly with 
the kinase domain of Lats1 (Figures 3.3A and B). Since I could not produce 
recombinant Lats2 in bacteria, I was unable to verify that the C-terminal segment 
of DCAF1 also interacts directly with the kinase domain of Lats2. However, the 
homology between the kinase domains of Lats1 and 2 suggests that this is the 
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Figure 3.1: DCAF1 interacts with Lats1/2 in vivo 
The experiment in (A) was performed by Wei Li. 
(A) and (B) 293T cells transfected with empty vector or Flag-HA (FH)-tagged 
DCAF1 were immunoprecipitated with anti-Flag and immunoblotted as indicated. 
(C) DCAF1 binds to the kinase domain of Lats1. 293T cells expressing Myc-
DCAF1 in combination with Flag-HA-Lats1 or the indicated mutants were lysed in 
RIPA buffer. Flag immunoprecipitates (M2) and total lysates were immunoblotted 
as indicated. Mouse IgG agarose was used for control (C) precipitations. 
(D) A diagram detailing the experimental results from (B), showing the 
requirement of the Lats1 kinase domain for binding DCAF1 in vivo. 
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Figure 3.2: Lats1 interacts with DCAF1 independently of its 
phosphorylation status 
Lysates and Flag immunoprecipitates from 293T cells transfected with HA-
DCAF1 and WT FH-Lats1 or the indicated phosphorylation site mutants were 
blotted as indicated. 
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Figure 3.3: The C-terminus of DCAF1 interacts with the kinase domain of 
Lats1 in vitro 
(A) Purified GST-Lats1-Cterm (residues 598-1130) precipitates in vitro 
transcribed and translated biotinylated (TnT) full-length DCAF1 but not the N-
terminal half of DCAF1. Purified GST-Lats1-Kinase domain (residues 598-1054) 
precipitates full-length and C-terminal TnT-DCAF1. As a control, TnT-DCAF1 
was subjected to pull down with GST. The GST-Lats1 precipitates and aliquots of 
TnT-DCAF1 along with respective mutants were blotted with Streptavidin-HRP. 
(B) Diagrams showing the Lats1 and DCAF1 constructs used in (A). 
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case. Since the C-terminal fragment of DCAF1 contains the WD40 domain, 
which is involved in substrate recruitment (86, 130), we hypothesized that 
CRL4DCAF1 recruits Lats1 and 2 in order to direct their ubiquitylation. 
Wei carried out experiments revealing that Lats1 and 2 are ubiquitylated in 
vivo and that while CRL4DCAF1 promoted Lats1 ubiquitylation in vivo and in vitro, 
Merlin expression largely reversed this effect (129). Moreover, Wei found that 
DCAF1 depletion significantly increased the half-life of Lats1 in cycloheximide-
treated cells, suggesting that CRL4DCAF1 targets Lats1 for proteasome-mediated 
degradation. This is consistent with the observation that Lats1 is 
polyubiquitylated in vivo (129).  
 
3.3: Merlin inhibits CRL4DCAF1 recruitment of Lats 
Our prior studies indicated that Merlin inhibits CRL4DCAF1 through its FERM 
domain to a carboxy terminal segment of DCAF1 (30). Patient-derived Merlin 
mutants lacking the central coiled-coil and carboxy terminal domains bind to 
DCAF1 but fail to suppress CRL4DCAF1 ligase activity, suggesting these segments 
are also required to inhibit ligase activity. To test whether Merlin inhibits 
CRL4DCAF1 by interfering with substrate recruitment, Wei tested whether Merlin 
expression disrupts the interaction between FH-DCAF1 and endogenous Lats1 in 
293T cells. He found that co-transfection with increasing quantities of HA-Merlin 
led to a dose-dependent decrease in the interaction between FH-DCAF1 and 
endogenous Lats1 (Figure 3.4A). To determine whether Merlin may interfere with 
Lats1 binding, I carried out immunoprecipitations to determine whether FH-Merlin 
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Figure 3.4: Merlin interacts with Lats1 and disrupts CRL4DCAF1-Lats1 
binding 
The experiment in (A) was performed by Wei Li. 
(A) 293T cells expressing FH-DCAF1 in combination with increasing quantities of 
HA-Merlin were immunoprecipitated with anti-Flag and immunoblotted as 
indicated. 
(B) Merlin’s coiled-coil/C-terminal domain binds to the Lats1 kinase domain. 
293T cells expressing HA-Lats1 in combination with Flag-HA-Merlin or the 
indicated mutants were lysed in RIPA buffer. Flag immunoprecipitates (M2) and 
total lysates were immunoblotted as indicated. Mouse IgG agarose was used for 
control (C) precipitations. 
(C) Merlin binds to the kinase domain of Lats1. 293T cells expressing Myc-Merlin 
in combination with the indicated Flag-HA-tagged Lats1 fusion proteins were 
lysed in RIPA buffer. Flag immunoprecipitates (M2) and total lysates were 
immunoblotted as indicated. Mouse IgG agarose was used for control (C) 
precipitations.  
(D) Diagram illustrates a model based on the definition of the sequence 
requirements for binding of DCAF1 to Lats and of Merlin to DCAF1. The WD40 
domain of DCAF1, which is implicated in substrate selection, binds directly to the 
kinase domain of Lats (right). Merlin binds through its FERM domain to the C-
terminal segment of DCAF1, disrupting the association of DCAF1 with Lats (left).
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and HA-Lats1 interact in vivo. Not only do FH-Merlin and HA-Lats1 interact in 
vivo, but Merlin’s FERM domain was neither necessary nor sufficient for binding 
in my experiments (Figure 3.4B). It is notable, however, that loss of the FERM 
domain causes a decrease in HA-Lats1 binding, suggesting that residues within 
the FERM domain may be necessary to promote interaction between Lats1 and 
Merlin’s coiled-coil or carboxy-terminal domains. Recent biochemical evidence 
suggests that Merlin’s FERM domain directly interacts with the amino-termini of 
Lats1 and 2 (131), suggesting that Merlin’s FERM domain is indeed important for 
Lats1 interactions. I carried out additional in vivo binding to determine that Merlin, 
like DCAF1, can bind to the kinase domain of Lats1 (Figure 3.4C). Combined, 
these results suggest that the coiled-coil and C-terminal domains of Merlin may 
occlude the binding site for Lats on the WD40 domain of DCAF1 (Figure 3.4D). 
Alternatively or in addition, Merlin may compete with DCAF1 for binding of the 
Lats kinase domain.  
 
3.4: Nuclear Merlin promotes YAP phosphorylation and inhibits 
proliferation 
Since CRL4DCAF1 accumulates predominantly in the nucleus (30), Wei Li 
examined whether Merlin needs to enter the nucleus to inactivate YAP and to 
induce proliferation arrest. Using an ERT2-Merlin fusion protein, Wei found that 
driving Merlin to the nucleus was sufficient to induce YAP phosphorylation and to 
cause a two-fold decrease in progression through G1 in NF2-mutant Meso-33 
cells (129). To determine whether Merlin’s nuclear localization is necessary to 
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induce YAP phosphorylation and reduce cell proliferation, Wei used mutation 
analysis to identify a four-residue mutant - Merlin Δ24-27 or Merlin 24-27A - 
which is completely defective in nuclear translocation. In contrast to WT Merlin, 
the nuclear localization defective mutants were highly defective in their ability to 
suppress proliferation, anchorage independent growth, or to induce YAP 
phosphorylation in Meso-33 cells (129). These mutants were still able to interact 
with the tight-junction associated protein Angiomotin, an established Merlin-
binding protein, suggesting that the deficiencies of these mutants are not due to 
gross folding defects. Combined, Wei’s experiments showed that Merlin needs to 
enter the nucleus to inactivate YAP and to suppress cell proliferation. 
 
3.5: CRL4DCAF1 inhibits Lats in the nucleus 
The core Hippo pathway components are generally considered to function 
at the cell cortex or in the cytosol (116). Lats1 and 2 were assumed to function in 
these compartments based on immunofluorescence experiments on cells 
overexpressing tagged forms of these proteins or subcellular fractionation 
experiments excluding nuclear fractions (132-134). Since active CRL4DCAF1 
exerts its pro-oncogenic function in the nucleus (30) and ubiquitylates Lats1 and 
2, we hypothesized that Lats1 and 2 also localize in the nucleus. Wei carried out 
fractionation and immunofluorescence experiments revealing that a majority of 
Lats1 and 2 are localized in the nucleus in untransformed Met5a mesothelial cell. 
Interestingly, following precipitation of endogenous Lats1 from cytosolic/crude 
membrane or nuclear fractions, Wei found that active Lats1 resides largely in the 
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nuclear fraction (129). This observation was corroborated using human liver 
epithelial cells and primary mouse fetal liver progenitor cells. Interestingly, these 
results suggest that MST or an unknown upstream kinase translocates into the 
nucleus to phosphorylate and activate Lats. 
Although Lats1 and 2 appear to localize predominantly in the nucleus in 
both sparse and confluent cells, Wei also observed that Lats1 localizes at the cell 
cortex in normal, but not NF2-mutant cells (129). Following this observation, Wei 
hypothesized that Merlin expression modifies the subcellular localization of Lats1 
in NF2-mutant cells. Indeed, transiently transfected WT Merlin localized 
predominantly at lamellipodia and membrane ruffles in Meso-33 cells and 
enhanced the recruitment of endogenous Lats1 to these compartments. Lats1 
interacts with Merlin in vivo (Figures 3.4B and C), in agreement with the recently 
proposed hypothesis that Merlin recruits Lats to the plasma membrane to 
promote its activation (132) and recent structural data showing that Merlin’s 
FERM domain interacts directly with an amino-terminal region on Lats1 and 2 
(131). 
 
3.6: Merlin does not suppress tumorigenesis from the cell cortex 
Based on our findings, I investigated the functional relevance of Merlin’s 
interaction with the Lats kinases at the cell cortex. I tested four patient-derived 
missense mutants, which fail to accumulate in the nucleus (L46R, L64P, L141P, 
and A211D), and one that enters into the nucleus but does not bind to DCAF1 
(E270G) (30). In addition, I examined the two synthetic nuclear-defective 
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mutants, Merlin 24-27A and Merlin Δ24-27. Co-immunoprecipitation analysis 
indicated that recombinant wild type Merlin combines with endogenous Lats1 
much less efficiently than with CRL4DCAF1 in an extraction buffer containing 0.5% 
Triton-X100 but no ionic detergent (Figures 3.5A and B). In addition, whereas all 
nuclear-defective and patient-derived mutants of Merlin failed to associate with 
DCAF1 in this assay, none of them exhibited reduced ability to interact with Lats1 
(Figures 3.5A and B). Similar results were obtained by using RIPA buffer 
containing 0.1% SDS (Figure 3.5C), although we note that this buffer may unfold 
the FERM domain of Merlin exposing hydrophobic segments (73). In agreement 
with these results, none of the patient-derived mutants exhibited reduced ability 
to recruit Lats1 to lamellipodia and membrane ruffles upon transient 
overexpression in Meso-33 cells (129). In contrast, they all failed to induce 
phosphorylation of YAP at Ser 127. These findings support the conclusion that 
Merlin suppresses tumorigenesis by inhibiting CRL4DCAF1, thereby stabilizing 
activated Lats in the nucleus, rather than by recruiting Lats to the plasma 
membrane. 
 
3.7: CRL4DCAF1-mediated inhibition of Lats and deregulated YAP signaling 
sustain the oncogenic properties of Merlin-deficient tumor cells 
Wei used genetic epistasis experiments to test the hypothesis that 
CRL4DCAF1 promotes tumorigenesis by inhibiting Lats1 and 2. Merlin-deficient 
tumor cells, including Meso-33 human mesothelioma and FC-1801 mouse 
schwannoma undergo a significant growth arrest upon DCAF1 depletion (30).
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Figure 3.5: Merlin does not suppress tumorigenesis from the cell cortex 
(A) 293T cells were transfected with empty vector (HA Ctrl) or Flag-HA-tagged 
Merlin (wild type or its mutants) and were lysed 24 hours later in a buffer 
containing 0.5% Triton X-100 without ionic detergent. Flag immunoprecipitates 
were washed using the same buffer. Flag immunoprecipitates and input were 
immunoblotted as indicated. 
(B) Fold enrichment of immunoprecipitated DCAF1 and Lats1 was estimated by 
densitometry of blots in (A), where enrichment is expressed as the total density 
of the immunoprecipitated bands normalized to their respective inputs. 
(C) As in (A) except using a more stringent buffer. RIPA buffer containing 0.1% 
SDS was used for cell lysis and immunoprecipitation. 
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Expression of WT Yap or YAP-5SA – a phospho-resistant and constitutively 
active YAP mutant – rescued the ability of DCAF1-depleted Meso-33 and FC-
1801 cells to proliferate (129). Moreover, YAP-5SA expression completely 
reversed the anti-tumorigenic effect of DCAF1 depletion in FC-1801 xenografts. 
Similarly, simultaneous knockdown of Lats1 and 2 rescued the ability of DCAF1-
depleted Merlin-deficient tumors to proliferate, grow independent of anchorage, 
and xenograft in nude mice. Together, these findings provided mechanistic 
evidence that dysregulated CRL4DCAF1 promotes tumorigenesis in Merlin-deficient 
cells by inactivating Lats1 and 2, thereby activating YAP (Figure 3.6). 
 
3.8: CRL4DCAF1 controls YAP/TAZ-dependent gene expression in NF2 
mutant tumors 
 Following our delineation of the mechanism by which DCAF1 promotes 
oncogenic signaling through activation of YAP in Merlin-deficient cells, we set out 
to explore the clinical relevance of our observations. I examined a panel of 11 
human malignant mesothelioma cell lines, seven of which carried inactivating 
mutations at the NF2 locus. Immunoblotting revealed that the NF2 mutant lines 
exhibited severely diminished levels of Lats1, but not Lats2, as compared to NF2 
wild type lines (Figures 3.7A and 3.7B, left). In addition, all except one of the NF2 
mutant cell lines displayed decreased phosphorylation of YAP, and 4 out of 7 
lines displayed increased expression of the YAP target gene CTGF (Figures 3.7A 
and 3.7B, right). These results are consistent with the conclusion that CRL4DCAF1 
74 
 
 
 
Figure 3.6: Merlin suppresses YAP/TAZ activity and oncogenic gene 
expression by inhibiting CRL4DCAF1 in the nucleus 
Merlin’s regulation of CRL4DCAF1 likely impinges on multiple downstream 
epigenetic mechanisms and blocks oncogenic gene expression. In contact 
inhibited cells, active Merlin translocates to the nucleus where it binds to and 
inhibits the CRL4DCAF1 E3 Ubiquitin ligase. Active or dysregulated CRL4DCAF1 
induces an oncogenic gene expression program by promoting downstream Hippo 
pathway targets via inhibition of the Lats1 and 2 kinases and through modulation 
of epigenetic modifiers and transcription factors. 
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Figure 3.7: CRL4DCAF1 controls YAP/TAZ-dependent gene expression in NF2 
mutant tumors 
(A) A panel of human mesothelioma cell lines, including Merlin-wild-type (WT) 
and Merlin-mutant, were cultured under the same condition. Lysates were 
immunoblotted as indicated. 
(B) Densitometry of Lats1 (left) and p-YAP/YAP (right) signals from blots in (A) 
was performed and plotted.**P<0.01. 
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promotes activation of YAP in malignant mesothelioma at least in part by 
increasing degradation of Lats1. 
Wei next examined whether loss of NF2 induces YAP-dependent 
oncogenic gene expression in mesothelioma patient samples by generating a 
gene expression signature that reflects CRL4DCAF1-dependent YAP activity. He 
established the gene expression signature by comparing the expression profile of 
Meso-33 cells depleted of DCAF1 or YAP/TAZ. Single knockdown of YAP or TAZ 
did not elicit a profound change in gene expression, consistent with the finding 
that only simultaneous YAP and TAZ depletion causes a proliferation arrest in 
Meso-33 to the same extent as DCAF1 loss (129). Expectedly, simultaneous 
YAP/TAZ depletion causes a significant decline in gene expression, of which 
almost 40% were similarly regulated by DCAF1. These results revealed that 
CRL4DCAF1 controls a large fraction of the YAP/TAZ gene expression program in 
NF2-mutant cells. Wei used the genes that were similarly regulated by YAP/TAZ 
and DCAF1 depletion as a signature to perform unsupervised hierarchical 
clustering of the gene expression profiles from 53 human mesotheliomas. 39 of 
these mesotheliomas harbored a mutation or genomic loss at the NF2 locus and, 
by and large, had a largely distinct gene expression program that segregated 
them from the NF2-positive mesotheliomas. Gene set enrichment analysis 
revealed that CRL4DCAF1-activated genes were highly enriched in NF2-mutant 
mesotheliomas compared with the remaining mesotheliomas. Importantly, among 
those DCAF1-activated genes, those that were also regulated by YAP and TAZ 
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were even more enriched. These data showed that CRL4DCAF1 controls YAP/TAZ-
dependent gene expression in NF2-mutant mesotheliomas (129). 
To examine the clinical relevance of our findings in NF2 tumors, we 
collaborated with Lu Zhou and C. Oliver Hanemann at the Plymouth University, 
UK, to analyze freshly explanted human schwannoma cells. Our prior studies 
showed that re-expression of Merlin or silencing of DCAF1 suppresses the 
proliferation of these cells (30). Re-expression of Merlin or DCAF1 depletion 
induced YAP phosphorylation to a similar extend in these cells, suggesting that 
CRL4DCAF1 also controls oncogenic YAP/TAZ signaling in patient-derived 
NF2-deficient schwannomas. Wei next collaborated with Matthias A. Karajannis 
and Matija Snuderl at NYU Langone Medical Center to examine Yap activation in 
40 human meningioma and vestibular schwannoma samples classified by NF2 
mutational status. Wei found that the inhibitory S127 phosphorylation of YAP was 
significantly lower in the NF2-mutant tumors as assessed by western blotting. 
Staining of formalin-fixed meningiomas revealed strong nuclear YAP expression 
in 73% of NF2-mutant samples. Overall, there was a strong positive correlation 
between nuclear YAP staining and weak/absent cytoplasmic phospho-YAP 
staining in tumors with low Merlin expression. Combined, these clinical findings 
support the hypothesis that CRL4DCAF1 inhibits Lats and thereby activates YAP in 
NF2-mutant tumors. 
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3.9: Discussion 
Drosophila genetics experiments provided strong evidence that Merlin functions 
with Ex to activate Hippo signaling (25). However, two recent landmark studies 
revealed separate, non-linear mechanisms by which Merlin promotes Hippo 
signaling. DJ Pan’s group found that Merlin could directly bind to Wts/Lats in both 
Drosophila and mammals, recruiting these proteins to the plasma membrane to 
be phosphorylated by active Mst1/2 (Figure 3.8A) (132). This study further used 
genetic experiments in mammalian cells to show that Merlin promotes 
downstream Hippo signaling independently of Mst1/2, revealing Merlin’s direct 
biochemical role in regulating the Hippo pathway. However, our findings showed 
that dysregulated CRL4DCAF1 promotes YAP function and TEAD-dependent 
transcription by ubiquitylating and inhibiting Lats1/2 in the nucleus (Fig. 3.8B) 
(129). Genetic experiments and analysis of Merlin mutations revealed that 
CRL4DCAF1-mediated inhibition of Lats1/2 sustains the tumorigenicity of Merlin-
deficient cells. Compellingly, analysis of clinical samples strongly suggested that 
this YAP- and TAZ-promoting circuit of the Hippo pathway functions in Merlin-
deficient malignancies. Furthermore, our experiments revealed that tumor-
derived Merlin mutants are invariably defective in binding to CRL4DCAF1 yet retain 
Lats1 binding, providing genetic evidence that Merlin’s interaction with Lats1 at 
the plasma membrane is not sufficient to suppress tumorigenesis. Merlin’s 
recruitment of Lats1 at the plasma membrane is an important and evolutionarily 
conserved non-canonical Hippo pathway mechanism. However, it appears that 
Merlin’s suppression of the CRL4DCAF1 E3 ubiquitin ligase is a paramount tumor 
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Figure 3.8: Cortical and nuclear models of Merlin’s regulation of Hippo 
signaling 
(A) At the plasma membrane, Merlin recruits the Lats kinases and coordinates 
their activation by Mst1, driving phosphorylation and inhibition of YAP/TAZ. 
(B) Dephosphorylated Merlin translocates to the nucleus and inhibits CRL4DCAF1, 
preventing this E3 ligase from ubiquitinating and inhibiting Lats1/2. These core 
Hippo pathway components, activated by an upstream kinase, phosphorylate 
and inactivate YAP/TAZ. 
80 
 
suppressive clamp embedded in the human Hippo pathway. In vivo insight into 
the contribution of both of these mechanisms in mammals will be an essential 
step in validating their significance in the context of normal function and 
tumorigenesis. These findings further emphasize the lack of conservation 
between the linear model for Hippo activation in Drosophila and the multifarious 
regulation of YAP and TAZ in mammals. Combined, insights over the past five 
years have shown that Merlin regulates the Hippo pathway at multiple levels, yet 
these signals seem to invariably converge to regulate YAP and TAZ activation 
(116). It will be important to determine the spatio-temporal hierarchy of Merlin’s 
effects on Hippo signaling and the importance of these pathways in 
pathogenically relevant tissues, which may unmask the most significant 
druggable targets for Merlin-deficient malignancies. 
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Chapter Four 
In vivo mouse modeling of CRL4DCAF1 function in Merlin-deficient 
Tumorigenesis 
 
4.1: Introduction 
Nf2 knockout mice succumb in utero, whereas heterozygous Nf2 mutant 
mice develop multiple malignancies, especially if an allele of p53 is 
simultaneously inactivated. The tumors arising in Nf2 mutant mice include 
hepatocellular carcinomas and osteosarcomas among others, but not 
schwannomas or meningiomas, which are the hallmark tumors of NF2 patients 
(135). This finding illustrates the differences in kinetics of loss of heterozygosity 
(LOH) between humans and mice, but also points to Merlin’s broad tumor 
suppressor function. Conditional biallelic inactivation of Nf2 in Schwann cells 
leads to Schwann cell hyperplasia and schwannoma formation (136), mimicking 
human neurofibromatosis type 2, which results from LOH at the NF2 locus (35). 
Furthermore, biallelic inactivation of Nf2 in arachnoidal cells leads to the 
formation of meningiomas, which have significant histological similarity to the 
corresponding human tumors (137). In a similar fashion, Nf2+/- mice have 
increased sensitivity to the carcinogenic effect of inhaled asbestos (138) and 
conditional deletion of Nf2 in mesothelial cells cooperates with loss of Ink4a/Arf 
and p53 to drive malignant mesothelioma (139). Conditional biallelic loss of Nf2 
in the liver was recently shown to result in hepatomegaly and formation of 
malignant tumors (140, 141). Liver-specific Nf2 deletion causes expansion of a 
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progenitor population able to differentiate at least partially along the ductal 
lineage (142) and more recent evidence suggests the cells arise from de-
differentiation of hepatocytes into a bipotential state (143). The complete 
penetrance observed in this model indicates that Merlin is a potent regulator of 
liver size and tumor suppression, and future studies using this model may 
provide great insight into Merlin’s normal biological function and role in tumor 
suppression. 
We previously found that DCAF1 is necessary for the growth of Nf2-/- 
Schwann cells injected in the rear flanks of nude mice (30). These preliminary 
results entreated investigation of the hypothesis that Merlin suppresses 
tumorigenesis in vivo through inhibition of CRL4DCAF1 using pathogenically 
relevant mouse models. I elected to use Merlin-deficient liver tumorigenesis 
models due to the pathogenic relevance in the mouse, where 10% of Nf2+/- mice 
develop liver tumors (135). I also set out to develop a genetically tractable model 
for Merlin-deficient malignant pleural mesothelioma, a disease which has a poor 
prognosis and few in vivo models to dissect its underlying genetics. 
 
4.2: Development of a Dcaf1 conditional allele 
To determine the in vivo role of CRL4DCAF1 in Merlin-deficient 
tumorigenesis, I developed a targeting strategy to conditionally delete Dcaf1 
exon 14 (Figure 4.1). Deletion of this exon, the largest in Dcaf1, truncates more 
than half of the coding region. In the unlikely event that this allele encodes a 
stable protein, it would lack its entire WD40 domain and a conserved helix-loop-
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Figure 4.1: Schematic of Dcaf1 targeting 
A targeting construct designed for the conditional deletion of Dcaf1 exon 14 is 
shown below its targeted endogenous locus. Flp recombinase-mediated excision 
of the Neo cassette was carried out to establish founder Dcaf1 conditional mice. 
Cre-mediated recombination of the conditional allele deletes exon 14 and causes 
an early stop codon in exon 15, terminating the transcript before the WD40 
domain of DCAF1. 
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helix which is necessary for interaction with DDB1 (144). Abolishing DDB1 
interaction would prevent DCAF1 from functioning within the CRL4DCAF1 ligase. I 
collaborated with the Rockefeller University Gene Targeting Resource Center 
which carried out the initial gene targeting steps in mouse embryonic stem cells 
(ESCs) and helped me design a Southern blotting strategy to identify positively 
targeted clones. Dcaf1 targeting resulted in ~5% positive clones based on the 
first round of Southern blotting (Figure 4.2A). These initial positive clones were 
subjected to a second round of Southern blotting to further assess proper 
integration of the targeting construct at the Dcaf1 locus. Blastocyst injections of 
targeted ES cells by the MSKCC Mouse Genetics Core yielded several highly 
chimeric mice which were bred with wild-type mice to obtain founders carrying 
the Dcaf1Flox allele (Figure 4.2B). These mice were then crossed with Flp-
expressing mice to excise the Neomycin cassette, thereby precluding any 
potential issues with hypomorphic function of the targeted allele which can arise 
due to defects in splicing. I developed a genotyping strategy with Peter 
Romanienko of the MSKCC Colony Management Group to differentiate between 
mice carrying the wild-type or targeted Dcaf1 allele (Figure 4.2C). To determine 
whether this conditional Dcaf1 allele directed Cre-mediated recombination at the 
Dcaf1 locus and subsequent ablation of DCAF1 protein, I isolated mouse 
embryonic fibroblasts (MEFs) from Dcaf1F/F mice. I infected these MEFs with 
control GFP-expressing lentivirus or Cre-expressing lentivirus. Immunoblotting 
DCAF1 confirmed complete loss of DCAF1 expression (Figure 4.2D).
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Figure 4.2: Confirmation of Dcaf1 targeting 
(A) Southern blot analysis using a probe specific to the Dcaf1 locus shows three 
representative positive clones obtained from targeting in mouse ES cells. 
(B) Southern blot analysis using a probe specific to the Dcaf11 locus reveal the 
presence of the targeted allele in Dcaf1F/+ founders (top) and a probe specific to 
the Neomycin cassette reveals single integration of the targeting construct in 
these mice (bottom). 
(C) Following removal of the Neomycin resistance cassette by breeding of 
DCAF1 mice with Flp mice, conditional Dcaf1 mice were bred to conditional Nf2 
mice and LSL-Luciferase (LucR) reporter mice to obtain Nf2F/F;Dcaf1F/F;LucR 
mice. A representative genotyping gel is shown to illustrate amplicons 
corresponding to the endogenous and targeted alleles of each gene. 
(D) Dcaf1F/F mouse embryonic fibroblasts infected with control lentivirus 
expressing GFP or lentivirus expressing GFP and Cre were lysed and 
immunoblotted as indicated. 
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4.3: Dcaf1 is necessary for Merlin-deficient tumorigenesis in a non-
germline genetically engineered mouse model 
To rapidly determine whether DCAF1 is necessary for the development or 
maintenance of Merlin-deficient tumors, I elected to use an orthotopic liver 
transplant model initially developed by Scott Lowe and colleagues (145). This 
model has proved to be effective in rapidly screening for tumor suppressors and 
oncogenes (146-148) and testing mechanism-based hypotheses of oncogene 
function in liver tumorigenesis (149). I isolated E13.5-14.5 bipotential fetal liver 
progenitor cells (LPCs) from Nf2Flox/Flox and Nf2Flox/Flox;Dcaf1Flox/Flox fetal livers and 
immortalized them with Cre, c-Myc, and a shRNA targeting p53. c-Myc 
expression and p53 depletion are necessary for LPC immortalization but not 
sufficient for tumorigenesis (147). I grew these cells, along with identically 
immortalized ApcFlox/Flox LPCs, in soft agar to assess their anchorage 
independent growth (Figure 4.3A). Surprisingly, Apc-/- LPCs displayed only 
modest growth in soft agar, despite APC functioning as a potent tumor 
suppressor in the mouse liver (147). Nf2-/- LPCs grew readily in soft agar, 
consistent with Merlin’s role as a tumor suppressor in the mouse (24, 135, 140). 
Importantly, Dcaf1 loss significantly reduced the ability of immortalized LPCs to 
grow in soft agar (Figure 4.3B), suggesting that CRL4DCAF1 is necessary to 
sustain oncogenic signaling in Merlin-deficient tumors. Although inactivation of 
Dcaf1 in freshly isolated and non-immortalized LPCs reduced the expression of 
CTGF, it did not increase the stability of Lats1 or the activation of YAP in both 
control and Nf2-/- non-immortalized LPCs (Figure 4.3C). These results suggest 
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Figure 4.3: Dcaf1 is necessary for the transformation of Nf2-deleted liver 
progenitor cells  
(A) Fetal liver progenitor cells (LPCs) isolated from Nf2Flox/Flox, 
Nf2Flox/Flox;Dcaf1Flox/Flox, or ApcFlox/Flox mice were transduced with Lenti-shp53-Cre 
and MSCV-Myc. These cells were seeded in soft agar and allowed to grow into 
colonies as shown. 
(B) The graph indicates the number of colonies in each well. Error bars indicate 
±SEM (n=3, **p<0.01). 
(C) LPCs isolated from Dcaf1Flox/Flox, Nf2Flox/Flox, or Nf2Flox/Flox;Dcaf1Flox/Flox mice 
were infected with Lenti-Cre. As a control, Dcaf1Flox/Flox LPCs were infected with 
Lenti-TdTomato. Total lysates from these cells were immunoblotted as indicated. 
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that CRL4DCAF1 can sustain oncogenic signaling of Merlin-deficient liver cells 
through ubiquitylation of targets independently of Lats1 and 2. These results also 
raise the possibility that CRL4DCAF1 induces expression of canonical Hippo target 
genes independently of flux through the Hippo pathway. 
I subsequently isolated LPCs from Nf2Flox/Flox and compound 
Nf2Flox/Flox;Dcaf1Flox/Flox mice also carrying a Cre-inducible Luciferase allele (LucR) 
and immortalized them using the method already described. Upon orthotopic 
subcapsular liver injection in nude mice, Nf2-/-;LucR LPCs yielded large tumors 
within one month (Figure 4.4A). Strikingly, simultaneous loss of Nf2 and Dcaf1 
completely abolished the ability of these cells to grow as tumors (Figures 4.4A-
C), providing genetic evidence that CRL4DCAF1 is necessary for the oncogenicity 
of Nf2 mutant liver cells. Notably, although the Nf2-/-;Dcaf1-/-;LucR LPCs did not 
proliferate or form tumors, bioluminescent imaging confirmed that they were still 
alive after one month, suggesting they may have undergone cellular senescence 
or quiescence. 
 
4.4: Dcaf1 deletion exacerbates hepatomegaly and liver tumorigenesis 
associated with conditional Nf2 loss 
Following the results from the non-germline genetically liver tumorigenesis 
model, I set out to determine whether CRL4DCAF1 is necessary for Merlin-deficient 
tumorigenesis in a spontaneous genetically engineered mouse model. To 
recombine conditional alleles in the liver, I used the Albumin-Cre (Alb-Cre) allele 
which directs Cre-mediated recombination in hepatocytes (150). Alb-Cre drives 
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Figure 4.4: Dcaf1 is necessary for the orthotopic growth of Nf2-/- fetal liver 
progenitors tumors 
(A) Nf2F/F;LucR and Nf2F/F;Dcaf1F/F;LucR LPCs were infected with shp53-Cre 
lentivirus and c-Myc retrovirus and implanted below the liver capsule of nude 
mice. Cell growth was monitored using bioluminescent imaging. Large tumor 
growth was evident in the Nf2-/- LPC-injected livers within 30 days. At lower 
thresholds, Dcaf1-/- LPCs were detectable throughout the experiment. A 
representative pair of mice is shown (n=5). 
(B) The average photon flux for an identically sized region of interest from the 
mice from the experiment in (A) was tracked over the course of 28 days. Error 
bars are ±SEM (n=5). 
(C) A whisker plot of average photon flux, as measured in (B), for each mouse 28 
days post-injection of LPCs. Error bars are ±SEM (n=5). Representative gross 
liver images are shown beneath respective groups. 
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Figure 4.4 (continued) 
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Cre expression parsimoniously in the fetal and neonatal liver, which is primarily a 
hematopoietic organ sparsely populated by hepatocytes. During late embryonic 
and early neonatal development, hematopoietic functions move to the bone 
marrow and the liver becomes increasingly hepatic in morphology and function. 
Within the first several postnatal weeks, the majority of the liver parenchyma is 
replaced by hepatocytes expressing Albumin, which in turn drive Cre expression 
in Alb-Cre mice (151). 
I bred Nf2F/F;Alb-Cre, Dcaf1F/F;Alb-Cre, and Nf2F/F;Dcaf1F/F;Alb-Cre mice 
and analyzed cohorts at 3, 6, 9, and 12 months to assess liver size and 
tumorigenesis. Consistent with the studies performed by the Pan and 
McClatchey groups, Nf2 deletion in the liver led to early expansion of Sox9+ bile 
duct cells or bipotential hepatobiliary progenitors (Figure 4.5) (24, 140). The liver 
weight to body weight ratio for normal mice is approximately 5% throughout adult 
life. Nf2 deletion in the liver caused a subtle increase in this ratio at 9 months and 
a more dramatic change at 12 months with livers reaching up to 25% of the total 
body mass (Figure 4.6). In agreement with prior observations (24, 140), the 
bipotential hepatobiliary progenitors and bile duct cells in the Nf2F/F;Alb-Cre livers 
arise in the within or immediately adjacent to the portal area (Figure 4.7). 
Importantly, loss of Dcaf1 did not counter the liver overgrowth phenotype elicited 
by Nf2 loss. Contrary to my predictions, loss of both Dcaf1 alleles in this context 
led to exacerbated hepatomegaly within 3 months (Figure 4.6). These changes 
were accompanied by increased Sox9+ bipotential hepatobiliary progenitors and 
bile duct cells (Figures 4.8). It was also recently reported that the Hippo pathway
93 
 
Figure 4.5: Expansion of Sox9+ bipotential hepatobiliary progenitors and 
bile duct cells in Nf2- and Nf2/Dcaf1-depleted livers at 3 months 
Serial paraffin sections from mice of the indicated genotypes were stained with 
Hematoxylin and Eosin (H&E) or immunostained for Sox9, a marker of bipotential 
hepatobiliary cells and bile duct cells in the liver. Mice were all three months of 
age at time of sacrifice. Representative images are shown at 5x magnification. 
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Figure 4.6: Nf2 loss and simultaneous Nf2/Dcaf1 loss causes hepatomegaly 
Graph shows the distribution of liver weight/body weight ratios for mice of the 
indicated genotypes at 3, 6, 9, and 12 months. Error bars indicate ±SEM 
(***p<0.0001). 
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Figure 4.7: Expansion of Sox9+ bipotential hepatobiliary progenitors and 
CK19+ bile duct cells Nf2 -depleted livers at 3 months 
Gross livers and serial paraffin sections from mice of the indicated genotypes at 
3 months were imaged. Paraffin sections were stained with H&E and 
immunostained for Sox9, Cytokeratin 19 (CK19; a bile duct epithelial cell 
marker), DCAF1, and YAP. In the Sox9 staining of WT liver, the black arrowhead 
indicates a normal bile duct with Sox9+ cells. Orange arrowheads indicate weakly 
positive Sox9+ hybrid periportal hepatocytes. CK19 staining shows differentiated 
bile duct epithelial cells. Representative microscopy images at 20x magnification 
are shown. 
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Figure 4.8: Dcaf1 deletion exacerbates the expansion of bipotential 
hepatobiliary progenitors and bile duct cells elicited by Nf2 deletion in the 
liver 
Gross livers and serial paraffin sections from mice of the indicated genotypes at 
3 months were imaged. Paraffin sections were stained with H&E and 
immunostained for Sox9, Cytokeratin 19 (CK19; a bile duct epithelial cell 
marker), DCAF1, and YAP. In the DCAF1 staining of Nf2/Dcaf1 double knockout 
liver, the black arrowhead indicate positive nuclear DCAF1 staining and therefore 
cells that escaped recombination of the Dcaf1 conditional allele. In the YAP 
immunostainings, the orange arrowheads show cells with strongly positive 
nuclear signal. 
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influences portal area zonation and profoundly affects the gene expression 
program in hepatocytes (152). Since Merlin regulates YAP activation in the liver 
(24, 132), Nf2 could abrogate normal liver zonation and induce hepatocyte de-
differentiation and/or hyperproliferation. Despite the previously observed 
decrease in S127 phosphorylated YAP and increase in nuclear YAP in Nf2-
deficient livers (24, 132), I did not observe a noticeable increase in YAP nuclear 
localization in Nf2-deficient livers as assessed by immunohistochemistry (Figure 
4.7). 
Nf2F/F;Dcaf1F/F;Alb-Cre mice were obtained at expected Mendelian ratios, 
however many did not survive into adulthood due to impaired liver function. 
Deletion of both Nf2 and Dcaf1 causes much of the liver parenchyma to be 
replaced by bile duct cells or bipotential hepatobiliary progenitors (Figure 4.8), I 
speculated that the synthetic functions of these livers are low since I observed 
early mortality in a notable fraction of these animals. The vast majority of the 
Nf2F/F;Dcaf1F/F;Alb-Cre mice died within one year, presumably due to impaired 
liver function and the presence of multifocal malignant tumors (Figure 4.9D). It 
was not uncommon for these mice to display profuse ascites (Figure 4.9E) or, 
less frequently, hemorrhagic ascites. In contrast, the majority of Nf2F/F;Alb-Cre 
mice lived for more than 12 months without ascites, despite the presence of 
tumors (Figure 4.9B). Loss of even one Dcaf1 allele exacerbated hepatomegaly 
and tumorigenesis (Figure 4.9C), although not to the same extent as the double 
knockout. These results suggested that Dcaf1 loss not only increases the 
expansion of abnormal parenchyma, but increases malignant tumor burden. Loss
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Figure 4.9: Dcaf1 deletion does not reduce hepatomegaly or tumorigenesis 
induced by Nf2 deletion in the liver 
(A) – (D) Representative livers from the mice of the indicated genotypes are 
shown. The livers were taken from mice 12 months of age, with the exception of 
(D), which was taken from a mouse at 10 months. Black arrowheads indicate 
tumor nodules. 
(E) An image taken of the mouse from (F) prior to liver extraction. The peritoneal 
cavity was filled with ascites. 
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 of Nf2 and either one or both Dcaf1 alleles led to an increase in cells with 
nuclear YAP (Figure 4.8), particularly in areas of abnormal parenchyma and 
tumorigenesis. Combined, these results suggest that Dcaf1 loss is not sufficient 
to mitigate oncogenic gene expression in Nf2-deficient liver tumorigenesis. 
Interestingly, Dcaf1 loss alone is not sufficient to overtly affect normal liver 
development. The liver from a 6-month Dcaf1F/F;Alb-Cre mouse is histologically 
unremarkable, an observation which was confirmed by Dr. Julie White, a 
comparative pathologist for the Laboratory of Comparative Pathology and the 
Genetically Engineered Mouse Phenotyping Service at Sloan Kettering Institute 
(Figures 4.10A-C). Dcaf1 deletion did not noticeably affect bile duct morphology 
(Figure 4.10E) nor YAP expression or localization as compared to wild type livers 
(compare Figures 4.10E and F with Figure 4.7). However, I noted an increase in 
the number of Sox9+ periportal hepatocytes in the Dcaf1 knockout liver which 
lacked CK19 expression, confirming that they were not of a bile duct lineage 
(Figures 4.10D and E). Notably, there was a dramatic increase in Sox9+ 
hepatocytes adjacent to nearly all discernible portal triads (Figures 4.10G and H). 
These Sox9+ periportal hepatocytes could be an expanded population of hybrid 
periportal hepatocytes, which can give rise to hepatocytes and bile duct epithelial 
cells (153). This raises the possibility that exacerbated proliferation of bile duct 
epithelial cells and bipotential hepatobiliary progenitors in Nf2F/F;Dcaf1F/+;Alb-Cre 
and Nf2F/F;Dcaf1F/F;Alb-Cre mice may be due to the expansion of the hybrid 
periportal hepatocyte niche resulting from Dcaf1 loss. 
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Figure 4.10: Dcaf1 deletion in the liver does not overtly affect organ 
morphology but induces the expansion of a periportal Sox9+ hepatocyte 
niche 
(A) Image of a 6 month Dcaf1F/F;Alb-Cre liver. 
(B)-(F) Serial sections of the liver in (A) were stained with H&E (B) or 
immunostained for DCAF1 (C), Sox9 (D), CK19 (E), and YAP (F). Representative 
images were taken at 20x magnification. 
(G) and (H) Serial sections of the liver in (A) were immunostained for Sox9 (G) or 
CK19 (H). Black arrowheads indicate bile duct epithelia. Orange arrowheads 
indicate some of the myriad Sox9+ periportal hepatocytes. These cells are not of 
a bile duct epithelial lineage as they lack CK19 expression. Representative 
images were taken at 10x magnification. 
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Figure 4.10 (continued) 
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4.5: Development of a mouse model to dissect genetics of malignant 
pleural mesothelioma 
The development of targeted therapies for malignant pleural 
mesothelioma (MPM) has been hampered by the apparent lack of actionable 
targets along the signaling pathways that are activated in this disease. Although 
about 75% of MPM carry mutations at the NF2 locus (Figure 4.11), the 
mechanism by which Merlin suppresses tumorigenesis in this tissue has 
remained, until recently, obscure. Studies in our lab revealed that loss of 
Merlin/NF2 drives the development and maintenance of MPM by activating the 
pro-oncogenic E3 ubiquitin ligase CRL4DCAF1, which in turn inhibits the Hippo 
pathway tumor suppressors Lats1 and 2 (30, 154). In light of our previous results 
and to further address the hypothesis that dysregulation of DCAF1 drives 
oncogenesis in Merlin-deficient mesothelioma, I set out to develop a Merlin-
deficient malignant pleural mesothelioma in vivo. 
Prior studies indicated that inactivation of Nf2 in combination with loss of 
Tp53 is sufficient to initiate the development of mesotheliomas bearing striking 
resemblance to human malignant mesotheliomas (139). These studies relied on 
injection of Adenoviral Cre into the pleural cavity of Nf2Flox/Flox;Tp53Flox/Flox mice. 
To establish a model of Nf2-deficient mesothelioma requiring fewer conditional 
alleles, I developed a lentivirus simultaneously encoding Cre and a miR30-based 
short hairpin targeting p53 (Figure 4.12A) (155). Injection of Lenti-shp53-Cre 
virus into the pleural cavity of a TdTomato reporter mouse revealed viral Cre-
mediated recombination of a LSL-TdTomato reporter on the visceral pleura 
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Figure 4.11: Integrated gene map showing loss of common tumor 
suppressors among 53 mesothelioma patients 
Adapted from Bott et al., 2011 (9). 
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Figure 4.12: Intrapleural injection of Lenti-shp53-Cre induces efficient loss 
of conditional alleles and knockdown of p53 
(A) A schematic of the Lenti-shp53-Cre viral vector. A short EF1a promoter 
drives expression of enhanced GFP and a miR30-based shRNA targeting p53. 
The PGK promoter drives expression of Cre. 
(B) Fluorescent dissecting microscopy was performed on lungs after intrapleural 
injection of Lenti-shp53-Cre in a LSL-TdTomato reporter mouse. 
(D) Lysates of Nf2F/F MEFs infected with the indicated lentiviruses were 
immunoblotted as indicated. 
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(Figure 4.12B). Lenti-shp53-Cre induced efficient knockdown of endogenous p53 
in Nf2F/F mouse embryonic fibroblasts (MEFs), even when p53 is upregulated 
following UV irradiation (Figure 4.12C). The virus also efficiently recombined the 
conditional Nf2 allele. Notably, injection of Lenti-shp53-Cre into the pleural cavity 
of Nf2Flox/Flox;LucR mouse resulted in the formation of thoracic neoplasia within 
four weeks following injection (Figure 4.13A). However, despite efficient in vitro 
knockdown of p53 and recombination of the conditional Nf2 allele, malignant 
tumors never developed in this model. Some of the injected mice developed what 
appeared to be tumor nodules as assessed by bioluminescent imaging, however 
their growth arrested within two months following injection of the virus (Figure 
4.13A). When I analyzed a set of animals which showed the highest signals, I 
observed a significant increase in the neoplasia size of Nf2F/F;LucR versus 
Nf2F/F;DCAF1F/F;LucR mice (Figure 4.13B). However, I emphasize that these 
were cherry-picked animals and some of the injected Nf2F/F;LucR animals 
showed little bioluminescent signal. Upon necropsy, I was not able to find any 
discernible tumor tissue in the virus-injected Nf2F/F;LucR which yielded the 
highest neoplasia signal. 
Based on these preliminary results, I speculated that more efficient 
knockdown of additional cooperating tumor suppressors may induce malignant 
pleural mesothelioma in this model. I used a tandem miRNA backbone to 
increase the knockdown efficiency of the shRNAs and include knockdown of the 
CDK inhibitor p16 and the p53 activator ARF, the protein products of Cdkn2a, 
one of the most frequently mutated genes in MPM (Figure 4.11).
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Figure 4.13: Injection of Lenti-shp53-Cre virus in Nf2 conditional mice does 
not induce malignant tumorigenesis 
(A) Injection of Lenti-shp53-Cre virus into the pleural cavity of Nf2F/F;LucR mice 
induce the growth of neoplasia within one month but growth arrested within two 
months. 
(B) The bioluminescent signal-bearing neoplastic tissue from Nf2F/F;LucR mice 
injected with Lenti-shp53-Cre was significantly higher than that of 
Nf2F/F;Dcaf1F/F;LucR animals. Graph shows bioluminescent intensity and pictures 
are representative images at 6 weeks. 
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Conditional deletion of the Cdkn2a locus, like Trp53, cooperates with Nf2 
deletion to induce tumorigenesis in germline conditional MPM models (139). I 
designed a new lentivirus encoding an enhanced miR30 backbone, called miR-E, 
which is more efficiently processed by the Drosha enzyme (156). I also designed 
this vector with a tandem miR-E cassette that directs multiplex expression of two 
shRNAs, one targeting p53 and another targeting both products of the Cdkn2a 
gene – p16-Ink4a and p19-ARF (Figure 4.14A). This virus was able to efficiently 
knockdown p16, p19, and p53 in MEFs (Figure 4.14B). Cre expression from the 
viral construct also recombined conditional alleles. However, despite these 
excellent in vitro results, this virus also failed to induce malignant tumorigenesis. 
I speculated that either incomplete knockdown or silencing of the miR30-
based shRNA was preventing sufficient depletion of the cooperating tumor 
suppressors in this model. To address this pitfall, I elected to use viral-mediated 
somatic genome engineering with multiplex CRISPR/Cas9 to permanently 
mutate cooperating tumor suppressors in Merlin-deficient MPM. The Ventura lab 
has recently used a multiplex Adenoviral CRISPR/Cas9 system to drive 
tumorigenesis in a lung cancer model with 100% penetrance (157). Following a 
similar strategy, we will induce MPM by injecting into the pleural cavity of adult 
Nf2F/F;LucR mice a dual-Adenovirus system including Adeno-Cre - to recombine 
the conditional Nf2 and LucR alleles - and a second Adenovirus - to inactivate 
Cdkn2a (Ink4a/ARF) using the CRISPR/Cas9 system. Tumor onset and 
expansion will be monitored using bioluminescent imaging. Adenovirus efficiently
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Figure 4.14: In vitro application of multiplex single-copy RNAi vector for 
simultaneous gene knockdown and Cre-mediated recombination 
(A) Schematic of a lentiviral vector encoding GFP, Cre, and tandem miR-E 
cassettes targeting Cdkn2a and p53. 
(B) Lysates of LSL-TdTomato reporter MEFs infected with the indicated 
lentiviruses were immunoblotted as indicated. Multiplex RNAi-mediated 
knockdown of both Cdkn2a and p53 is efficient, and corresponding downstream 
pathways are concomitantly downregulated. 
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infects the pleural mesothelium of mice (139), and the transient expression of the 
CRISPR/Cas9 system precludes undesired off-target effects resulting from 
extended CRISPR/Cas9-sgRNA expression. Intrapleural administration of 
Adeno-Cre and a multiplex CRISPR/Cas9-sgRNA Adenovirus into conditional 
Nf2;LucR mice can yield inactivation of six alleles or more while avoiding the long 
and inefficient breeding strategy required for germline genetically engineered 
mouse models. 
I obtained a multiplex CRISPR/Cas9-sgRNA shuttle vector from the 
Ventura lab and cloned into it guide RNAs targeting the Cdkn2a and Trp53 loci 
(Figure 4.15A). I also replaced the Cas9 cDNA with Cre in order to drive 
recombination of conditional alleles and to uncouple the guide RNAs from Cas9 
as an additional safety precaution. I transfected this sgTrp53/sgCdkn2a-Cre 
vector into Cas9-expressing LSL-TdTomato MEFs where I observed Cre-induced 
TdTomato expression in the transfected cells. I carried out a mismatch-sensitive 
endonuclease assay to detect indels within the target loci. This assay confirmed 
that the vector directs Cas9-mediated endonuclease activity and indel formation 
at the Trp53 and Cdkn2a loci (Figure 4.15B). Western blotting of these cells 
lysed one week post-transfection revealed only modest knockdown of 
endogenous p53, p16, and p19 (Figure 4.15C). After ten more days, I saw a 
positive selection for the TdTomato+ transfected cells. This observation coincided 
with positive selection of cells in which p53 and p16/p19 expression were 
abolished (Figure 4.15C). These in vitro results confirmed the efficacy of this 
construct in mediating simultaneous excision of conditional alleles and somatic 
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Figure 4.15: Development of a multiplex CRISPR/Cas9 system for somatic 
mutation of Cdk2na and Trp53 
(A) Schematic of control (a) and tumor suppressor-targeting (b and c) vectors 
driving simultaneous expression of Cre recombinase. 
(B) gDNA extracted from Cas9-expressing MEFs transfected with the vectors in 
(A) were subjected to a mismatch-sensitive endonuclease assay revealing indels 
in the Trp53 and Cdkn2a loci as indicated by cleaved amplicons. 
(C) MEFs from (B) were lysed after 7 or 17 days post-transfection and 
immunoblotted as indicated. 
(D) Proposed in vivo application of multiplex CRISPR/Cas9 system in conditional 
animals to dissect MPM genetics. 
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alterations in cooperating tumor suppressors. Viraquest produced high titer 
sgTrp53/sgCdkn2a-Cre adenovirus along with a control sgEmpty-sgEmpty-Cre 
adenovirus for in vivo application. I now plan to inject these viruses, along with 
Cas9-expressing adenovirus, into the pleural cavity of Nf2F/F;LucR mice to induce 
Merlin-deficient MPM (Figure 4.15D).  
 
4.6: Discussion 
 
4.6.1: Nf2-deficient liver tumorigenesis models 
My preliminary genetic experiments revealed that Dcaf1 is necessary to 
sustain tumorigenicity of Nf2-deficient bipotential fetal liver progenitor cells 
(LPCs). Western blotting suggested that DCAF1 does not regulate Hippo 
signaling in LPCs as it does in other Merlin-deficient cells including schwannoma 
and mesothelioma (154). These results implied that CRL4DCAF1 sustains 
oncogenic signaling in LPCs through a mechanism independent of Lats1 and 2 
inhibition. Our previous findings revealed that DCAF1 promotes oncogenic gene 
expression through alternative pathways in addition to YAP and TAZ (154). 
These findings are consistent with the notion that CRL4DCAF1 has multiple 
ubiquitylation targets which may be differentially expressed and whose signaling 
mechanisms vary between cells. 
I subsequently assessed the requirement of DCAF1 in Merlin-deficient 
tumorigenesis in the adult mouse liver using Alb-Cre to drive recombination of 
the Nf2 and Dcaf1 conditional alleles in hepatocytes. At first glance, these 
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experiments yielded overtly negative results as I observed a dramatic increase in 
hepatomegaly and tumorigenesis of compound Nf2/Dcaf1-deficient livers versus 
those with Nf2 loss alone. However, there are two factors that could explain how 
Dcaf1 loss exacerbates Nf2-deficient phenotypes in the liver. Firstly, DCAF1 
immunohistochemistry on compound Nf2/Dcaf1 knockout livers suggested the 
presence of cells escaping Dcaf1 recombination (Figure 4.8). Interestingly, 
DCAF1 has been implicated as functioning in mammalian cell competition (103, 
158). Notably, when DCAF1 was depleted, these cells underwent apoptosis and 
were extruded from the cell culture layer when they were surrounded by normal 
cells but not other DCAF1-depleted cells. If DCAF1 is also functioning in cell 
competition in the liver, it is plausible that those cells escaping recombination 
expand and outgrow. If these cells escaped recombination due to low expression 
of Albumin, such as in a periportal bipotential progenitor or a transient amplifying 
cell that lacks full hepatocytes or bile duce epithelial characteristics, then perhaps 
they are able to out-compete their neighboring cells and grow without restraint, 
resulting in hyperplasia arising from a bipotential progenitor or bile duct epithelial 
niche. I observed areas of DCAF1+ cells scattered throughout compound 
Nf2/Dcaf1 knockout livers and within their tumors, however the majority of the 
tumors appeared Dcaf1-negative. It may be possible that the “winner” DCAF1+ 
cells are initially required to establish a hyperproliferative niche which then loses 
DCAF1 expression following differentiation into (or through) an Albumin-
expressing phase. 
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 A second factor which could explain how Dcaf1 loss exacerbates Nf2-
deficient hepatomegaly and liver tumorigenesis lies in the expansion of a 
bipotential hepatobiliary progenitor niche. While loss of Dcaf1 alone did not affect 
normal liver function nor did it affect normal liver pathology, there was a notable 
expansion of Sox9+ periportal hepatocytes. Consistent with recent findings, the 
normal mouse liver has low-expressing periportal Sox9+ cells which are negative 
for the bile duct marker Cytokeratin-19 (Figure 4.7) (153). These cells 
morphologically resemble hepatocytes yet they express Sox9, indicative of a 
bipotential progenitor phenotype. Yimlamai et al. recently found that loss of Nf2 in 
hepatocytes leads to dedifferentiation into hepatobiliary progenitors - or what 
they refer to as atypical ductal cells - using lineage tracing models (143). Most 
recently, however, findings by Font-Burgada et al. revealed hybrid periportal 
hepatocytes can generate both ductal cells and hepatocytes, and moreover, can 
repopulate the damaged liver to a greater extent than normal hepatocytes or 
bipotential oval cells (153). These findings raise the intriguing possibility that Nf2 
loss in hybrid periportal hepatocytes give rise to the Sox9+ atypical ductal cells in 
this model. The Sox9+ periportal hepatocytes I observed in the Dcaf1-depleted 
liver may very well be an enlarged bipotential hepatobiliary progenitor niche. The 
expansion of this niche, which may be a target of Merlin-deficient hyperplasia 
and tumorigenesis, could then exacerbate the Nf2-deficient phenotype in the 
liver. Consistent with this hypothesis, the highly disorganized Nf2/Dcaf1 knockout 
livers are heavily populated by Sox9+ duct-like structures, of which only a fraction 
are CK19+ (Figure 4.8). This suggests that these cells are bipotential progenitors 
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not arising from a bile duct lineage. To address this hypothesis, I will need to 
definitively differentiate these populations with additional markers. 
Speculation aside, the origin of bipotential hepatobiliary cells and/or bile 
duct epithelial hyperplasia following Nf2 and Nf2/Dcaf1 loss is an outstanding 
question that is part of a broader issue in the field of liver development, 
regeneration, and tumorigenesis. The stem cell niche of the liver - a normally 
quiescent organ which has very little parenchymal cell turnover - has been a 
subject of intense research and contention in the past decade. Acute liver injury 
induces hepatocyte proliferation which can reconstitute a 70% loss in liver mass 
in a matter of weeks (159). When hepatocyte proliferation is blocked, however, 
the origin of those cells which regenerate the liver parenchyma remains elusive. 
Within this enigma may lie the origin of Nf2 and Nf2/Dcaf1-deficient 
tumorigenesis in the mouse liver, and thereby an explanation of the exacerbated 
phenotypes resulting from Nf2 and Dcaf1 deletion in the liver. However, it is 
important to note that Nf2 loss-driven tumorigenesis in the liver is more 
pathogenically relevant in the mouse. Whereas NF2 patients do not suffer to any 
significant extent from liver tumors, mice with only one functional Nf2 allele suffer 
from a wide array of malignant tumors - including those arising in the liver – due 
to differences in the kinetics of loss of heterozygosity (135). This major difference 
favors the use of a more clinically relevant model to study NF2/Merlin loss-driven 
tumorigenesis. 
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4.6.2: Nf2-deficient malignant pleural mesothelioma models 
A recent personal communication with Anton Berns corroborated my in 
vivo findings showing lentiviral shRNA-mediated knockdown of cooperating 
tumor suppressors to drive Merlin-deficient MPM is ineffective. His lab tried to 
use an almost identical approach with lentiviral-mediated knockdown of 
cooperating tumor suppressors to induce MPM in mice but found this technique 
to be insufficient to drive tumorigenesis. He assured me that the small fraction of 
p53 remaining in the infected cells following shRNA-mediated knockdown is 
sufficient to arrest growth in this model. This correspondence with Anton Berns 
reinforced my decision to develop an analogous model using CRISPR/Cas9-
mediated somatic alterations. Due to the permanent deletion of the targeted 
alleles and positive selection of Cdkn2a- and Trp53-mutated cells induced by 
sgTrp53/sgCdkn2a-Cre in vitro, I am optimistic that adenovirus expressing this 
construct will induce MPM upon intrapleural injection in conditional Nf2 mice. 
Once I am able to reliably and quickly induce MPM using this virus in Nf2F/F;LucR 
mice, I will determine whether CRL4DCAF1 is necessary for Merlin-deficient 
tumorigenesis by injecting the same virus into Nf2F/F;Dcaf1F/F;LucR mice. 
Analysis of the resulting MPM tumors will also reveal whether YAP/TAZ is 
activated and ensuing oncogenic signaling is upregulated in this model, as it is in 
human Merlin-deficient MPM (154). This in vivo MPM model, if successful, could 
provide compelling pre-clinical rationale for DCAF1 inhibition in Merlin-deficient 
MPM. Furthermore, it can serve as a pre-clinical model to test the efficacy of 
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targeted therapies in preventing the initiation and progression of a genetically-
defined MPM. 
I am developing an analogous lentiviral strategy to mediate multiplex 
somatic deletions of cooperating tumor suppressors using recently published 
methods (160). This system will allow for a flexible somatic deletion of tumor 
suppressors which can be used to rapidly model patient-derived mutations and 
test mechanistic-based hypotheses. One hypothesis that I’d like to address using 
this model is whether mutations in Lats1 and 2 in combination with cooperating 
tumor suppressors (i.e. Cdkn2a and Trp53) are sufficient to drive MPM. This 
hypothesis arises from the observation that Lats1 and 2 are mutated in MPM (9, 
161, 162), which is notable since members of the core Hippo kinase cascade are 
not significantly mutated in human cancer (27). Combined, mutations in LATS1/2 
and NF2 may comprise a very high proportion of human MPM with dysregulated 
Hippo signaling. Testing these hypotheses in vivo has been hampered by the 
difficulty of multi-allele germline mouse genetics, a hurdle for which a virus 
mediating multiplex somatic genome alterations is well suited. Exploring the 
underlying genetics and oncogenic signaling pathways activated in these MPM 
models could provide a platform to derive and test the mechanistic-based 
therapies which are required to treat this fatal cancer. 
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Chapter Five 
Mechanism-based pharmocological targeting of NF2-mutant malignancies 
 
5.1: Introduction 
Merlin has emerged as a major effector of contact inhibition and adhesion 
signaling, and is encoded by the NF2 tumor suppressor which becomes 
inactivated in the familial cancer syndrome Neurofibromatosis type 2 (NF2). Loss 
of Merlin function contributes to the development of sporadic meningiomas, 
ependymomas, and schwannomas, which are also the hallmark tumors arising in 
NF2 patients. Merlin is frequently lost in malignant pleural mesothelioma (MPM) 
and to a lesser extent in other solid tumors, implicating NF2 as a broadly 
functioning tumor suppressor (163-165). The last decade has seen notable 
strides towards elucidating the intracellular signaling underlying Merlin’s tumor 
suppressive functions. Since its discovery in 1993, we have learned that Merlin is 
a multifunctional protein which shuttles between the cell cortex and the nucleus 
in a manner reminiscent but antithetic to that of the cell adhesion and signaling 
component β-catenin (30, 164, 165). At the cell cortex, Merlin interacts with the 
scaffold and signaling protein Angiomotin to suppress mitogenic signaling 
through Rac, thereby inhibiting PAK (29). Merlin also regulates mitogenic 
signaling by suppressing mTORC1 in mesothelial and meningeal cells (18, 19). 
Interestingly, inactivation of NF2 confers sensitivity to rapalogs in bladder cancer 
and Cetuximab-resistant lung cancer, suggesting that mTORC1 signaling broadly 
sustains oncogenic signaling in Merlin-deficient cells (166, 167). 
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Recently, we discovered that the de-phosphorylated conformer of Merlin 
accumulates in the nucleus and suppresses tumorigenesis by inhibiting the Cullin 
E3 ubiquitin ligase CRL4DCAF1 (30). Depletion of DCAF1, the substrate 
recognition component of the ligase, blocked the hyperproliferation caused by 
inactivation of Merlin. Importantly, tumor-derived mutations invariably disrupted 
Merlin’s ability to enter into the nucleus, to interact with CRL4DCAF1, or to inhibit its 
ligase activity. Finally, depletion of DCAF1 inhibited the hyperproliferation of 
Schwannoma cells isolated from NF2 patients and suppressed the oncogenic 
potential of Merlin-deficient Schwannoma and mesothelioma cell lines (30). 
Intriguingly, the oncogenic program of gene expression controlled by CRL4DCAF1 
included TEAD target genes, suggesting that Merlin controls Hippo signaling by 
inhibiting CRL4DCAF1. Following up on this hypothesis, we found that de-
repressed CRL4DCAF1 targets Lats1 and 2 for ubiquitylation and inhibition in the 
nucleus and thus activates YAP-driven transcription and oncogenesis. Analysis 
of clinical samples indicated that this oncogenic pathway is consistently activated 
in human NF2 mutant mesotheliomas, Schwannomas, and meningiomas (129). 
There are few treatment options for NF2 patients and standard 
chemotherapies for MPM are ineffective. In this chapter, I set out to establish a 
mechanism-based therapy for Merlin-deficient MPM, a rare but almost universally 
fatal cancer. Multimodal therapy including surgery and chemotherapy extends 
patient survival by only a few months from the median survival of 1.5 years (168). 
Mechanism-based inhibition of the oncogenic signaling pathways underlying 
NF2-deficient tumorigenesis would be of particular value in fast-growing and 
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aggressive cancers such as MPM. During this study, I found that inhibition of 
CRL4DCAF1 using MLN4924 - a NEDD8 Activating Enzyme (NAE) inhibitor - 
sensitizes cells to traditional chemotherapy and additional mechanism-based 
therapies. By inhibiting CRL4DCAF1-mediated oncogenic signaling in combination 
with standard chemotherapy and mechanism-based therapies, we are able to 
significantly reduce the growth of NF2-deficient tumors. 
 
5.2: DCAF1 depletion reduces the growth of Merlin-deficient malignant 
pleural mesothelioma cells 
Based on our previous observation that DCAF1 depletion reduces the 
tumorigenic potential of Merlin-deficient tumors (30), I set out to test whether 
acute loss of DCAF1 reduces the growth of Merlin-deficient MPM cell lines. 
siRNA-mediated depletion of DCAF1 reduced the proliferation of Meso-33, a 
Merlin-deficient MPM line (Figures 5.1A and B). VAMT, another Merlin-deficient 
line, displayed higher dependency on DCAF1 for proliferation (Figure 5.1A). 
Since DCAF1 depletion elicited a notable reduction in proliferation within four 
days, I speculated that a therapeutic regimen of DCAF1 depletion in Merlin-
deficient tumors would induce a similar proliferation arrest. Tetracycline-inducible 
knockdown of DCAF1 using two independent shRNAs (Figure 5.1C) consistently 
reduced proliferation of Merlin-deficient MPM cells which largely correlated with 
the extent of DCAF1 depletion (Figures 5.1C and D). In light of the anti-
proliferative effects of DCAF1 depletion in these models, I hypothesized that 
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Figure 5.1: Acute DCAF1 depletion reduces the growth of Merlin-deficient 
MPM cells 
(A) Merlin deficient Meso-33 and VAMT cells were transfected with control siRNA 
or a DCAF1 siRNA SMARTpool and subjected to MTT cell proliferation assay for 
three days beginning at 48 hours post-transfection. Average values for three 
technical replicates were normalized to cells treated with a control siRNA.  
(B) Western blotting indicating efficient knockdown of DCAF1 from the same 
batch of cells in (A) 72 hours post-transfection. Cell lysates were immunoblotted 
as indicated. 
(C) Meso-33 and VAMT cell lines stably expressing TripZ vectors mediating 
doxycycline-inducible expression of control or DCAF1 shRNAs were treated ± 
doxycycline for 72 hours. Lysates were imunoblotted as indicated. 
(D) Meso-33 (left) and VAMT (right) cells from (C) were subjected to MTT 
proliferation assay for the indicated times following doxycycline administration. 
Average values for three technical replicates were normalized to that of control 
shRNA-treated cells. 
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pharmacological inhibition of CRL4DCAF1 would likewise counteract oncogenic 
signaling and hyperproliferation in Merlin-deficient MPM. 
 
5.3: NF2-mutant mesothelioma is sensitive to MLN4924-mediated CRL4DCAF1 
inhibition 
MLN4924 is a first-in-class inhibitor of NAE, blocking conjugation of 
NEDD8 to target proteins (169). Cullin E3 ligases, including CRL4DCAF1, are the 
best-characterized targets of neddylation. Neddylation of the cullin subunit at a 
conserved lysine residue promotes a conformational shift that fully activates 
ubiquitin ligase conjugating activity (91, 170, 171). While several factors influence 
the activity of E3 ligases, including the abundance of adaptor modules, many E3 
ligases display decreased ubiquitylation of target proteins upon NEDD8 depletion 
via MLN4924 treatment (172). To address whether I could acutely block 
dysregulated CRL4DCAF1 by inhibiting NEDD8 activation, I first confirmed that the 
fraction of Cul4 associated with DCAF1 is de-neddylated by MLN4924 (Figure 
5.2A). To assess whether neddylation is necessary for the ubiquitin conjugating 
activity of CRL4DCAF1, I carried out an in vivo ubiquitylation assay by transfecting 
cells with Flag-HA-tagged DCAF1 (FH-DCAF1) and Myc-tagged ubiquitin. 
Following precipitation of DCAF1, I observed a MLN4924-induced dose-
dependent decrease in the precipitation of lower weight ubiquitylated species 
(Figure 5.2B). I speculate that the higher molecular weight species which are not 
regulated by MLN4924 are likely auto-ubiquitylated DCAF1, whose conjugation 
may not depend on the conformational shift induced by neddylation of Cul4. 
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Figure 5.2: MLN4924 reduces the pool of active CRL4DCAF1 
(A) 293T cells transfected with Flag-HA-tagged DCAF1 (FH-DCAF1) were 
treated with the indicated concentrations of MLN4924 for 4 hours and then lysed 
in RIPA buffer. Input and FLAG immunoprecipitates were immunoblotted as 
indicated. 
(B) COS-7 cells were transfected with FH-DCAF1 and Myc-Ubiquitin as indicated 
and then treated with MLN4924 at the indicated concentrations for 4 hours. 
FLAG immunoprecipitates and input were immunoblotted as indicated. 
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These in vitro findings along with the well-characterized anti-tumorigenic 
activities of MLN4924 encouraged me to assess the preclinical efficacy of NAE 
inhibition in Merlin-deficient MPM as a method to inhibit dysregulated CRL4DCAF1. 
MLN4924 was particularly effective in inhibiting the growth of the rapidly 
proliferating Merlin-deficient MPM lines JMN, Meso-33, VAMT, H2052, and 
Meso-37. The slowest growing lines, Meso-9 and Meso-10, were presumably 
less susceptible to the anti-mitogenic effects of MLN4924 due to their longer cell 
cycle. The half-maximal growth inhibition (GI50) of the faster-growing Merlin-
deficient lines ranged from 0.24 to 0.56 µM with an average of 0.42 µM (Figures 
5.3A and C), whereas the Merlin-positive MPM lines 211H, H-Meso, H2452, and 
H28 had GI50 values spanning 0.13 to 1.11 µM with an average GI50 of 0.54 µM 
(Figures 5.3B and D). Notably, the immortalized but untransformed mesothelial 
cell lines Met5a and LP9 were particularly resistant to MLN4924 (Figure 5.3B), 
suggesting that MPM is more sensitive to the anti-proliferative effects of 
MLN4924 versus normal tissue. 
 
5.4: MLN4924 suppresses oncogenic signaling in Merlin-deficient cells 
In Meso-33 and VAMT cells, MLN4924 reduces Cullin neddylation within 
two hours followed by a subtle but noticeable increase in phosphorylation of YAP 
at its inhibitory phosphorylation site Serine 127 (Figure 5.4A). In VAMT, this 
leads to a notable decline in the expression of Cyr61, an established YAP 
transcriptional target. Extended MLN4924 administration halted cell-cycle 
progression as assessed by reduced Rb phosphorylation in Meso-33 and 
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Figure 5.3: Merlin-deficient MPM lines are particularly sensitive to 
CRL4DCAF1 
(A) Merlin deficient MPM lines were treated with increasing doses of MLN4924 
and subjected to MTT growth proliferation assay after 72 hours of treatment. 
Proliferation of MLN4924-treated cells was normalized to respective DMSO-
treated controls. Error bars are ±SEM (n=3). 
(B) NF2-positive/BAP1-positive MPM lines (211H and H-Meso) or immortalized 
mesothelial lines (Met5A and LP9) were treated as in (A). The immortalized but 
untransformed mesothelial lines are particularly resistant to MLN4924. 
(C) MPM lines carrying both NF2 and BAP1 mutations were treated as in (A). 
The slow growing Meso-10 line is particularly resistant to MLN4924. 
(D) MPM lines with mutated BAP1 which express Merlin were treated as in (A). 
These lines have GI50 values exceeding 1µM. 
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Figure 5.4: MLN4924 suppresses oncogenic signaling and promotes cell 
cycle arrest in Merlin-deficient MPM cells 
(A) and (B) Lysates from Meso-33 and VAMT treated with 0.5µM MLN4924 for 
the indicated times were immunoblotted as indicated. 
(C) In vivo Lats1 ubiquitylation assay. 293T cells were transfected as indicated. 
24 hours following transfection, cells were treated with the proteasome inhibitor 
MG132 for 4 hours to accumulate ubiquitylated proteins. Cells were also treated 
with the indicated µM concentration of MLN4924 for 4 hours prior to lysis in a 
denaturing buffer. Input and nickel precipitates were immunoblotted as indicated. 
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Figure 5.4 (continued) 
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reduced Histone H3 phosphorylation in both cell lines (Figure 5.4B). MLN4924 
did not consistently inhibit other oncogenic pathways in Merlin-deficient tumors 
including that of FAK, ERK, or mTORC (Figures 5.4A and B). These results 
suggested that NAE inhibition in Merlin-deficient MPM cells may reduce pro-
tumorigenic YAP signaling. I conducted a ubiquitylation assay to determine 
whether MLN4924 blocks the ability of CRL4DCAF1 to ubiquitylate and inhibit the 
Hippo pathway kinase Lats1. While Merlin expression only marginally reduced 
ubiquitylation of Lats1, MLN4924 administration caused a dose-dependent 
decrease in Lats1 ubiquitylation (Figure 5.4C). These data suggest that 
MLN4924 blocks inhibitory ubiquitylation of Lats1, thereby promoting inhibitory 
phosphorylation of oncogenic YAP. Since dysregulation of YAP-dependent 
transcription contributes heavily to the oncogenicity of NF2-mutant cells (129), 
the ability of MLN4924 to inhibit CRL4DCAF1-mediated ubiquitylation of Lats may 
represent a critical anti-tumorigenic effect. 
 
5.5: MLN4924 cooperates with chemotherapy to significantly delay Merlin-
deficient MPM tumorigenesis 
The pro-apoptotic effects of MLN4924 have been largely attributed to the 
stabilization of the replication licensing factor CDT1, thereby inducing DNA re-
replication and contributing to DNA damage and apoptosis (173, 174). Notably, 
CUL4A and CUL4B are strongly linked to the DNA damage response. Blocking 
CRL4 ligase activity disrupts nucleotide excision repair (NER) mediated by 
CRL4DDB2 and CRL4CSA, which function in global genome NER and transcription 
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coupled NER, respectively. Recently it was discovered that MLN4924 blocks Ku-
mediated DSB repair (175). Consistently, several studies have characterized 
cooperation between MLN4924 and DNA cross-linking agents (173, 176-179). I 
set out to determine whether MLN4924 synergizes with cisplatin - a platinum-
containing DNA cross-linking drug which is used in combination with the folate 
antimetabolite pemetrexed as first-line chemotherapy for MPM. Treatment of 
Merlin-deficient cells with MLN4924, cisplatin, or both resulted in DNA damage 
as shown by Chk1 and Histone H2AX phosphorylation (Figure 5.5A). While 
cisplatin induced CDT1 degradation to halt the cell cycle as a result of DNA 
damage, MLN4924 stabilized CDT1 even in the presence of cisplatin. While 
MLN4924 and cisplatin caused a comparable level of apoptosis in Merlin-
deficient MPM, the combination of the two compounds led to a synergistic 
increase in apoptosis (Figure 5.5B). To assess the efficacy of MLN4924 and first-
line chemotherapy in vivo, I assessed the anti-tumorigenic activity of these 
compounds in two Merlin-deficient MPM xenograft models – VAMT and Meso-10. 
Single agent MLN4924 therapy yielded a statistically significant delay in growth 
(Figures 5.6A and B). In both models, first-line chemotherapeutics cisplatin and 
pemetrexed modestly outperformed MLN4924. Combination therapy with 
MLN4924, cisplatin, and pemetrexed yielded the most effective growth delay, 
consistent with the synergistic apoptosis induced by MLN4924 and cisplatin in 
vitro (Figures 5.5A and B and Figures 5.6A and B). It is worth noting that Meso-
10 was highly resistant to MLN4924 in vitro as compared to the other Merlin-
deficient cell lines which were faster growing in cell culture (Figures 5.3A and C). 
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Figure 5.5: NAE inhibition cooperates with traditional MPM chemotherapy 
(A) Meso-33 and VAMT were treated with vehicle or the indicated drugs at their 
respective GI50 concentrations for 24 hours. Cell lysates were immunoblotted as 
indicated. 
(B) Meso-33 and VAMT cells were treated with vehicle or the indicated drugs at 
twice their respective GI50 concentrations for 72 hours and then subjected to an 
Annexin-5/PI apoptosis assay. Error bars indicate ±SEM (VAMT, n=3; Meso-33, 
n=2).
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Figure 5.6: Pathogenic mutations disrupt the ability of Merlin to bind to 
DCAF1 or to inhibit CRL4DCAF1 
(A) 15 x 106 VAMT cells were injected bilaterally in the rear flanks of NSG mice. 
After xenografts exceeded 100mm3, mice were treated with vehicle or the 
indicated drugs. All cisplatin treatments were 3 mg/kg (intraperitoneally, once 
every 7 days), pemetrexed treatments 100 mg/kg (intraperitoneally, once daily, 5 
days on, 2 days off), and MLN4924 treatments 90 mg/kg (subcutaneously, twice 
per day, three times per week M-W-F). A 7-day holiday was provided between 
chemotherapy regimens while the MLN4924 was administered continuously. 
Data are means ± SEM (n≥12). ***P < 0.001, unpaired T-test. 
(B) 8 x 106 Meso-10 cells were injected bilaterally in the rear flanks of NSG mice 
which were then treated as in (A). Data are means ± SEM (n≥12). ***P < 0.001, 
unpaired T-test. 
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However, Meso-10 grew nearly twice as fast as VAMT in vivo, despite it being 
one of the fastest-growing Merlin-deficient MPM lines in culture (compare Y-axes 
in Figures 5.6A and B). 
 
5.6: NAE inhibition coupled with mechanism-based therapeutics cooperate 
to delay Merlin-deficient MPM 
Our in vitro and in vivo efficacy studies revealed that MLN4924 
administration does not inhibit mTORC1 signaling in Merlin-deficient MPM 
(Figures 5.4A and B). These results suggest that DCAF1 promotes oncogenic 
signaling independently of flux through the mTORC1-PI3K signaling axis. 
Interestingly, Merlin-deficient MPM lines are significantly more sensitive to the 
cytostatic effect of Rapamycin than Merlin-positive lines (19). We rationalized 
that inhibition of DCAF1 and mTORC/PI3K signaling would inhibit two prominent 
signaling pathways sustaining MPM tumorigenesis. A serious drawback of 
Rapamycin or Rapalog use in cancer is that these compounds release mTORC1-
mediated negative feedback loops that function to restrain AKT-TOR signaling, 
leading to hyperactivation of both AKT and ERK in MPM lines (19, 180-184). 
Rapamycin blocks activation of S6K but releases feedback inhibition of IGF-1 by 
phosphorylating IRS-1 (183) whereas ERK is likely activated through loss of 
mTORC1-mediated phosphorylation and stabilization of GRB10 (184). GDC-
0980, a dual mTOR/PI3K inhibitor, blocks mTORC1 signaling without activating 
feedback by simultaneously inhibiting PI3K (185). We confirmed that GDC-0980 
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blocks mTORC1 signaling without activating Akt or ERK in several Merlin-
deficient MPM lines including Meso-33 (Figure 5.7A, Inset). Single agent therapy 
with GDC-0980 in VAMT xenografts yielded marginally higher, albeit statistically 
insignificant, efficacy relative to MLN4924 alone (Figure 5.7A). Since MLN4924 
does not inhibit mTORC1 signaling, I speculated that combination therapy with 
MLN4924 and GDC-0980 would inhibit two of the major signaling pathways 
sustaining MPM proliferation. Indeed, simultaneous GDC-0980 and MLN4924 
treatment resulted in tumor stasis (Figure 5.7A) which exceeded the efficacy of 
either single agent alone, standard first-line chemotherapy and combination 
therapy with MLN4924 (Figures 5.5C and D).  
I collaborated with the Charles Rudin lab and the Antitumor Assessment 
Core at MSKCC to obtain two MPM patient-derived xenografts (PDXs). Western 
blotting revealed that Ru19, a rapidly growing epithelioid PDX, completely lacked 
Merlin expression (Figure 5.7B, Inset). Ru19 retained expression of BAP1, a 
deubiquitinase which is frequently lost or mutated in MPM (9, 186) and other 
cancers (187, 188). In contrast, I found that the slow-growing Ru13 PDX 
expresses Merlin but is BAP1-deficient. I elected to use Ru19 as a preclinical 
Merlin-deficient MPM PDX model based on its mutational status. Ru19 grew 
sizable tumors within two weeks following subcutaneous injection in NSG mice 
(Figure 5.7B). Single agent MLN4924 and GDC-0980 induced significant tumor 
delay (P<0.01 and P<0.001, respectively). Notably, combined MLN4924 and 
GDC-0980 treatment induced tumor stasis (P<0.001) (Figure 5.7B). Combined, 
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Figure 5.7: MLN4924 combined with mTORC1/PI3K inhibition induces MPM 
tumor stasis 
The western blot in (A, Inset) was performed by Kamalika Moulick. 
(A) 8-10 x 106 VAMT cells were injected bilaterally in the rear flanks of NSG 
mice. After xenografts exceeded 100mm3, mice were treated with vehicle or the 
indicated drugs. MLN4924 treatments were 120 mg/kg (subcutaneously, twice 
per day, three times per week M-W-F). GDC-0980 treatments were 5 mg/kg 
(oral, once per day, five times per week). Data are means ± SEM (n=10). ***P < 
0.001, unpaired T-test. (Inset) Lysates from Meso-33 cells treated with 
increasing concentrations of GDC-0980 were immunoblotted as indicated. 
(B) Serially transplanted Ru19 tumors were injected unilaterally in the rear flanks 
of NSG mice. After tumors exceeded 100mm3, mice were treated as in (A). Data 
are means ± SEM (n=7). *P < 0.05, unpaired T-test. (Inset) Lysates from Ru13 
and Ru19 PDXs were immunoblotted as indicated. 
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these data suggest that dual inhibition of CRL4DCAF1 and mTORC1/PI3K 
abrogates two of the key oncogenic signaling pathways in Merlin-deficient MPM. 
 
5.7: Discussion 
As personal cancer care progresses, it has become clear that some 
tumors are less amenable to targeted therapy than others. These difficult tumors 
lack the overexpression/amplification of well-known oncogenes such as EGFR, 
and instead appear to rely upon poorly characterized signaling pathways 
resulting from deregulation of specific tumor suppressors. Malignant pleural 
mesothelioma (MPM) seems to be predominantly driven by loss of tumor 
suppressors including NF2, BAP1, and CDKN2A. Targeted personalized care for 
patients affected with MPM is therefore likely to stem from dissection of the 
oncogenic signaling ensuing secondarily to tumor suppressor loss. In Merlin-
deficient MPM, we found that dysregulated CRL4DCAF1 promotes oncogenic 
signaling through its inhibition of the Lats1 and 2 kinases, thereby activating YAP 
and TAZ (129). In this study, I found that inhibition of NAE using MLN4924 
reduces CRL4DCAF1 activity. Neddylation is required to fully activate the Cullin 
backbone of the CRL4DCAF1 E3 ubiquitin ligase, and disrupting this post-
translational modification reduces its ubiquitin conjugating activity and specifically 
reduces ubiquitylation of Lats1 in vivo. Retaining active Lats1 and 2 thereby 
inhibits YAP/TAZ and ensuing oncogenic signaling. MLN4924 also broadly 
affects CRL ligases and therefore regulates other signaling pathways (172). 
Indeed, MLN4924 induces DNA re-replication and apoptosis through inhibition of 
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CRL4CDT2 and inhibits multiple DNA damage repair pathways (144, 173-175, 
189). NAE inhibition using MLN4924 provides a targeted therapy by inhibiting 
CRL4DCAF1 but also elicits a broad chemotherapeutic effect by simultaneously 
inducing DNA damage and abrogating its repair. 
A notable observation that arose from the xenograft experiments was that 
Meso-10 is more susceptible to MLN4924 in vivo, whereas it is relatively resistant 
to the compound in vitro. This finding could be attributed to the rapid in vivo 
growth of Meso-10, where it grows at a similar rate or likely accelerated rate 
relative to VAMT - an MPM line that proliferates rapidly in culture. This finding 
may point to in vivo chemotherapeutic or mechanistic-based effects of MLN4924 
that are otherwise lacking in cell culture. The oncogenic pathways necessary for 
cell proliferation and survival in vivo may be more sensitive to NAE inhibition than 
those necessary for in vitro proliferation, supporting the need for pathogenically 
relevant tumorigenesis models. 
Our lab previously found that Merlin suppresses MPM tumorigenesis by 
regulating mTORC1 (19). mTORC1 was shown to drive proliferation in canonical 
NF2 tumors including meningioma and schwannoma (18), suggesting that 
dysregulated mTORC1 signaling broadly promotes Merlin-deficient 
tumorigenesis. Dual mTOR/PI3K inhibition significantly reduces Merlin-deficient 
MPM tumorigenesis. Combining mTOR/PI3K blockade with MLN4924 – which 
blocks dysregulated CRL4DCAF1 – abrogates two of the driving oncogenic 
pathways in Merlin-deficient MPM. When combined, MLN4924 and GDC-0980 
induced tumor stasis in the MPM line VAMT. In contrast to VAMT, the Ru19 
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MPM PDX was highly sensitive to MLN4924 and GDC-0980 monotherapies, 
suggesting that both compounds inhibit critical pathways in this cancer. 
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Chapter Six 
Discussion and future directions 
 
6.1: Merlin’s nuclear and cortical tumor suppressor functions 
The biochemical mechanisms underlying Merlin-mediated growth 
suppression are unraveling at an accelerating rate, with several critical 
observations occurring within the past five years. It is becoming increasingly 
clear that Merlin suppresses cell proliferation through two modes that are defined 
by functions at the cortex or in the nucleus. By linking Par3 to α-catenin at 
adherens junctions, Merlin promotes cell adhesions and thereby tissue 
organization in skin epithelium (60). At tight junctions, Merlin’s binding to 
Angiomotin releases Rich, which inactivates Rac and thereby attenuates 
mitogenic signaling (7, 29). As Angiomotin directly suppresses Hippo signaling in 
the cytoplasm (123, 124, 126) and promotes YAP activity in the nucleus (127), 
further insight is needed to understand the contextual relevance of these 
observations as well as how Merlin may be involved. Moreover, as α-catenin 
inhibits YAP and Wnt-β-catenin signaling, Merlin’s potential regulation of these 
pathways through interactions with α-catenin warrants investigation. In contrast 
to Merlin’s cortex-specific roles that largely influence cell junctions and Rac 
signaling, intercellular and cortical cues lead to accumulation of 
dephosphorylated Merlin, which translocates to the nucleus and attenuates 
oncogenic gene expression via inhibition of CRL4DCAF1 (30). As CRL4DCAF1 
regulates several proteins that broadly control transcription and epigenetics (100, 
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106, 108, 190), Merlin is poised to dramatically alter the expression of genes in 
response to adhesion signaling. Furthermore, Merlin’s inhibition of CRL4DCAF1 
prevents this E3 ligase from ubiquitinating and inhibitiing the Lats kinases, 
maintaining a clamp to restrict Hippo signaling to YAP (129). Along with the 
findings that Merlin recruits Lats1 at the plasma membrane to promote Hippo 
signaling, these recently discovered mechanisms link Merlin to a pathway that 
has potent affects on cell proliferation, stemness, and contact inhibition (1, 116, 
129, 132). 
Recently, it was found that genetic ablation of Merlin promotes drug 
resistance in melanoma, suggesting that loss of Merlin can drive tumor evolution 
following initial cancer-causing oncogenic insults (191). Moreover, unpublished 
preliminary findings in our lab reveal that Merlin suppresses pancreatic cancer 
metastasis in the mouse. This finding reiterates Merlin’s broad tumor suppressive 
role and highlights the need to establish Merlin’s biochemical functions in normal 
tissue and to delineate the vital pathways dysregulated in Merlin-deficient 
tumorigenesis. The signaling pathways known to be regulated by Merlin lay as a 
cornerstone for understanding Merlin’s functions in adhesion signaling and tumor 
suppression. Research to define the importance and hierarchy of these 
pathways, particularly in the pursuit of drugable targets in Merlin-deficient tumors, 
can be expected in the near future. While in vivo models will be paramount in 
identifying and alleviating pathogenic aberrations resulting from Merlin loss, 
biochemical investigations including a more detailed analysis of the inactive and 
active forms of Merlin as well as the Merlin-CRL4DCAF1 interaction will shed light 
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on Merlin’s normal function and guide the advent of therapies targeting Merlin-
deficient malignancies. 
 
6.2: Mouse models of Merlin-deficient tumorigenesis 
The development of germline mouse models to address pathogenically 
relevant Merlin-deficient tumors has been hampered by various roadblocks. 
Differences in the kinetics and tissue specificity of loss of heterozygosity in Nf2+/- 
mice leads to the development of tumors that are not seen in NF2 patients (135). 
NF2 tumors including schwannomas have been difficult to effectively model since 
they are slow-growing (136) and multiple cooperating oncogenic lesions are 
required to drive tumorigenesis in the mouse mesothelium (139). Nf2 loss in the 
liver leads to a highly penetrant and reproducible phenotype (24, 140), but 
ultimately this model is not pathogenically relevant since Merlin does not appear 
to be substantially lost in liver cancers. The development and unique 
regenerative potential of the liver adds further complexity to the interpretation of 
genetic experiments. Nf2 loss in the liver increases a bipotential hepatobiliary 
niche during early development of the liver (24), strongly suggesting genetic 
manipulations driven by Albumin-Cre are not isolated to mature hepatocytes but 
are instead shared with a population of progenitors whose origins remain elusive. 
  In order to develop a pathogenically relevant Merlin-deficient mouse 
model, I set out to induce Merlin-deficient MPM using viruses to simultaneously 
recombine conditional alleles and inhibit or delete cooperating tumor 
suppressors. Preliminary efforts using RNAi-mediated knockdown of tumor 
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suppressors was unsuccessful in vivo, presumably due to the lack of complete 
knockdown. To address this shortcoming, I developed a strategy to somatically 
mutate cooperating MPM tumor suppressor genes using virally delivered 
CRISPR/Cas9 constructs. Based on the ease and versatility of current somatic 
genome engineer approaches as well as the success of Merlin-deficient MPM 
models using compound conditional alleles (139), I am optimistic that this 
strategy will lead to a flexible and pathogenically relevant MPM mouse model to 
explore Nf2 genetics. Furthermore, this model could provide a genetically defined 
Merlin-deficient model to explore the pre-clinical efficacy of novel therapeutics. 
 
6.3: Mechanism-based therapies for Merlin-deficient malignancies 
Preliminary in vitro and in vivo experiments revealed that inhibition of 
dysregulated CRL4DCAF1 in Merlin-deficient malignancies restrains oncogenic 
signaling pathways sustaining tumor development (30, 129). I found that the 
NEDD8 Activating Enzyme (NAE) inhibitor MLN4924 blocks full activation of 
CRL4DCAF1 and suppresses its ubiquitin conjugating activity. MLN4924 blocks the 
proliferation of NF2-mutant MPM cells and significantly delays the growth of 
Merlin-deficient MPM xenografts. Traditional front-line chemotherapy with 
cisplatin and pemetrexed cooperates with MLN4924 in tumor killing, in part 
through inducing DNA damage in cells where MLN4924 has abrogated DNA 
repair pathways. MLN4924 cooperates more extensively with the dual 
mTOR/PI3K inhibitor GDC-0980, revealing that inhibition of two key oncogenic 
signaling pathways in NF2-mutant MPM shows extraordinary pre-clinical efficacy. 
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For the vast majority of patients, MPM is a death sentence. Traditional 
chemotherapy extends patient survival by only a matter of months. The 
observation of tumor stasis in a Merlin-deficient MPM PDX is quite remarkable, 
and raises a very real possibility for clinical trials. Notably, MLN4924 is in Phase I 
clinical trials while GDC-0980 is already in Phase II trials. Newer mTOR inhibitors 
and second generation NAE inhibitors may also soon be available, although a 
combined therapy trial with MLN4924 and GDC-0980 is closer to fruition since 
both drugs are already in the clinic. 
 It will be important to address the role of mechanism-based therapeutics in 
other Merlin-deficient tumors such as thyroid carcinoma, renal carcinoma, 
gliomas, as well as canonical NF2 tumors including schwannomas, 
meningiomas, and ependymomas. NF2 tumors are mostly slow growing and may 
be far less susceptible to the chemotherapeutic effects of MLN4924 or the 
proliferation-inhibiting effects of GDC-0980. Tumor onset in NF2 often occurs 
during adolescence or early adulthood. It may be particularly difficult for young 
patients to tolerate these drugs, particularly in a combination therapy that is more 
likely to cause toxicity. Additionally, drugging NF2-mutant intracranial tumors - 
such as glioblastomas - faces the added complexity of surpassing the blood-
brain barrier. GDC-0980 unfortunately has low brain penetrance, although a 
derivative of the compound was optimized for brain penetrance and could be a 
viable alternative in this case (192, 193). While the brain penetrance of MLN4924 
has not been directly tested, its ability to pass the blood-brain barrier was inferred 
based on its low molecular weight and high lipid solubility (194). 
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As the predominant oncogenic signaling pathways regulated in NF2-
mutant malignancies and patients are uncovered, we will be better able to tailor 
rational mechanism-based therapies. Although NF2-related tumors and early 
stage Merlin-deficient mesotheliomas are particularly difficult to treat, these 
tumors tend to be non-metastatic. Since these cancers are limited to the primary 
site, they are genetically homogenous relative to disseminated metastatic 
cancers and patients receiving mechanism-based therapies are more likely to 
respond effectively to treatment. CRL4DCAF1 controls a large portion of the 
oncogenic gene expression in Merlin-deficient tumors (30, 129) and therapies 
targeting CRL4DCAF1 or its most pertinent downstream oncogenic effectors in 
these cases may elicit a strong clinical outcome. 
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Chapter 7 
Materials and methods 
 
7.1: Materials 
 
7.1.1: Antibodies 
 See Table 7.1 for antibodies used in these studies. The DCAF1 antibody 
produced in our lab was described in (30). The Myc 9E11 antibody used was 
produced in the Sloan Kettering Monoclonal Antibody Core Facility. 
 
7.1.2: Cell lines 
 Human mesothelioma cell lines 211H, H2452, H28, H-Meso, JMN, Meso-
9, Meso-10, Meso-37, VAMT, and H2051 were cultured as previously described 
(19). LP9 and Met5A immortalized mesothelial cells and Merlin-deficient 
mesothelioma Meso-33 cells were cultured in MCDB 110:199 Earle’s 
supplemented with EGF (10 ng/ml, Invitrogen #PHG0311), Hydrocortisone (50 
µg/ml, CalBioChem #3867), ITS (1%, Invitrogen #I2521), antibiotics (1%, Gemini 
Bio # 400-101), Fetal Bovine Serum (FBS, 15%, Invitrogen #10437-028), and L-
Glutamine (2 mM, Invitrogen # 25030-081). LP9 and Met5a were also cultured in 
RPMI 1640 supplemented with 10% FBS, antibiotics, and L-Glutamine. COS-7, 
293FT, AND 293T cells were cultured in DMEM-HG supplemented with 
antibiotics, 10% FBS, and L-Glutamine. To generate FC-1801 Nf2-/- mouse 
Schwannoma cells, primary mouse Schwann cell cultures from E12.5 Nf2Flox/Flox 
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Table 7.1: Antibodies 
Antigen Product Company Application 
β Actin A3376 Sigma WB 
BAP1 SC-28383 Santa Cruz WB 
CDT1 8064 Cell Signaling WB 
Chk1 SC-8408 Santa Cruz WB 
p-Chk1 Ser345 2348 Cell Signaling WB 
Cytokeratin 19 TROMA-III DSHB IHC, 1.2 µg/ml 
Cre MAB3120 Millipore WB 
CTGF SC-14939 Santa Cruz WB 
Cyr61 SC-13100 Santa Cruz WB 
DCAF1 In-house In-house WB 
DCAF1 14966 Cell Signaling WB, IHC (7.5 µg/ml) 
DDB1 A300-462A Bethyl WB 
Erk2 SC-154 Santa Cruz WB 
p-Erk Thr202/Tyr204 9106 Cell Signaling WB 
FAK 05-537 Millipore WB 
p-FAK Tyr397 44624G Invitrogen WB 
GFP 1814460 Roche WB 
HA MMS-101R Covance WB 
p-H2AX Ser139 2577 Cell Signaling WB 
p-Histone H3 Ser10 9701 Cell Signaling WB 
Merlin SC-332 Santa Cruz WB 
Merlin ab88957 Abcam WB 
Merlin 12888 Cell Signaling WB 
Myc clone 9E11 In-house WB 
NEDD8 1571-1 Abcam WB 
p16 SC-1207 Santa Cruz WB 
p19 7543 Millipore WB 
p21 SC-6246 Santa Cruz WB 
p53 2524 Cell Signaling WB 
p70S6K 2708 Cell Signaling WB 
p-p70S6K Thr389 9206 Cell Signaling WB 
RhoGDI SC-360 Santa Cruz WB 
Rb 554136 BD WB 
p-Rb Ser807/811 9308 Cell Signaling WB 
S6 Ribosomal Protein SC-74459 Santa Cruz WB 
p-S6 Ser240/244 2215 Cell Signaling WB 
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Table 7.1 (continued) 
Antigen Product Company Application 
SOX9 AB5535 Millipore IHC (0.5 µg/ml) 
TdTomato (dsRed) 6324 Clontech WB 
Tubulin T6074 Sigma WB 
Biotin (Strep-HRP) RPN1231V Sigma WB 
YAP 4912 Cell Signaling WB 
YAP 12395 Cell Signaling WB 
YAP 14074 Cell Signaling WB, IHC (0.05 µg/ml) 
p-YAP Ser127 4911 Cell Signaling WB 
Lats1 3477 Cell Signaling WB 
Lats2 5888 Cell Signaling WB 
Lats2 13646 Cell Signaling WB 
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embryos were infected with adenoviral Cre (Ad5CMVCre, University of Iowa 
Gene Transfer Vector Core, Iowa City, IA, USA) and immortalized in vitro (195). 
Human schwannoma cells were kindly provided by NF2 patients after informed 
consent. Primary human Schwann cells and schwannoma cells were isolated 
and cultured as previously described (15). E13.5 fetal liver progenitor cells 
(LPCs) were isolated from conditional mice as described previously (149). LPCs 
were immortalized using retrovirus expressing MSCV-Myc (generously provided 
by Scott Lowe) and pHAGE-GFP-shp53-Cre lentivirus described below. Cas9-
expressing MEFs were produced by infecting them with lentivirus produced from 
lentiCas9-Blast (Addgene #52962). Unless otherwise indicated, experiments 
were performed on cells grown to 70-90% confluency in complete medium. 
 
7.1.3: Mice 
Animal studies were conducted in accordance with protocols approved by 
the Institutional Animal Care and Use Committee of MSKCC. Drug efficacy 
experiments using xenografts were managed by Elisa de Stanchina and 
performed by Qi Li at the Sloan Kettering Antitumor Assessment Facility. Sub-
capsular liver injections of LPCs were carried out in collaboration with the 
Antitumor Assessment Facility essentially as described previously (149). 
Albumin-Cre mice were obtained from The Jackson Laboratory (Stock 003574). 
Nf2Flox/Flox mice were obtained from Tyler Jacks. LSL-Luciferase and LSL-
TdTomato mice were a generously provided by Scott Lowe. These alleles were 
originally obtained from The Jackson Laboratory and backcrossed to B6. 
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The Dcaf1 conditional allele was produced in collaboration with the 
Rockefeller University Gene Targeting Resource Center and the Sloan Kettering 
Transgenic Mouse Core. With preliminary help from Laetitia Kasprzyk, I designed 
a targeting construct based on pKOII from Nabeel Bardeesy. The pKOII-Dcaf1 
targeting construct comprises a deletion region consisting of exon 14 of Dcaf1 
(VprBp) flanked by LoxP sites for Cre-mediated recombination and distal long 
and short arms of homology with a 3’ Diptheria Toxin (DT) cassette. An additional 
5’ DT cassette was provided by Willie Mark and was PCR cloned between the 
AatII and NotI sites. A long arm of homology comprising 7295 bp and 
corresponding to genomic sequence 28228-35522 was PCR cloned from mouse 
BAC clone RP23-201C3 between NotI and SalI. The 5’ LoxP site was cloned in 
between XmaI and SmaI. The deletion region comprising 1890 bp corresponding 
to genomic sequence 35523-37412 was cloned from CY2.4 mouse genomic 
DNA between SacII and BamHI. The short arm of homology comprising 4632 bp 
corresponding to genomic sequence 37413-42022 was also PCR cloned from 
CY2.4 mouse DNA between XhoI and KpnI. The final construct was transformed 
into STBL2 bacteria and analyzed by restriction analysis for plasmid integrity. 
pKOII-Dcaf1 was linearized using AatII prior to ES cell electroporation. 
Electroporation, clone isolation, and initial screening was performed by Ekatarina 
Zafranskaia at the Rockefeller University Gene Targeting Resource Center 
directed by Chingwen Yang. With help from Chingwen Yang and Peter 
Romanienko, I designed a Southern blotting strategy to confirm 3’ homologous 
recombination using a probe hybridizing to Dcaf1 bp 44,423-45,656 on genomic 
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DNA digested with BglI. The expected hybridized DNA fragment size was 17.3 kb 
for the WT allele and 8.4 kb for the successfully targeted conditional allele. I 
designed a second strategy to confirm 5’ homologous recombination using 
probes hybridizing to Dcaf1 bp 25604-26083, 25674-26024, or 25254-25491 on 
genomic DNA digested with EcoRI. Expected hybridized DNA fragment size was 
26 kb for the WT allele and 12.5 kb for the successfully targeted conditional 
allele. Positively targeted clones were further confirmed using a probe hybridizing 
the Neomycin cassette. Positive clones were injected into albino blastocysts by 
the MSKCC Mouse Genetics Core. Highly chimeric mice were used to produce 
founders which were then crossed with Flp mice to remove the Neomycin 
cassette. Loss of the Neomycin cassette was confirmed by genotyping. Dcaf1F/F 
mice were bred to homozygosity without issue and confirmed using genotyping 
primers amplifying genomic DNA between bp 35,285-35,575: 
Forward primer 5’-ACTTTTAGCCCAAGCTTGCCTT-3’ 
Reverse primer: 5’- GGCATCAAGCCTAAGAACTGACA-3’ 
The WT allele yielded a band of ~300 bp, the conditional allele yields a band of 
~400 bp. Dcaf1F/F mice were kept in a stably breeding colony and sperm from a 
confirmed fertile male was frozen for long-term storage. 
 
7.1.4: Plasmids 
To generate a vector encoding Merlin bearing an amino-terminal Flag-HA 
tag, a cDNA encoding the Flag peptide was subcloned upstream of the 
sequences encoding the HA tag in pXJ40-HA-Merlin and the resulting cDNA 
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encoding Flag-HA-Merlin was subcloned in pRK5. To generate point mutations in 
Merlin, the resulting expression vector, pRK5-FH-Merlin, was subjected to site-
directed mutagenesis using the Quickchange mutagenesis Kit (Stratagene). To 
generate pRK5-Merlin-FH, which encodes Merlin bearing a carboxy-terminal 
Flag-HA tag, PCR products encoding Merlin and the Flag-HA tag were subcloned 
in pRK5. pRK5-Myc-DCAF1 was constructed by subcloning a cDNA encoding 
human DCAF1 (ATCC) in pRK5-Myc. To generate pRK5-FH-DCAF1, we 
replaced the sequences encoding the Myc epitope in pRK5-Myc-DCAF1 with 
sequences encoding the Flag-HA tag. His-Myc-Ubiquitin was generously 
provided by Michele Pagano (Department of Pathology, NYU School of Medicine, 
New York, NY). pHA-Ub was described previously (196) and was generously 
provided by Pengbo Zhou (Pathology and Laboratory Medicine, Weill Cornell 
Medical College) 
Constructs encoding truncation mutants of DCAF1 were generated by 
subcloning PCR products of a cDNA encoding human DCAF1 in pRK5-Myc and 
pRK5-FH. Retroviral vectors encoding FH-DCAF1 and mutants thereof were 
generated by subcloning the corresponding cDNAs in pBabe-hygro. Lentiviral 
vectors encoding Merlin-WT and Merlin-L64P were generated by subcloning the 
corresponding cDNAs in pLenti6/V5-D-TOPO (Invitrogen). pcDNA3-Myc-Lats1 
and pcDNA3-Myc-Lats2 were generously provided by DJ Pan. To generate a 
vector encoding Lats1 or Lats2 bearing an amino-terminal HA or Flag-HA tag, the 
cDNA encoding Lats1 or Lats2 from the above pcDNA3 constructs was 
subcloned downstream of the sequences encoding the HA or Flag-HA tag in 
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pRK5-HA or pRK5-Flag-HA vector. Site-directed mutagenesis was used to 
generate phosphorylation site mutants of Lats1. Constructs encoding truncation 
mutants of DCAF1 and Lats1 were generated by subcloning PCR products of a 
cDNA encoding human DCAF1 or human Lats1 from the above vectors in pRK5-
Myc, pRK5-FH, or pGEX vectors. 
pHAGE-GFP-miR30-Cre and pHAGE-GFP-miRE-Cre vectors containing 
shRNAs targeting Renilla luciferase (control), p53, and p16/p19 were cloned from 
a parental pHAGE vector kindly provided by Jae Shim of Weill Cornell Medical 
College. Briefly, a miR30 or miRE cassette provided by the Scott Lowe lab at 
MSKCC was cloned into pHAGE-GFP upstream of the GFP cDNA between a 
SalI and MluI site. A PGK promoter was cloned between MluI and NheI. Cre was 
cloned between NheI and NdeI. To insert miR30-based shRNAs into this vector, 
the entire miR30 cassette containing the shRNA from a MLP vector (Scott Lowe 
lab) was cut out with XhoI and MluI and cloned into the linear pHAGE-GFP-
miR30-Cre vector cut with the same enzymes. The pHAGE vectors carrying 
tandem shRNAs were designed based on a tandem-miRE MLP vector (MLPtE) 
with help from Chun-Hao Huang of the Scott Lowe lab. A miRtE cassette 
containing a shRNA of interest could be cut out of MLPtE with SbfI and MluI and 
cloned into the recipient miRtE-containing plasmid (either MLPtE or pHAGE-
miRtE-Cre) digested with BstXI and MluI. 
pX33Cre was cloned by swapping out Cre in place of Cas9 in pX333 
(Addgene #64073). sgRNAs targeting Trp53 and Cdkn2a were cloned into 
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pX33Cre in the same manner as for pX333, as described previously (157). 
sgRNA sequences were as follows:  
sgCdkn2a: 5’-TGCGATATTTGCGTTCCGCTGGG-3’ 
sgTrp53: 5’-GACCCTGTCACCGAGACCCCTGG-3’ 
 
7.1.5: Compounds 
MG132 was obtained from Calbiochem (#474790), solubilized in DMSO, 
and used at a working concentration of 10-25 µM. MLN4924 was generously 
provided by Takeda Pharmaceutical Company and solubilized in DMSO for in 
vitro experiments or 10% Captisol for in vivo experiments. GDC-0980 was 
generously provided by Genentech and was solubilized in DMSO for in vitro 
experiments or 0.5% methylcellulose with 0.1% Tween-80 for in vivo 
experiments. Cisplatin was obtained from the Sloan Kettering Pharmacy and 
solubilized in saline for in vivo experiments or from Sigma and solubilized in DMF 
for in vitro experiments. Pemetrexed (Alimta) was obtained from the Sloan 
Kettering Pharmacy and solubilized in saline for in vivo experiments. 
 
7.2: Methods 
 
7.2.1: Apoptosis assay 
Meso-33 and VAMT treated with cisplatin and MLN4924 were subjected to 
a Annexin-V/PI apoptosis assay using the Annexin V : FITC Apoptosis Detection 
Kit II (BD #556570) according to manufacturer’s instructions. Annexin V- and PI-
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positive cells were determined using FACS by the MSKCC Flow Cytometry Core 
Facility using a BD FACSCalibur Cell Analyzer. 
 
7.2.2: Bioluminescent imaging 
 Mice were anesthetized using isoflurane and injected retro-orbitally with 
1.5 mg (75 mg/kg) of D-luciferin. Animals were imaged in an IVIS 100 chamber 
within 5 minutes of luciferin injection and data were collected using Living Image 
software from Xenogen. To calculate average photon flux, a circular region of 
interest encompassing the pleural cavity was measured. Background 
luminescence was subtracted. 
 
7.2.3: BrdU incorporation assay 
Unless otherwise indicated, Meso-33 and Met5A cells were plated at 2.5 x 
104 per cm2 on fibronectin-coated coverslips and were deprived of growth factors 
for 24 hours. They were then incubated with complete medium supplemented 
with BrdU for 24 hours. After fixation with 100% cold methanol, cells were stained 
with BrdU Labeling and Detection Kit I (Roche). When indicated, cells were lysed 
in SDS-boiling buffer (10 mM Tris ph 7.5, 1% SDS, 50 mM NaF, 1 mM NaVO4) 
and subjected to SDS-PAGE and immunoblotting. 
 
7.2.4: Gene expression and silencing 
Transient transfections in COS-7 and 293T were performed using 
Lipofectamine 2000 or Oligofectamine (Invitrogen). MEFs and Meso-33 were 
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transfected using the Lonza HUVEC Nucleofector Kit and Amaxa Nucleofector 
Device with program A-034. Retroviral and lentiviral vectors encoding 
recombinant proteins or shRNAs targeting Merlin (#1: RHS3979-97079645 and 
#2: RHS3979-97079647 from Open Biosystems) or DCAF1 (#1: 
TRCN0000129909; #2: TRCN0000129831 from Open Biosystems) were 
generated as previously described (197). DCAF1 GIPZ miR30-based shRNAs 
were obtained from Dharmacon (#1: V2THS_255610; #2: V2THS_74081) and 
subcloned into pTRIPZ along with a non-targeting control shRNA. Cells were 
incubated with infectious particles in the presence of 10 µg/ml Polybrene (Sigma) 
overnight. After recovery in complete medium for 24 hours, Meso-33 cells and 
FC-1801 cells were placed under selection medium containing 2 µg/ml 
puromycin, 200 µg/ml hygromycin, 500 µg/ml G418, or 10 µg/ml blasticidin. 
Meso-33 and Met5A cells were transfected with 75 pmol of ON-TARGETplus 
SMARTpool against DCAF1 or ON-TARGETplus siCONTROL Non-targeting 
pool (Dharmacon). 
 
7.2.5: GI50 calculations 
 GI50 values were calculated based on the 72-hour growth of cells in 96-
well plates following DMSO or MLN4924 treatment as assessed by MTT assay 
(ThermoFisher #M6494). Fresh media containing DMSO or MLN4924 was 
replaced daily. Drug-treated samples were normalized to DMSO-treated controls. 
Data from three biological replicates with three technical replicates each were 
used to derive a nonlinear regression curve using GraphPad Prism software. The 
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IC50 value for each curve was established using the dose-response equation 
log(inhibitor) vs. response – Variable slope (four parameters). 
 
7.2.6: GST pull down assay 
GST fusion proteins containing the FERM domain of Merlin and mutants 
thereof (WT, L46R, F62S, L64P, L141P, G197C, A211D, E270G) were 
expressed in BL21 (DE3) competent cells (Invitrogen C6000-03) and purified 
from lysates using glutathione-Sepharose 4B beads (GE Healthcare 17-0756-
01). A TnT SP6 High-Yield Expression System (Promega L3261) was used to 
transcribe and translate DCAF1 in the presence of biotinylated lysine tRNA 
(Promega L5061). Ten µl of the TnT reaction, containing less than or equal to 1 
µg of DCAF1, was diluted in 0.5 ml of Binding Buffer (20 mM Tris pH7.5, 100 mM 
NaCl, 2 mM EDTA, 10% Glycerol, 0.05% NP-40, 0.5 mM DTT, and protease 
inhibitors) and incubated with 0.5 µg, 1 µg, or 2 µg of each GST-FERM fusion 
protein immobilized on Sepharose-Glutathione for 2 hours at 4°C. After washing 
with Binding Buffer, the samples were analyzed by SDS-PAGE and 
immunoblotting. GST fusion proteins containing Lats1 residues 598-1054 (GST-
Lats1-Kinase Domain) or 598-1130 (GST-Lats1-Cterm) were expressed and 
purified in the same manner. The same expression system was used to 
transcribe and translate DCAF1 or Merlin in the presence of biotinylated lysine 
tRNA. 10 µl of the TnT reaction, containing less than or equal to 1 µg of DCAF1 
or Merlin, was diluted in 0.5 ml of Binding Buffer and incubated with GST-Lats1 
fragment fusion protein immobilized on Sepharose-Glutathione for 2 hours at 
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4°C. After washing with Binding Buffer, the samples were analyzed by SDS-
PAGE and immunoblotting. 
 
7.2.7: Immunohistochemistry 
 Immunohistochemistry protocols for DCAF1, YAP, Cytokeratin 19 (CK19), 
and Sox9 were optimized in collaboration with Afsar Barlas at the MSKCC 
Molecular Cytology Core. Immunostaining was performed on 4% 
paraformaldehyde-fixed paraffin-embedded tissue on a Ventana Benchmark XT 
automated immunohistochemistry instrument. Antibody catalog numbers and 
working concentrations are shown in Table 7.1. For YAP, DCAF1, and Sox-9, 
primary antibody was incubated for 5 hours and secondary antibody (7.5 µg/ml 
biotinylated goat anti-rabbit IgG, Vector Labs #PK6101) was incubated for 1 
hour. CK19 primary was incubated for 6 hours and secondary antibody (1:200 
biotinylated rabbit anti-rat IgG, Vector Labs #BA-4000) was incubated for 52 
minutes. 
 
7.2.8: Immunoprecipitation and immunoblotting  
  293FT or 293T cells in 6-well plates were transiently transfected with 1 μg 
of pRK5 plasmids expressing tagged DCAF1 and 1 μg of pRK5 plasmids 
expressing tagged Lats1 or Lats2 using Lipofectamine 2000 (Invitrogen) or 
Polyethylenimine (PEI) and were lysed 24 hours later with RIPA buffer or RIPA 
buffer without SDS as indicated. To isolate Flag-HA-DCAF1, extracts were pre-
cleared with Mouse IgG-Agarose (Sigma A0919) for one hour and then incubated 
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with anti-FLAG M2 Affinity Gel (Sigma) at 4°C for 2 hours. Immunoprecipitates 
were washed three or four times with RIPA buffer or RIPA buffer without SDS as 
indicated, and bound proteins were dissociated in 20 µL 1x SDS sample buffer 
(25 mM Tris pH 6.8, 4% SDS, 5% Glycerol, bromophenol blue). Eluted proteins 
were separated on 4-12% Bis-Tris SDS-PAGE gels (Invitrogen) and transferred 
to nitrocellulose or Immobilon-P membranes (Millipore). Membranes were 
incubated in blocking buffer (5% skim milk, 0.1% Tween, 10 mM Tris at pH 7.6, 
100 mM NaCl) for 0.5-1 hour at room temperature and then with primary 
antibodies diluted in blocking buffer for another hour at the same temperature or 
overnight at 4°C. After three washes, the membranes were incubated with goat 
anti Rabbit HRP-conjugated antibody (1:10,000; Santa Cruz sc-2054) or goat 
anti-mouse HRP-conjugated antibody (1:10,000; Santa Cruz sc-2005) at room 
temperature for 1 hour and subjected to chemiluminescence using ECL (Pierce 
#1856136). When indicated, cells were lysed in SDS-boiling buffer (10 mM Tris 
pH 7.5, 1% SDS, 50 mM NaF, 1 mM NaVO4) and subjected to SDS-PAGE and 
immunoblotting. 
 
7.2.9: Intrapleural injections 
 Intrapleural injections of lentivirus were carried out as described previously 
(198). The mouse was anesthetized using isoflurane and the right side was 
shaved from hind limb to forelimb to expose the ribcage. The fully anesthetized 
mouse was placed on its left side with the right side of the ribcage facing 
upwards and made slightly convex by placing a small tube or other small object 
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underneath the mouse. A 1 cm incision was made through the skin exposing the 
ribcage at the level of the diaphragm where the border between the liver and 
lungs can be clearly identifited. Scissors or forceps were used to gently spread 
the connective tissue surrounding the incision to allow for access and 
visualization of the injection site. Counting two to three ribs above the liver/lung 
border, a insulin syringe was inserted between the ribs resting on the top of a rib 
at an angle of ~40° towards the head of the animal. The syringe was inserted 
when the animal exhaled so that the lungs receded from the chest wall and the 
syringe was less likely to puncture the lung. After pushing the syringe into the 
pleural cavity, the needle head was quickly but smartly angled upwards so as to 
avoid piercing the lung. Immediately after positioning the needle head, the 
plunger of the syringe was carefully pushed down to inject ~250 µl of virus 
concentrate in ~3-5 seconds. A successful injection was often accompanied by a 
distinct fluttering motion of the lung, presumably due to the pressure differential 
introduced by the addition of liquid into the pleural cavity. 
 
7.2.10: Lats in vivo ubiquitylation assay  
293T cells in 6-well plates were transfected using Lipofectamine 2000 
(Invitrogen) with 1 µg of pHis-Myc-Ub and 0.5 µg of pRK5-HA-Lats1, 1 µg of 
pRK5-Myc-DCAF1, and 0.25 µg pRK5-Myc-Merlin. Cells were treated with 10 µM 
MG132 for 4 hours and ±MLN4924 at the indicated concentrations before 
harvest. 24 hours after transfection, cells were scraped into cold PBS and 10% of 
the sample was lysed in SDS lysis buffer and reserved for immunoblotting of the 
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total lysate. The remaining 90% of each sample was lysed in 1 ml of Guanidinium 
chloride lysis buffer (6 M Guanidinium-HCL, 0.1 M NaHPO4, 0.01 M Tris/HCL, 
pH 8.0, 20 mM Imidazole, 10 mM β-mercaptoethanol), sonicated, and centrifuged 
to. Equal quantities of cleared protein lysates, as extrapolated from the quantified 
SDS aliquots, were incubated with 100 µl Ni-NTA magnetic beads (Qiagen 
#36111) for 2 hours at room temperature. After incubation, Ni-NTA magnetic 
beads were washed once with each of Guanidinium washing buffer (6 M 
Guanidinium-HCL, 0.1 M NaHPO4, 0.01 M Tris/HCL, pH 8.0, 10 mM β-
mercaptoethanol, 0.2% Triton X-100), Urea washing buffer I (8 M Urea, 0.1 M 
NaHPO4, 0.01 M Tris/HCL, pH 8.0, 10 mM β-mercaptoethanol, 0.2% Triton X-
100), Urea washing buffer II (8 M Urea, 0.1 M NaHPO4, 0.01 M Tris/HCL, pH 
6.3, 10 mM β-mercaptoethanol, 0.2% Triton X-100) and Urea washing buffer III 
(8 M Urea, 0.1 M NaHPO4, 0.01 M Tris/HCL, pH 6.3, 10 mM β-mercaptoethanol, 
0.1% Triton X-100 ). Bound proteins were dissociated in 20 µL SDS 
sample/elution buffer supplemented with 250 mM Imidazole and 5% β-
mercaptoethanol and immunoblotted as indicated. 
 
7.2.11: Preclinical efficacy in Merlin-deficient xenografts 
Preclinical xenograft experiments were performed in collaboration with the 
MSKCC Antitumor Assessment Facility. VAMT, Meso-10, and Ru19 xenografts 
were implanted in the rear flank of female NOD-scid IL2Rgammanull (NSG) mice 
obtained from the MSKCC Genomics Core. VAMT and Meso-10 received 
bilateral injections whereas Ru19 received unilateral injections due to the 
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heterogeneous growth of PDXs. Drug treatments begun once tumors reached 
approximately 100mm3. Tumors were measured by caliper every 3-4 days and 
mice were sacrificed if tumors reached 1000mm3 or if they began to ulcerate. 
 
7.2.12: Soft agar and tumorigenicity assay 
For soft agar assay, cells were trypsinized, resuspended in complete 
medium, and plated in 0.34% low gelling temperature agarose (Sigma A9414) in 
complete medium at 2x104 (Meso-33 cells), 1.2x104 (FC-1801 cells), or 1.5x104 
(LPCs) per well in 24-well Ultra Low Cluster Plates (Costar). For the FC-1801 
tumorigenicity assay, 1×106 cells were suspended in PBS and injected 
subcutaneously into the right flank of nude mice. Tumor volumes were 
determined by caliper measurement. Animal studies were conducted in 
accordance with protocols approved by the Institutional Animal Care and Use 
Committee of MSKCC. 
 
7.2.13: Statistical methods 
 Statistical significance was determined by Student’s t-test unless indicated 
otherwise. 
 
7.2.14: T7E1 assay 
Analysis of genomic alterations induced by CRISPR/Cas9 was determined 
using a T7E1 assay essentially as previously described (199). Briefly, the 
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genomic region surrounding the CRISPR/Cas9 cleavage site was amplified by 
PCR. 
For the Trp53 locus, the primers used were: 
Forward: 5’- CAGAAGATATCCTGGTAAGG-3’ 
Reverse: 5’- CTACAGGCTGAAGAGGAACC-3’ 
For the Cdkn2a locus, the primers used were: 
Forward: 5’-ATCCGAGTAGTTAACAGCGG-3’ 
Reverse: 5’- GGTGGGTAAAATGGGAACTT-3’ 
The amplicons were subjected to a cycle of melting and re-annealing to hybridize 
putatively heterogeneous amplicons (i.e. sense strand with WT sequence, 
antisense strand with an altered sequence) and then digested with T7E1, which 
recognizes and cleaves DNA at mismatched regions. Amplicons were run on a 
2.5% agarose gel. 
 
7.2.15: Ubiquitylation assay 
Ten cm diameter plates of COS-7 cells were transfected using 
Lipofectamine 2000 with 3 µg of pRK5-Flag-HA-DCAF1 and 2 µg of pHis-Myc-Ub 
in combination with indicated quantities of pRK5-HA-Merlin, or with 3 µg of pRK5-
Flag-HA-DCAF1 and 2 µg of pHA-Ub in combination with 3 µg of pRK5-Myc-
Merlin-WT, pRK5-Myc-Merlin1-339, pRK5-Myc-Ezrin or empty vector. When 
indicated, cells were treated with 25 µM MG132 for 6 hours. Lysates containing 
0.5 mg of proteins were subjected to immunoprecipitations and western blotting 
as already described. 
170 
 
REFERENCES 
1. McClatchey AI, and Yap AS. Contact inhibition (of proliferation) redux. 
Current opinion in cell biology. 2012;24(5):685-94. 
2. Hanahan D, and Weinberg RA. Hallmarks of cancer: the next generation. 
Cell. 2011;144(5):646-74. 
3. Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, 
Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B, et al. Alteration in 
a new gene encoding a putative membrane-organizing protein causes 
neuro-fibromatosis type 2. Nature. 1993;363(6429):515-21. 
4. Trofatter J, MacCollin M, Rutter J, Murrell J, Duyao M, Parry D, Eldridge 
R, Kley N, Menon A, and Pulaski K. A novel moesin-, ezrin-, radixin-like 
gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 
1993;75(4):826. 
5. Lallemand D, Curto M, Saotome I, Giovannini M, and McClatchey AI. NF2 
deficiency promotes tumorigenesis and metastasis by destabilizing 
adherens junctions. Genes Dev. 2003;17(9):1090-100. 
6. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, 
Gutmann DH, Ponta H, and Herrlich P. The NF2 tumor suppressor gene 
product, merlin, mediates contact inhibition of growth through interactions 
with CD44. Genes Dev. 2001;15(8):968-80. 
7. Okada T, Lopez-Lago M, and Giancotti FG. Merlin/NF-2 mediates contact 
inhibition of growth by suppressing recruitment of Rac to the plasma 
membrane. J Cell Biol. 2005;171(2):361-71. 
8. Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, and Testa JR. 
Frequent mutations of NF2 and allelic loss from chromosome band 22q12 
in malignant mesothelioma: evidence for a two-hit mechanism of NF2 
inactivation. Genes, chromosomes & cancer. 1999;24(3):238-42. 
9. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake 
RA, Zakowski MF, Reva B, et al. The nuclear deubiquitinase BAP1 is 
commonly inactivated by somatic mutations and 3p21.1 losses in 
malignant pleural mesothelioma. Nature genetics. 2011;43(7):668-72. 
10. Bianchi AB, Hara T, Ramesh V, Gao J, Klein-Szanto AJ, Morin F, Menon 
AG, Trofatter JA, Gusella JF, Seizinger BR, et al. Mutations in transcript 
isoforms of the neurofibromatosis 2 gene in multiple human tumour types. 
Nature genetics. 1994;6(2):185-92. 
171 
 
11. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies 
H, Edkins S, Hardy C, Latimer C, et al. Systematic sequencing of renal 
carcinoma reveals inactivation of histone modifying genes. Nature. 
2010;463(7279):360-3. 
12. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, and Yu Q. 
Merlin is a potent inhibitor of glioma growth. Cancer Res. 
2008;68(14):5733-42. 
13. Rustgi AK, Xu L, Pinney D, Sterner C, Beauchamp R, Schmidt S, Gusella 
JF, and Ramesh V. Neurofibromatosis 2 gene in human colorectal cancer. 
Cancer genetics and cytogenetics. 1995;84(1):24-6. 
14. McClatchey AI, and Fehon RG. Merlin and the ERM proteins--regulators 
of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 
2009;19(5):198-206. 
15. Kaempchen K, Mielke K, Utermark T, Langmesser S, and Hanemann CO. 
Upregulation of the Rac1/JNK signaling pathway in primary human 
schwannoma cells. Hum Mol Genet. 2003;12(11):1211-21. 
16. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, and Jacks T. 
Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the 
p21-activated kinase, Pak1. Mol Cell. 2003;12(4):841-9. 
17. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan 
JP, Gupta V, Ratner N, Der CJ, et al. The Nf2 tumor suppressor, merlin, 
functions in Rac-dependent signaling. Dev Cell. 2001;1(1):63-72. 
18. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-
Rachamimov AO, Gusella JF, and Ramesh V. NF2/merlin is a novel 
negative regulator of mTOR complex 1, and activation of mTORC1 is 
associated with meningioma and schwannoma growth. Mol Cell Biol. 
2009;29(15):4250-61. 
19. Lopez-Lago MA, Okada T, Murillo MM, Socci N, and Giancotti FG. Loss of 
the tumor suppressor gene NF2, encoding merlin, constitutively activates 
integrin-dependent mTORC1 signaling. Mol Cell Biol. 2009;29(15):4235-
49. 
20. Rong R, Tang X, Gutmann DH, and Ye K. Neurofibromatosis 2 (NF2) 
tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through 
binding to PIKE-L. Proc Natl Acad Sci U S A. 2004;101(52):18200-5. 
21. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, and Testa 
JR. Re-expression of the tumor suppressor NF2/merlin inhibits 
172 
 
invasiveness in mesothelioma cells and negatively regulates FAK. 
Oncogene. 2006;25(44):5960-8. 
22. Jin H, Sperka T, Herrlich P, and Morrison H. Tumorigenic transformation 
by CPI-17 through inhibition of a merlin phosphatase. Nature. 
2006;442(7102):576-9. 
23. Ammoun S, Flaiz C, Ristic N, Schuldt J, and Hanemann CO. Dissecting 
and targeting the growth factor-dependent and growth factor-independent 
extracellular signal-regulated kinase pathway in human schwannoma. 
Cancer Res. 2008;68(13):5236-45. 
24. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, 
Anders RA, and Pan D. The Merlin/NF2 tumor suppressor functions 
through the YAP oncoprotein to regulate tissue homeostasis in mammals. 
Dev Cell. 2010;19(1):27-38. 
25. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, 
Jafar-Nejad H, and Halder G. The tumour-suppressor genes NF2/Merlin 
and Expanded act through Hippo signalling to regulate cell proliferation 
and apoptosis. Nat Cell Biol. 2006;8(1):27-36. 
26. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li 
L, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved 
in cell contact inhibition and tissue growth control. Genes Dev. 
2007;21(21):2747-61. 
27. Kieran FH, Xiaomeng Z, and David MT. The Hippo pathway and human 
cancer. Nature Reviews Cancer. 2013. 
28. Sher I, Hanemann CO, Karplus PA, and Bretscher A. The tumor 
suppressor merlin controls growth in its open state, and phosphorylation 
converts it to a less-active more-closed state. Dev Cell. 2012;22(4):703-5. 
29. Yi C, Troutman S, Fera D, Stemmer-Rachamimov A, Avila JL, Christian N, 
Persson NL, Shimono A, Speicher DW, Marmorstein R, et al. A tight 
junction-associated Merlin-angiomotin complex mediates Merlin's 
regulation of mitogenic signaling and tumor suppressive functions. Cancer 
cell. 2011;19(4):527-40. 
30. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, 
Giovannini M, Hanemann CO, Long SB, et al. Merlin/NF2 suppresses 
tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the 
nucleus. Cell. 2010;140(4):477-90. 
173 
 
31. Sherman L, Xu H, Geist R, Saporito-Irwin S, Howells N, Ponta H, Herrlich 
P, and Gutmann D. Interdomain binding mediates tumor growth 
suppression by the NF2 gene product. Oncogene. 1997;15(20):2505-9. 
32. Gonzalez-Agosti C, Wiederhold T, Herndon ME, Gusella J, and Ramesh 
V. Interdomain interaction of merlin isoforms and its influence on 
intermolecular binding to NHE-RF. J Biol Chem. 1999;274(48):34438-42. 
33. Lallemand D, Saint-Amaux AL, and Giovannini M. Tumor-suppression 
functions of merlin are independent of its role as an organizer of the actin 
cytoskeleton in Schwann cells. J Cell Sci. 2009;122(Pt 22):4141-9. 
34. Zoch A, Mayerl S, Schulz A, Greither T, Frappart L, Rübsam J, Heuer H, 
Giovannini M, and Morrison H. Merlin Isoforms 1 and 2 Both Act as 
Tumour Suppressors and Are Required for Optimal Sperm Maturation. 
PloS one. 2015;10(8). 
35. Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, and Nunes FP. 
Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of 
research and diagnostic laboratory findings. Hum Mutat. 2007;28(1):1-12. 
36. Bretscher A, Edwards K, and Fehon RG. ERM proteins and merlin: 
integrators at the cell cortex. Nat Rev Mol Cell Biol. 2002;3(8):586-99. 
37. Shimizu T, Seto A, Maita N, Hamada K, Tsukita S, Tsukita S, and 
Hakoshima T. Structural basis for neurofibromatosis type 2. Crystal 
structure of the merlin FERM domain. J Biol Chem. 2002;277(12):10332-
6. 
38. Johnson KC, Kissil JL, Fry JL, and Jacks T. Cellular transformation by a 
FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene. 
2002;21(39):5990-7. 
39. LaJeunesse DR, McCartney BM, and Fehon RG. Structural analysis of 
Drosophila merlin reveals functional domains important for growth control 
and subcellular localization. J Cell Biol. 1998;141(7):1589-99. 
40. Gary R, and Bretscher A. Ezrin self-association involves binding of an N-
terminal domain to a normally masked C-terminal domain that includes the 
F-actin binding site. Mol Biol Cell. 1995;6(8):1061-75. 
41. Li Q, Nance MR, Kulikauskas R, Nyberg K, Fehon R, Karplus PA, 
Bretscher A, and Tesmer JJ. Self-masking in an intact ERM-merlin 
protein: an active role for the central alpha-helical domain. J Mol Biol. 
2007;365(5):1446-59. 
174 
 
42. Pearson MA, Reczek D, Bretscher A, and Karplus PA. Structure of the 
ERM protein moesin reveals the FERM domain fold masked by an 
extended actin binding tail domain. Cell. 2000;101(3):259-70. 
43. Heiska L, Alfthan K, Grönholm M, Vilja P, Vaheri A, and Carpén O. 
Association of ezrin with intercellular adhesion molecule-1 and -2 (ICAM-1 
and ICAM-2). Regulation by phosphatidylinositol 4, 5-bisphosphate. J Biol 
Chem. 1998;273(34):21893-900. 
44. Tsukita S, Oishi K, Sato N, Sagara J, and Kawai A. ERM family members 
as molecular linkers between the cell surface glycoprotein CD44 and 
actin-based cytoskeletons. J Cell Biol. 1994;126(2):391-401. 
45. Nguyen R, Reczek D, and Bretscher A. Hierarchy of merlin and ezrin N- 
and C-terminal domain interactions in homo- and heterotypic associations 
and their relationship to binding of scaffolding proteins EBP50 and 
E3KARP. J Biol Chem. 2001;276(10):7621-9. 
46. Gutmann DH, Haipek CA, and Hoang Lu K. Neurofibromatosis 2 tumor 
suppressor protein, merlin, forms two functionally important intramolecular 
associations. J Neurosci Res. 1999;58(5):706-16. 
47. Meng JJ, Lowrie DJ, Sun H, Dorsey E, Pelton PD, Bashour AM, Groden J, 
Ratner N, and Ip W. Interaction between two isoforms of the NF2 tumor 
suppressor protein, merlin, and between merlin and ezrin, suggests 
modulation of ERM proteins by merlin. J Neurosci Res. 2000;62(4):491-
502. 
48. Rong R, Surace EI, Haipek CA, Gutmann DH, and Ye K. Serine 518 
phosphorylation modulates merlin intramolecular association and binding 
to critical effectors important for NF2 growth suppression. Oncogene. 
2004;23(52):8447-54. 
49. Surace EI, Haipek CA, and Gutmann DH. Effect of merlin phosphorylation 
on neurofibromatosis 2 (NF2) gene function. Oncogene. 2004;23(2):580-7. 
50. Hennigan RF, Foster LA, Chaiken MF, Mani T, Gomes MM, Herr AB, and 
Ip W. Fluorescence resonance energy transfer analysis of merlin 
conformational changes. Mol Cell Biol. 2010;30(1):54-67. 
51. Kissil JL, Johnson KC, Eckman MS, and Jacks T. Merlin phosphorylation 
by p21-activated kinase 2 and effects of phosphorylation on merlin 
localization. J Biol Chem. 2002;277(12):10394-9. 
52. Serrano I, McDonald PC, Lock F, Muller WJ, and Dedhar S. Inactivation of 
the Hippo tumour suppressor pathway by integrin-linked kinase. Nat 
Commun. 2013;4(2976. 
175 
 
53. Shaw RJ, McClatchey AI, and Jacks T. Regulation of the 
neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion 
and growth arrest stimuli. J Biol Chem. 1998;273(13):7757-64. 
54. Laulajainen M, Muranen T, Carpen O, and Gronholm M. Protein kinase A-
mediated phosphorylation of the NF2 tumor suppressor protein merlin at 
serine 10 affects the actin cytoskeleton. Oncogene. 2008;27(23):3233-43. 
55. Alfthan K, Heiska L, Gronholm M, Renkema GH, and Carpen O. Cyclic 
AMP-dependent protein kinase phosphorylates merlin at serine 518 
independently of p21-activated kinase and promotes merlin-ezrin 
heterodimerization. J Biol Chem. 2004;279(18):18559-66. 
56. Kim HA, DeClue JE, and Ratner N. cAMP-dependent protein kinase A is 
required for Schwann cell growth: interactions between the cAMP and 
neuregulin/tyrosine kinase pathways. J Neurosci Res. 1997;49(2):236-47. 
57. Tang X, Jang SW, Wang X, Liu Z, Bahr SM, Sun SY, Brat D, Gutmann 
DH, and Ye K. Akt phosphorylation regulates the tumour-suppressor 
merlin through ubiquitination and degradation. Nat Cell Biol. 
2007;9(10):1199-207. 
58. Qi Q, Liu X, Brat DJ, and Ye K. Merlin sumoylation is required for its tumor 
suppressor activity. Oncogene. 2013. 
59. McClatchey AI, and Giovannini M. Membrane organization and 
tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev. 
2005;19(19):2265-77. 
60. Gladden AB, Hebert AM, Schneeberger EE, and McClatchey AI. The NF2 
tumor suppressor, Merlin, regulates epidermal development through the 
establishment of a junctional polarity complex. Dev Cell. 2010;19(5):727-
39. 
61. Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, Zwarthoff E, 
Lutchman M, Rouleau GA, Jaaskelainen J, Vaheri A, et al. 
Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and 
CD44 and associates with actin-containing cytoskeleton. J Cell Sci. 
1997;110 ( Pt 18)(2249-60. 
62. McCartney BM, and Fehon RG. Distinct cellular and subcellular patterns 
of expression imply distinct functions for the Drosophila homologues of 
moesin and the neurofibromatosis 2 tumor suppressor, merlin. J Cell Biol. 
1996;133(4):843-52. 
176 
 
63. Shaw RJ, McClatchey AI, and Jacks T. Localization and functional 
domains of the neurofibromatosis type II tumor suppressor, merlin. Cell 
Growth Differ. 1998;9(4):287-96. 
64. Gonzalez-Agosti C, Xu L, Pinney D, Beauchamp R, Hobbs W, Gusella J, 
and Ramesh V. The merlin tumor suppressor localizes preferentially in 
membrane ruffles. Oncogene. 1996;13(6):1239-47. 
65. Scherer S, and Gutmann D. Expression of the neurofibromatosis 2 tumor 
suppressor gene product, merlin, in Schwann cells. Journal of 
neuroscience research. 1996;46(5):595-605. 
66. Murthy A, Gonzalez-Agosti C, Cordero E, Pinney D, Candia C, Solomon 
F, Gusella J, and Ramesh V. NHE-RF, a regulatory cofactor for Na(+)-H+ 
exchange, is a common interactor for merlin and ERM (MERM) proteins. J 
Biol Chem. 1998;273(3):1273-6. 
67. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, 
Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR, et al. Yap1 acts 
downstream of alpha-catenin to control epidermal proliferation. Cell. 
2011;144(5):782-95. 
68. Silvis MR, Kreger BT, Lien WH, Klezovitch O, Rudakova GM, Camargo 
FD, Lantz DM, Seykora JT, and Vasioukhin V. alpha-catenin is a tumor 
suppressor that controls cell accumulation by regulating the localization 
and activity of the transcriptional coactivator Yap1. Science signaling. 
2011;4(174):ra33. 
69. Choi SH, Estarás C, Moresco JJ, Yates JR, and Jones KA. α-Catenin 
interacts with APC to regulate β-catenin proteolysis and transcriptional 
repression of Wnt target genes. Genes Dev. 2013;27(22):2473-88. 
70. Jessica SB, and Stephen PJ. Ubiquitylation, neddylation and the DNA 
damage response. Open Biology. 2015. 
71. Ernkvist M, Luna Persson N, Audebert S, Lecine P, Sinha I, Liu M, 
Schlueter M, Horowitz A, Aase K, Weide T, et al. The Amot/Patj/Syx 
signaling complex spatially controls RhoA GTPase activity in migrating 
endothelial cells. Blood. 2009;113(1):244-53. 
72. Stickney JT, Bacon WC, Rojas M, Ratner N, and Ip W. Activation of the 
tumor suppressor merlin modulates its interaction with lipid rafts. Cancer 
Res. 2004;64(8):2717-24. 
73. Mani T, Hennigan RF, Foster LA, Conrady DG, Herr AB, and Ip W. FERM 
domain phosphoinositide binding targets merlin to the membrane and is 
177 
 
essential for its growth-suppressive function. Mol Cell Biol. 
2011;31(10):1983-96. 
74. Okada M, Wang Y, Jang SW, Tang X, Neri LM, and Ye K. Akt 
phosphorylation of merlin enhances its binding to phosphatidylinositols 
and inhibits the tumor-suppressive activities of merlin. Cancer Res. 
2009;69(9):4043-51. 
75. Brault E, Gautreau A, Lamarine M, Callebaut I, Thomas G, and 
Goutebroze L. Normal membrane localization and actin association of the 
NF2 tumor suppressor protein are dependent on folding of its N-terminal 
domain. J Cell Sci. 2001;114(Pt 10):1901-12. 
76. Bensenor LB, Barlan K, Rice SE, Fehon RG, and Gelfand VI. Microtubule-
mediated transport of the tumor-suppressor protein Merlin and its mutants. 
Proc Natl Acad Sci U S A. 2010;107(16):7311-6. 
77. Xu HM, and Gutmann DH. Merlin differentially associates with the 
microtubule and actin cytoskeleton. J Neurosci Res. 1998;51(3):403-15. 
78. Smole Z, Thoma CR, Applegate KT, Duda M, Gutbrodt KL, Danuser G, 
and Krek W. Tumor Suppressor NF2/Merlin Is a Microtubule Stabilizer. 
Cancer Res. 2014;74(1):353-62. 
79. Hennigan R, Moon C, Parysek L, Monk K, Morfini G, Berth S, Brady S, 
and Ratner N. The NF2 tumor suppressor regulates microtubule-based 
vesicle trafficking via a novel Rac, MLK and p38(SAPK) pathway. 
Oncogene. 2012. 
80. Lee J, and Zhou P. DCAFs, the missing link of the CUL4-DDB1 ubiquitin 
ligase. Mol Cell. 2007;26(6):775-80. 
81. O'Connell BC, and Harper JW. Ubiquitin proteasome system (UPS): what 
can chromatin do for you? Current opinion in cell biology. 2007;19(2):206-
14. 
82. Muranen T, Gronholm M, Renkema GH, and Carpen O. Cell cycle-
dependent nucleocytoplasmic shuttling of the neurofibromatosis 2 tumour 
suppressor merlin. Oncogene. 2005;24(7):1150-8. 
83. Kressel M, and Schmucker B. Nucleocytoplasmic transfer of the NF2 
tumor suppressor protein merlin is regulated by exon 2 and a CRM1-
dependent nuclear export signal in exon 15. Human Molecular Genetics. 
2002;11(19):2269-78. 
178 
 
84. Zhang S, Feng Y, Narayan O, and Zhao LJ. Cytoplasmic retention of HIV-
1 regulatory protein Vpr by protein-protein interaction with a novel human 
cytoplasmic protein VprBP. Gene. 2001;263(1-2):131-40. 
85. Zhao LJ, Mukherjee S, and Narayan O. Biochemical mechanism of HIV-I 
Vpr function. Specific interaction with a cellular protein. J Biol Chem. 
1994;269(22):15577-82. 
86. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, and Zheng N. Molecular 
architecture and assembly of the DDB1-CUL4A ubiquitin ligase 
machinery. Nature. 2006;443(7111):590-3. 
87. Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson S, 
Florens L, Washburn M, and Skowronski J. Lentiviral Vpr usurps Cul4-
DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle. Proceedings of 
the National Academy of Sciences of the United States of America. 
2007;104(28):11778-83. 
88. Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, and 
Margottin-Goguet F. HIV1 Vpr arrests the cell cycle by recruiting 
DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle. 
2007;6(2):182-8. 
89. Li T, Robert EI, van Breugel PC, Strubin M, and Zheng N. A promiscuous 
alpha-helical motif anchors viral hijackers and substrate receptors to the 
CUL4-DDB1 ubiquitin ligase machinery. Nature structural & molecular 
biology. 2010;17(1):105-11. 
90. Li T, Chen X, Garbutt KC, Zhou P, and Zheng N. Structure of DDB1 in 
complex with a paramyxovirus V protein: viral hijack of a propeller cluster 
in ubiquitin ligase. Cell. 2006;124(1):105-17. 
91. Petroski MD, and Deshaies RJ. Function and regulation of cullin-RING 
ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6(1):9-20. 
92. Maitra S, Kulikauskas RM, Gavilan H, and Fehon RG. The tumor 
suppressors Merlin and Expanded function cooperatively to modulate 
receptor endocytosis and signaling. Current biology : CB. 2006;16(7):702-
9. 
93. Conlon I, and Raff M. Size control in animal development. Cell. 
1999;96(2):235-44. 
94. Lloyd AC. The regulation of cell size. Cell. 2013;154(6):1194-205. 
95. Ahn J, Hao C, Yan J, DeLucia M, Mehrens J, Wang C, Gronenborn A, and 
Skowronski J. HIV/simian immunodeficiency virus (SIV) accessory 
179 
 
virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the 
E3 ubiquitin ligase complex CRL4DCAF1. The Journal of biological 
chemistry. 2012;287(15):12550-8. 
96. Yu J, Zheng Y, Dong J, Klusza S, Deng WM, and Pan D. Kibra functions 
as a tumor suppressor protein that regulates Hippo signaling in 
conjunction with Merlin and Expanded. Dev Cell. 2010;18(2):288-99. 
97. Chen CL, Gajewski KM, Hamaratoglu F, Bossuyt W, Sansores-Garcia L, 
Tao C, and Halder G. The apical-basal cell polarity determinant Crumbs 
regulates Hippo signaling in Drosophila. Proc Natl Acad Sci U S A. 
2010;107(36):15810-5. 
98. Schwefel D, Groom HC, Boucherit VC, Christodoulou E, Walker PA, Stoye 
JP, Bishop KN, and Taylor IA. Structural basis of lentiviral subversion of a 
cellular protein degradation pathway. Nature. 2013. 
99. Lee J, Lee J, Kim H, Kim K, Park H, Kim J-Y, Lee S, Kim I, Kim J, Lee M, 
et al. EZH2 generates a methyl degron that is recognized by the 
DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Molecular cell. 
2012;48(4):572-86. 
100. Kim K, Kim JM, Kim JS, Choi J, Lee YS, Neamati N, Song JS, Heo K, and 
An W. VprBP has intrinsic kinase activity targeting histone H2A and 
represses gene transcription. Mol Cell. 2013;52(3):459-67. 
101. Ahn J, Vu T, Novince Z, Guerrero-Santoro J, Rapic-Otrin V, and 
Gronenborn AM. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, 
a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for 
proteasome-dependent degradation. J Biol Chem. 2010;285(48):37333-
41. 
102. Laguette N, Bregnard C, Hue P, Basbous J, Yatim A, Larroque M, 
Kirchhoff F, Constantinou A, Sobhian B, and Benkirane M. Premature 
Activation of the SLX4 Complex by Vpr Promotes G2/M Arrest and 
Escape from Innate Immune Sensing. Cell. 2014;156(1-2):134-45. 
103. Tamori Y, Bialucha CU, Tian AG, Kajita M, Huang YC, Norman M, 
Harrison N, Poulton J, Ivanovitch K, Disch L, et al. Involvement of Lgl and 
Mahjong/VprBP in cell competition. PLoS biology. 2010;8(7):e1000422. 
104. Kassmeier MD, Mondal K, Palmer VL, Raval P, Kumar S, Perry GA, 
Anderson DK, Ciborowski P, Jackson S, Xiong Y, et al. VprBP binds full-
length RAG1 and is required for B-cell development and V(D)J 
recombination fidelity. The EMBO journal. 2012;31(4):945-58. 
180 
 
105. Kaur M, Khan M, Kar A, Sharma A, and Saxena S. CRL4-DDB1-VPRBP 
ubiquitin ligase mediates the stress triggered proteolysis of Mcm10. 
Nucleic acids research. 2012;40(15):7332-46. 
106. Kim K, Heo K, Choi J, Jackson S, Kim H, Xiong Y, and An W. Vpr-binding 
protein antagonizes p53-mediated transcription via direct interaction with 
H3 tail. Mol Cell Biol. 2012;32(4):783-96. 
107. Chao Y, Shu-Yan J, Qian-Qian S, Qing-Yuan S, and Heng-Yu F. CRL4-
DCAF1 ubiquitin E3 ligase directs protein phosphatase 2A degradation to 
control oocyte meiotic maturation. Nature Communications. 2015;6(8017. 
108. Yu C, Zhang YL, Pan WW, Li XM, Wang ZW, Ge ZJ, Zhou JJ, Cang Y, 
Tong C, Sun QY, et al. CRL4 complex regulates mammalian oocyte 
survival and reprogramming by activation of TET proteins. Science. 
2013;342(6165):1518-21. 
109. Tan L, and Shi YG. Tet family proteins and 5-hydroxymethylcytosine in 
development and disease. Development. 2012;139(11):1895-902. 
110. Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 
2010;19(4):491-505. 
111. Zhao B, Tumaneng K, and Guan KL. The Hippo pathway in organ size 
control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 
2011;13(8):877-83. 
112. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler 
W, Lee JT, Avruch J, et al. Mst1 and Mst2 maintain hepatocyte 
quiescence and suppress hepatocellular carcinoma development through 
inactivation of the Yap1 oncogene. Cancer cell. 2009;16(5):425-38. 
113. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, 
Calvisi DF, Kim JM, et al. The Hippo-Salvador pathway restrains hepatic 
oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad 
Sci U S A. 2010;107(18):8248-53. 
114. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold 
MJ, Lee JS, et al. Hippo signaling is a potent in vivo growth and tumor 
suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A. 
2010;107(4):1437-42. 
115. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang 
J, Simpson RM, et al. Mammalian Mst1 and Mst2 kinases play essential 
roles in organ size control and tumor suppression. Proc Natl Acad Sci U S 
A. 2010;107(4):1431-6. 
181 
 
116. Johnson R, and Halder G. The two faces of Hippo: targeting the Hippo 
pathway for regenerative medicine and cancer treatment. Nature reviews 
Drug discovery. 2014;13(1):63-79. 
117. Harvey K, and Tapon N. The Salvador-Warts-Hippo pathway - an 
emerging tumour-suppressor network. Nat Rev Cancer. 2007;7(3):182-91. 
118. Grusche FA, Richardson HE, and Harvey KF. Upstream regulation of the 
hippo size control pathway. Current biology : CB. 2010;20(13):R574-82. 
119. Saburi S, Hester I, Fischer E, Pontoglio M, Eremina V, Gessler M, 
Quaggin SE, Harrison R, Mount R, and McNeill H. Loss of Fat4 disrupts 
PCP signaling and oriented cell division and leads to cystic kidney 
disease. Nature genetics. 2008;40(8):1010-5. 
120. Mao Y, Mulvaney J, Zakaria S, Yu T, Morgan KM, Allen S, Basson MA, 
Francis-West P, and Irvine KD. Characterization of a Dchs1 mutant mouse 
reveals requirements for Dchs1-Fat4 signaling during mammalian 
development. Development. 2011;138(5):947-57. 
121. Visser-Grieve S, Hao Y, and Yang X. Human homolog of Drosophila 
expanded, hEx, functions as a putative tumor suppressor in human cancer 
cell lines independently of the Hippo pathway. Oncogene. 
2012;31(9):1189-95. 
122. Vanessa SR-O, Sarat C, Nen CP, Poulikos IP, Maurizio S, Elizabeth M, 
José B, Sylvie G, and Neal R. mTOR Kinase Inhibition Causes Feedback-
Dependent Biphasic Regulation of AKT Signaling. Cancer Discovery. 
2011;1(3):248-59. 
123. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, and Hong W. Hippo 
pathway-independent restriction of TAZ and YAP by angiomotin. J Biol 
Chem. 2011;286(9):7018-26. 
124. Paramasivam M, Sarkeshik A, Yates JR, Fernandes MJ, and McCollum D. 
Angiomotin family proteins are novel activators of the LATS2 kinase tumor 
suppressor. Mol Biol Cell. 2011;22(19):3725-33. 
125. Wang W, Huang J, and Chen J. Angiomotin-like proteins associate with 
and negatively regulate YAP1. J Biol Chem. 2011;286(6):4364-70. 
126. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, and Guan KL. Angiomotin is 
a novel Hippo pathway component that inhibits YAP oncoprotein. Genes 
Dev. 2011;25(1):51-63. 
127. Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe 
LC, Liu Q, Shimono A, Sudol M, Holmgren L, et al. The p130 isoform of 
182 
 
angiomotin is required for Yap-mediated hepatic epithelial cell proliferation 
and tumorigenesis. Science signaling. 2013;6(291):ra77. 
128. Li Y, Wei Z, Zhang J, Yang Z, and Zhang M. Structural basis of the 
binding of Merlin FERM domain to the E3 ubiquitin ligase substrate 
adaptor DCAF1. The Journal of biological chemistry. 2014;289(21):14674-
81. 
129. Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, 
Snuderl M, Ladanyi M, Hanemann CO, Zhou P, et al. Merlin/NF2 loss-
driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the 
hippo pathway kinases Lats1 and 2 in the nucleus. Cancer cell. 
2014;26(1):48-60. 
130. Jin J, Arias EE, Chen J, Harper JW, and Walter JC. A family of diverse 
Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S 
phase destruction of the replication factor Cdt1. Mol Cell. 2006;23(5):709-
21. 
131. Youjun L, Hao Z, Fengzhi L, Siew Wee C, Zhijie L, Zhiyi W, Zhou Y, 
Fusheng G, Chun Jye L, Wancai X, et al. Angiomotin binding-induced 
activation of Merlin/NF2 in the Hippo pathway. Cell Research. 
2015;25(7):801-17. 
132. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, and Pan D. Spatial organization 
of Hippo signaling at the plasma membrane mediated by the tumor 
suppressor Merlin/NF2. Cell. 2013;154(6):1342-55. 
133. Toji S, Yabuta N, Hosomi T, Nishihara S, Kobayashi T, Suzuki S, Tamai 
K, and Nojima H. The centrosomal protein Lats2 is a phosphorylation 
target of Aurora-A kinase. Genes to cells : devoted to molecular & cellular 
mechanisms. 2004;9(5):383-97. 
134. Yang X, Yu K, Hao Y, Li DM, Stewart R, Insogna KL, and Xu T. LATS1 
tumour suppressor affects cytokinesis by inhibiting LIMK1. Nat Cell Biol. 
2004;6(7):609-17. 
135. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, 
and Jacks T. Mice heterozygous for a mutation at the Nf2 tumor 
suppressor locus develop a range of highly metastatic tumors. Genes 
Dev. 1998;12(8):1121-33. 
136. Giovannini M, Robanus-Maandag E, van der Valk M, Niwa-Kawakita M, 
Abramowski V, Goutebroze L, Woodruff JM, Berns A, and Thomas G. 
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of 
human neurofibromatosis type 2. Genes Dev. 2000;14(13):1617-30. 
183 
 
137. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet 
M, Janin A, Thomas G, Gutmann DH, and Giovannini M. Nf2 gene 
inactivation in arachnoidal cells is rate-limiting for meningioma 
development in the mouse. Genes Dev. 2002;16(9):1060-5. 
138. Fleury-Feith J, Lecomte C, Renier A, Matrat M, Kheuang L, Abramowski 
V, Levy F, Janin A, Giovannini M, and Jaurand MC. Hemizygosity of Nf2 is 
associated with increased susceptibility to asbestos-induced peritoneal 
tumours. Oncogene. 2003;22(24):3799-805. 
139. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van 
der Valk M, van de Vijver M, and Berns A. A conditional mouse model for 
malignant mesothelioma. Cancer cell. 2008;13(3):261-71. 
140. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M, 
and McClatchey AI. Nf2/Merlin controls progenitor homeostasis and 
tumorigenesis in the liver. Genes Dev. 2010;24(16):1718-30. 
141. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, 
Anders RA, and Pan D. The Merlin/NF2 Tumor Suppressor Functions 
through the YAP Oncoprotein to Regulate Tissue Homeostasis in 
Mammals. Dev Cell. 2010;19(1):27-38. 
142. Breuhahn K, and Schirmacher P. A Cellular View of Nf2 in Liver 
Homeostasis and Tumorigenesis. Developmental Cell. 2010;19(3):363-4. 
143. Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, 
Gurung B, Shrestha K, Cahan P, Stanger BZ, and Camargo FD. Hippo 
pathway activity influences liver cell fate. Cell. 2014;157(6):1324-38. 
144. Fischer ES, Scrima A, Bohm K, Matsumoto S, Lingaraju GM, Faty M, 
Yasuda T, Cavadini S, Wakasugi M, Hanaoka F, et al. The molecular 
basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and 
activation. Cell. 2011;147(5):1024-39. 
145. Zender L, Xue W, Cordon-Cardo C, Hannon GJ, Lucito R, Powers S, 
Flemming P, Spector MS, and Lowe SW. Generation and analysis of 
genetically defined liver carcinomas derived from bipotential liver 
progenitors. Cold Spring Harb Symp Quant Biol. 2005;70(251-61. 
146. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, 
Kubicka S, Luk JM, Schirmacher P, et al. An oncogenomics-based in vivo 
RNAi screen identifies tumor suppressors in liver cancer. Cell. 
2008;135(5):852-64. 
147. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan 
ST, Luk JM, Wigler M, Hannon GJ, et al. Identification and validation of 
184 
 
oncogenes in liver cancer using an integrative oncogenomic approach. 
Cell. 2006;125(7):1253-67. 
148. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans 
MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, et al. CDK9-mediated 
transcription elongation is required for MYC addiction in hepatocellular 
carcinoma. Genes Dev. 2014;28(16):1800-14. 
149. Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, and 
Lowe SW. Mouse model of intrahepatic cholangiocarcinoma validates 
FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl 
Acad Sci U S A. 2013;110(48):19513-8. 
150. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, 
Shelton KD, Lindner J, Cherrington AD, and Magnuson MA. Dual roles for 
glucokinase in glucose homeostasis as determined by liver and pancreatic 
beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 
1999;274(1):305-15. 
151. Weisend CM, Kundert JA, Suvorova ES, Prigge JR, and Schmidt EE. Cre 
activity in fetal albCre mouse hepatocytes: Utility for developmental 
studies. Genesis. 2009;47(12):789-92. 
152. Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak 
CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, et al. YAP 
Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading 
to Tumor Regression. Cell reports. 2015. 
153. Font-Burgada J, Shalapour S, Ramaswamy S, Hsueh B, Rossell D, 
Umemura A, Taniguchi K, Nakagawa H, Valasek MA, Ye L, et al. Hybrid 
Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise 
to Cancer. Cell. 2015;162(4):766-79. 
154. Pasmant E, Louvrier C, Luscan A, Cohen J, Laurendeau I, Vidaud M, 
Vidaud D, Goutagny S, Kalamarides M, and Parfait B. Neurofibromatosis 
type 2 French cohort analysis using a comprehensive NF2 molecular 
diagnostic strategy. Neuro-Chirurgie. 2015. 
155. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, 
and Lowe SW. Probing tumor phenotypes using stable and regulated 
synthetic microRNA precursors. Nature genetics. 2005;37(11):1289-95. 
156. Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai 
DY, Barbosa IA, Kwon JS, Guan Y, et al. An optimized microRNA 
backbone for effective single-copy RNAi. Cell reports. 2013;5(6):1704-13. 
185 
 
157. Maddalo D, Manchado E, Concepcion CP, Bonetti C, Vidigal JA, Han YC, 
Ogrodowski P, Crippa A, Rekhtman N, de Stanchina E, et al. In vivo 
engineering of oncogenic chromosomal rearrangements with the 
CRISPR/Cas9 system. Nature. 2014;516(7531):423-7. 
158. Yamashita K, Ide M, Furukawa KT, Suzuki A, Hirano H, and Ohno S. 
Tumor suppressor protein Lgl mediates G1 cell cycle arrest at high cell 
density by forming an Lgl-VprBP-DDB1 complex. Molecular biology of the 
cell. 2015. 
159. Michalopoulos G. Liver regeneration. Journal of cellular physiology. 
2007;213(2):286-300. 
160. Vidigal JA, and Ventura A. Rapid and efficient one-step generation of 
paired gRNA CRISPR-Cas9 libraries. Nat Commun. 2015;6(8083. 
161. Miyanaga A, Masuda M, Tsuta K, Kawasaki K, Nakamura Y, Sakuma T, 
Asamura H, Gemma A, and Yamada T. Hippo pathway gene mutations in 
malignant mesothelioma: revealed by RNA and targeted exon sequencing. 
Journal of thoracic oncology : official publication of the International 
Association for the Study of Lung Cancer. 2015;10(5):844-51. 
162. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka 
S, Horio Y, Hida T, Kondo Y, et al. LATS2 is a tumor suppressor gene of 
malignant mesothelioma. Cancer Res. 2011;71(3):873-83. 
163. Yingxiang L, Angela IP, Haiwei M, Cansu C, Aizhan B, Elliot A-G, Nik J, 
Eric AH, David F, Hao Y, et al. A versatile reporter system for CRISPR-
mediated chromosomal rearrangements. Genome Biology. 2015. 
164. Cooper J, and Giancotti FG. Molecular insights into NF2/Merlin tumor 
suppressor function. FEBS letters. 2014;588(16):2743-52. 
165. Li W, Cooper J, Karajannis MA, and Giancotti FG. Merlin: a tumour 
suppressor with functions at the cell cortex and in the nucleus. EMBO 
reports. 2012. 
166. Matthew WS, Karen EK, Anne FF, Marc FD, Bernard EW, Anthony NI, 
and Erik SK. BRG-1 is required for RB-mediated cell cycle arrest. 
Proceedings of the National Academy of Sciences. 2000. 
167. Anbarasi K, Kathirvel G, Bhaskar K, David R, and Steve MP. 
Downregulation of SWI/SNF chromatin remodeling factor subunits 
modulates cisplatin cytotoxicity. Experimental Cell Research. 2012. 
168. Ladanyi M, Zauderer M, Krug L, Ito T, McMillan R, Bott M, and Giancotti F. 
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as novel targets 
186 
 
for therapeutic development and risk assessment. Clinical cancer 
research : an official journal of the American Association for Cancer 
Research. 2012. 
169. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, 
Brownell JE, Burke KE, Cardin DP, Critchley S, et al. An inhibitor of 
NEDD8-activating enzyme as a new approach to treat cancer. Nature. 
2009;458(7239):732-6. 
170. David MD, Laura AB, Daniel CS, Harold WH, Michal H, and Brenda AS. 
Structural insights into NEDD8 activation of cullin-RING ligases: 
conformational control of conjugation. Cell. 2008;134(6):995-1006. 
171. Saha A, and Deshaies RJ. Multimodal activation of the ubiquitin ligase 
SCF by Nedd8 conjugation. Molecular cell. 2008. 
172. Bennett EJ, Rush J, Gygi SP, and Harper JW. Dynamics of cullin-RING 
ubiquitin ligase network revealed by systematic quantitative proteomics. 
Cell. 2010;143(6):951-65. 
173. Wei-Wei P, Jian-Jie Z, Chao Y, Ying X, Lian-Jun G, Hai-Yi Z, Dawang Z, 
Fang-Zhou S, and Heng-Yu F. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) 
as a potential chemotherapeutic target for ovarian surface epithelial 
cancer. The Journal of biological chemistry. 201341):29680-91. 
174. Lin JJ, Milhollen MA, Smith PG, Narayanan U, and Dutta A. NEDD8-
targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S 
phase, triggering checkpoint activation, apoptosis, and senescence in 
cancer cells. Cancer Res. 2010;70(24):10310-20. 
175. Jessica SB, Natalia L, Matylda S-C, Sébastien B, Carlos le S, Patrick C, 
Petra B, Yaron G, and Stephen PJ. Neddylation Promotes Ubiquitylation 
and Release of Ku from DNA-Damage Sites. Cell reports. 2015. 
176. Steffan TN, Kevin RK, Peter GS, Claudia ME, Anthony P, Sean AB, 
Michael M, Stephen B, Michael T, Allison B, et al. Disrupting Protein 
NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin 
Resistance in Ovarian Cancer. Clinical Cancer Research. 
2013;19(13):3577-90. 
177. Amir AJ, Etsuko S, Jonghoon P, Jennifer LB, Mark RC, Susan CM, Peter 
GS, Michael AM, Allison JB, and Anindya D. Overcoming platinum 
resistance in preclinical models of ovarian cancer using the neddylation 
inhibitor MLN4924. Molecular cancer therapeutics. 2013. 
178. Garcia K, Blank JL, Bouck DC, Liu XJ, and Sappal DS. Nedd8-activating 
enzyme inhibitor MLN4924 provides synergy with mitomycin C through 
187 
 
interactions with ATR, BRCA1/BRCA2, and chromatin dynamics 
pathways. Molecular cancer …. 2014. 
179. Kee Y, Huang M, Chang S, Moreau LA, and Park E. Inhibition of the 
Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. 
Molecular Cancer …. 2012. 
180. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, 
McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, and 
Cichowski K. A negative feedback signaling network underlies oncogene-
induced senescence. Cancer cell. 2006;10(6):459-72. 
181. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, and Smith D. mTOR 
inhibition induces upstream receptor tyrosine kinase signaling and 
activates Akt. Cancer research. 2006. 
182. Tremblay F, Brûlé S, Um SH, and Li Y. Identification of IRS-1 Ser-1101 as 
a target of S6K1 in nutrient-and obesity-induced insulin resistance. 
Proceedings of the …. 2007. 
183. Shi Y, Yan H, Frost P, Gera J, and Lichtenstein A. Mammalian target of 
rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by 
up-regulating the insulin-like growth factor receptor/insulin receptor …. 
Molecular cancer therapeutics. 2005. 
184. Yu Y, Yoon S-OO, Poulogiannis G, Yang Q, Ma XM, Villén J, Kubica N, 
Hoffman GR, Cantley LC, Gygi SP, et al. Phosphoproteomic analysis 
identifies Grb10 as an mTORC1 substrate that negatively regulates insulin 
signaling. Science (New York, NY). 2011;332(6035):1322-6. 
185. Wallin J, Edgar K, Guan J, Berry M, Prior W, Lee L, Lesnick J, Lewis C, 
Nonomiya J, Pang J, et al. GDC-0980 is a novel class I PI3K/mTOR 
kinase inhibitor with robust activity in cancer models driven by the PI3K 
pathway. Molecular cancer therapeutics. 2011;10(12):2426-36. 
186. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, 
Dogan AU, Pass HI, Trusa S, et al. Germline BAP1 mutations predispose 
to malignant mesothelioma. Nature genetics. 2011;43(10):1022-5. 
187. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, 
Windpassinger C, Wackernagel W, Loy S, Wolf I, et al. Germline 
mutations in BAP1 predispose to melanocytic tumors. Nature genetics. 
2011;43(10):1018-21. 
188. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, 
Council ML, Matatall KA, Helms C, and Bowcock AM. Frequent mutation 
188 
 
of BAP1 in metastasizing uveal melanomas. Science. 
2010;330(6009):1410-3. 
189. Fousteri M, Vermeulen W, van Zeeland AA, and Mullenders LH. Cockayne 
syndrome A and B proteins differentially regulate recruitment of chromatin 
remodeling and repair factors to stalled RNA polymerase II in vivo. 
Molecular cell. 2006;23(4):471-82. 
190. Yoshizawa T, Karim MF, Sato Y, Senokuchi T, Miyata K, Fukuda T, Go C, 
Tasaki M, Uchimura K, Kadomatsu T, et al. SIRT7 controls hepatic lipid 
metabolism by regulating the ubiquitin-proteasome pathway. Cell 
metabolism. 2014;19(4):712-21. 
191. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, 
Heckl D, Ebert BL, Root DE, Doench JG, et al. Genome-scale CRISPR-
Cas9 knockout screening in human cells. Science. 2014;343(6166):84-7. 
192. Becker CM, Oberoi RK, McFarren SJ, Muldoon DM, Pafundi DH, Pokorny 
JL, Brinkmann DH, Ohlfest JR, Sarkaria JN, Largaespada DA, et al. 
Decreased affinity for efflux transporters increases brain penetrance and 
molecular targeting of a PI3K/mTOR inhibitor in a mouse model of 
glioblastoma. Neuro-Oncology. 2015. 
193. Heffron TP, Salphati L, Alicke B, Cheong J, Dotson J, Edgar K, Goldsmith 
R, Gould SE, Lee LB, Lesnick JD, et al. The design and identification of 
brain penetrant inhibitors of phosphoinositide 3-kinase α. Journal of 
medicinal chemistry. 2012;55(18):8007-20. 
194. Hua W, Li C, Yang Z, Li L, Jiang Y, Yu G, Zhu W, Liu Z, Duan S, Chu Y, et 
al. Suppression of glioblastoma by targeting the overactivated protein 
neddylation pathway. Neuro Oncol. 2015. 
195. Lallemand D, Manent J, Couvelard A, Watilliaux A, Siena M, Chareyre F, 
Lampin A, Niwa-Kawakita M, Kalamarides M, and Giovannini M. Merlin 
regulates transmembrane receptor accumulation and signaling at the 
plasma membrane in primary mouse Schwann cells and in human 
schwannomas. Oncogene. 2008. 
196. Treier M, Staszewski LM, and Bohmann D. Ubiquitin-dependent c-Jun 
degradation in vivo is mediated by the delta domain. Cell. 1994;78(5):787-
98. 
197. Pylayeva Y, Guo W, and Giancotti FG. Analysis of integrin signaling in 
genetically engineered mouse models of mammary tumor progression. 
Methods Enzymol. 2007;426(439-61. 
189 
 
198. Servais EL, Colovos C, Kachala SS, and Adusumilli PS. Pre-clinical 
mouse models of primary and metastatic pleural cancers of the lung and 
breast and the use of bioluminescent imaging to monitor pleural tumor 
burden. Current protocols in pharmacology / editorial board, SJ Enna. 
2011;Chapter 14(Unit14 21. 
199. Gonzalez F, Zhu Z, Shi ZD, Lelli K, Verma N, Li QV, and Huangfu D. An 
iCRISPR platform for rapid, multiplexable, and inducible genome editing in 
human pluripotent stem cells. Cell stem cell. 2014;15(2):215-26. 
 
